0001530766 2026-01-01 2026-03-31 0001530766 2026-05-13 0001530766 2026-03-31 0001530766 2025-12-31 0001530766 us-gaap:RelatedPartyMember 2026-03-31 0001530766 us-gaap:RelatedPartyMember 2025-12-31 0001530766 STEX:RestrictedGoldMember 2026-03-31 0001530766 STEX:RestrictedGoldMember 2025-12-31 0001530766 us-gaap:GoldMember 2026-03-31 0001530766 us-gaap:GoldMember 2025-12-31 0001530766 STEX:SeriesCNinePercentageConvertiblePreferredStockMember 2026-03-31 0001530766 STEX:SeriesCNinePercentageConvertiblePreferredStockMember 2025-12-31 0001530766 us-gaap:SeriesAPreferredStockMember 2026-03-31 0001530766 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001530766 us-gaap:SeriesBPreferredStockMember 2026-03-31 0001530766 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001530766 us-gaap:SeriesCPreferredStockMember 2026-03-31 0001530766 us-gaap:SeriesCPreferredStockMember 2025-12-31 0001530766 us-gaap:SeriesDPreferredStockMember 2026-03-31 0001530766 us-gaap:SeriesDPreferredStockMember 2025-12-31 0001530766 us-gaap:SeriesEPreferredStockMember 2026-03-31 0001530766 us-gaap:SeriesEPreferredStockMember 2025-12-31 0001530766 us-gaap:SeriesFPreferredStockMember 2026-03-31 0001530766 us-gaap:SeriesFPreferredStockMember 2025-12-31 0001530766 2025-01-01 2025-12-31 0001530766 2025-01-01 2025-03-31 0001530766 us-gaap:CommonStockMember 2025-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001530766 us-gaap:RetainedEarningsMember 2025-12-31 0001530766 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001530766 us-gaap:NoncontrollingInterestMember 2025-12-31 0001530766 us-gaap:CommonStockMember 2024-12-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001530766 us-gaap:RetainedEarningsMember 2024-12-31 0001530766 us-gaap:NoncontrollingInterestMember 2024-12-31 0001530766 2024-12-31 0001530766 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001530766 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001530766 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2026-01-01 2026-03-31 0001530766 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001530766 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001530766 us-gaap:CommonStockMember 2026-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001530766 us-gaap:RetainedEarningsMember 2026-03-31 0001530766 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2026-03-31 0001530766 us-gaap:CommonStockMember 2025-03-31 0001530766 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001530766 us-gaap:RetainedEarningsMember 2025-03-31 0001530766 us-gaap:NoncontrollingInterestMember 2025-03-31 0001530766 2025-03-31 0001530766 STEX:ViralClearMember 2026-03-31 0001530766 STEX:BioSigAIMember 2025-12-31 0001530766 STEX:GLDYServiceCoLLCMember 2026-03-31 0001530766 STEX:GLDYServiceCoLLCMember 2026-01-01 2026-03-31 0001530766 2026-01-01 2026-01-31 0001530766 country:US 2026-03-31 0001530766 country:CA 2026-03-31 0001530766 srt:ConsolidatedEntityExcludingVariableInterestEntitiesVIEMember 2026-03-31 0001530766 us-gaap:SeriesCPreferredStockMember 2026-01-01 2026-03-31 0001530766 us-gaap:SeriesCPreferredStockMember 2025-01-01 2025-03-31 0001530766 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001530766 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001530766 STEX:PerformanceBasedRestrictedStockUnitMember 2026-01-01 2026-03-31 0001530766 STEX:PerformanceBasedRestrictedStockUnitMember 2025-01-01 2025-03-31 0001530766 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001530766 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001530766 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0001530766 us-gaap:RestrictedStockMember 2025-01-01 2025-03-31 0001530766 STEX:StreamexExchangeCorporationMember 2025-05-28 2025-05-28 0001530766 STEX:SharePurchaseAgreementMember 2025-05-28 2025-05-28 0001530766 STEX:SharePurchaseAgreementMember 2025-05-28 0001530766 2025-11-04 2025-11-04 0001530766 2025-05-28 2025-05-28 0001530766 STEX:ThirdpartyConsultantsMember us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001530766 STEX:ThirdpartyConsultantsMember us-gaap:CommonStockMember 2026-03-31 0001530766 STEX:ThirdpartyConsultantsMember 2026-01-01 2026-03-31 0001530766 us-gaap:TradeNamesMember 2025-05-28 0001530766 2025-05-28 0001530766 us-gaap:TechnologyBasedIntangibleAssetsMember 2025-05-28 0001530766 STEX:SecuritizationPlatformMember 2025-05-28 0001530766 STEX:BlockchainIntegrationMember 2025-05-28 0001530766 STEX:LegalAndComplianceFrameWorkMember 2025-05-28 0001530766 us-gaap:TradeNamesMember 2026-03-31 0001530766 us-gaap:TradeNamesMember 2025-12-31 0001530766 us-gaap:DevelopedTechnologyRightsMember 2026-03-31 0001530766 us-gaap:DevelopedTechnologyRightsMember 2025-12-31 0001530766 STEX:LegalAndComplianceFrameWorkMember 2026-03-31 0001530766 STEX:LegalAndComplianceFrameWorkMember 2025-12-31 0001530766 us-gaap:PatentsMember 2026-03-31 0001530766 us-gaap:PatentsMember 2025-12-31 0001530766 us-gaap:TradeNamesMember 2026-03-31 0001530766 us-gaap:TradeNamesMember 2025-12-31 0001530766 us-gaap:DevelopedTechnologyRightsMember 2026-03-31 0001530766 us-gaap:DevelopedTechnologyRightsMember 2025-12-31 0001530766 dei:LegalContactMember 2026-03-31 0001530766 dei:LegalContactMember 2025-12-31 0001530766 us-gaap:PatentsMember 2026-03-31 0001530766 us-gaap:PatentsMember 2025-12-31 0001530766 us-gaap:TradeNamesMember 2026-01-01 2026-03-31 0001530766 us-gaap:DevelopedTechnologyRightsMember 2026-01-01 2026-03-31 0001530766 dei:LegalContactMember 2026-01-01 2026-03-31 0001530766 us-gaap:PatentsMember 2026-01-01 2026-03-31 0001530766 us-gaap:TradeNamesMember 2025-01-01 2025-03-31 0001530766 us-gaap:DevelopedTechnologyRightsMember 2025-01-01 2025-03-31 0001530766 dei:LegalContactMember 2025-01-01 2025-03-31 0001530766 us-gaap:PatentsMember 2025-01-01 2025-03-31 0001530766 STEX:ComplianceFrameworkMember 2026-03-31 0001530766 us-gaap:ComputerEquipmentMember 2026-03-31 0001530766 us-gaap:ComputerEquipmentMember 2025-12-31 0001530766 us-gaap:FurnitureAndFixturesMember 2026-03-31 0001530766 us-gaap:FurnitureAndFixturesMember 2025-12-31 0001530766 STEX:TestingAndDemoEquipmentMember 2026-03-31 0001530766 STEX:TestingAndDemoEquipmentMember 2025-12-31 0001530766 us-gaap:LeaseholdImprovementsMember 2026-03-31 0001530766 us-gaap:LeaseholdImprovementsMember 2025-12-31 0001530766 2026-02-26 0001530766 STEX:SharePurchaseAgreementMember 2025-12-09 2025-12-09 0001530766 STEX:SharePurchaseAgreementMember 2025-12-09 0001530766 STEX:SharePurchaseAgreementMember 2025-12-31 0001530766 STEX:SharePurchaseAgreementMember 2025-01-01 2025-12-31 0001530766 STEX:EmpressRoyaltyCorpMember 2026-01-01 2026-01-31 0001530766 STEX:EmpressRoyaltyCorpMember 2026-01-01 2026-03-31 0001530766 STEX:RestrictedMember 2025-12-31 0001530766 STEX:UnrestrictedMember 2025-12-31 0001530766 srt:MaximumMember STEX:BrinksBaileeAgreementMember 2025-11-04 0001530766 STEX:UnrestrictedMember 2026-02-28 0001530766 STEX:RestrictedGoldMember 2026-02-05 0001530766 2026-02-05 2026-02-05 0001530766 STEX:UnrestrictedMember 2026-03-31 0001530766 STEX:TwoRelatedPartyMember 2026-03-31 0001530766 us-gaap:RelatedPartyMember 2026-01-01 2026-03-31 0001530766 STEX:StreamexLtdMember 2026-01-01 2026-03-31 0001530766 STEX:StreamexLtdMember STEX:ChiefInvestOfficerMember 2026-03-31 0001530766 STEX:StreamexLtdMember STEX:GeneralCounselOfficersMember 2026-03-31 0001530766 STEX:StreamexLtdMember 2026-03-31 0001530766 STEX:PremiumFinanceAgreementMember 2025-08-27 0001530766 STEX:PremiumFinanceAgreementMember 2025-08-27 2025-08-27 0001530766 2025-12-17 0001530766 2025-11-04 0001530766 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2025-11-04 0001530766 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2025-12-17 0001530766 us-gaap:SubsequentEventMember 2027-11-04 0001530766 us-gaap:SubsequentEventMember 2027-12-17 0001530766 us-gaap:SubsequentEventMember 2027-11-04 2027-11-04 0001530766 us-gaap:SubsequentEventMember 2027-12-17 2027-12-17 0001530766 srt:MaximumMember us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001530766 srt:MinimumMember 2026-03-31 0001530766 2026-02-06 0001530766 2026-02-06 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:TradeNamesMember 2025-05-28 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember STEX:DevelopedTechnologyMember 2025-05-28 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember STEX:LegalAndComplianceFrameWorkMember 2025-05-28 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2025-05-28 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputCommonStockPriceMember 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputCommonStockPriceMember 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputIndicatedConversionPriceMember 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputIndicatedConversionPriceMember 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputFloorPriceMember 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputFloorPriceMember 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPrepaymentRateMember 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPrepaymentRateMember 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputPrepaymentPremiumMember 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputPrepaymentPremiumMember 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputRegistrationProbabilityMember 2026-02-06 0001530766 us-gaap:FairValueInputsLevel3Member STEX:MeasurementInputRegistrationProbabilityMember 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001530766 us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0001530766 us-gaap:FairValueInputsLevel3Member 2026-03-31 0001530766 us-gaap:FairValueInputsLevel1Member 2026-03-31 0001530766 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001530766 us-gaap:PreferredStockMember 2026-03-31 0001530766 us-gaap:ConvertiblePreferredStockMember 2026-01-01 2026-03-31 0001530766 us-gaap:ConvertiblePreferredStockMember 2026-03-31 0001530766 us-gaap:InvestorMember 2024-01-12 2024-01-12 0001530766 2024-01-12 0001530766 us-gaap:OverAllotmentOptionMember 2026-01-22 2026-01-22 0001530766 2026-01-22 2026-01-22 0001530766 STEX:SalesAgreementMember 2026-01-01 2026-03-31 0001530766 us-gaap:InvestorMember 2026-03-31 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-09-05 2025-09-05 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-09-04 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-09-05 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-12-30 2025-12-30 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-12-29 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2025-12-30 0001530766 us-gaap:EmployeeStockOptionMember STEX:TwoThousandTwentyThreeLongTermIncentivePlanMember 2026-03-31 2026-03-31 0001530766 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001530766 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001530766 us-gaap:WarrantMember 2026-03-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember 2026-02-01 2026-02-01 0001530766 STEX:CommonStockOneMember 2026-02-01 2026-02-01 0001530766 STEX:CommonStockOneMember 2026-02-01 0001530766 STEX:CommonStockTwoMember 2026-02-01 2026-02-01 0001530766 STEX:CommonStockTwoMember 2026-02-01 0001530766 STEX:CommonStockThreeMember 2026-02-01 2026-02-01 0001530766 STEX:CommonStockThreeMember 2026-02-01 0001530766 STEX:CommonStockFourMember 2026-02-01 2026-02-01 0001530766 STEX:CommonStockFourMember 2026-02-01 0001530766 STEX:CommonStockFiveMember 2026-02-01 2026-02-01 0001530766 STEX:CommonStockFiveMember 2026-02-01 0001530766 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2026-01-01 2026-03-31 0001530766 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2026-01-01 2026-03-31 0001530766 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2026-01-01 2026-03-31 0001530766 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2026-01-01 2026-03-31 0001530766 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2026-01-01 2026-03-31 0001530766 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2026-01-01 2026-03-31 0001530766 us-gaap:PerformanceSharesMember STEX:ShareBasedCompensationAwardTrancheFourMember 2026-01-01 2026-03-31 0001530766 STEX:ShareBasedCompensationAwardTrancheFourMember 2026-01-01 2026-03-31 0001530766 us-gaap:PerformanceSharesMember STEX:ShareBasedCompensationAwardTrancheFiveMember 2026-01-01 2026-03-31 0001530766 STEX:ShareBasedCompensationAwardTrancheFiveMember 2026-01-01 2026-03-31 0001530766 us-gaap:PerformanceSharesMember 2026-01-01 2026-03-31 0001530766 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0001530766 STEX:RestrictedStockOneMember 2026-03-31 0001530766 STEX:RestrictedStockTwoMember 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember 2026-03-16 2026-03-16 0001530766 2026-03-16 2026-03-16 0001530766 us-gaap:CommonStockMember 2026-03-16 2026-03-16 0001530766 2026-03-16 0001530766 us-gaap:PerformanceSharesMember 2026-03-16 2026-03-16 0001530766 STEX:ShareBasedCompensationAwardTrancheMember 2026-03-16 0001530766 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2026-03-16 0001530766 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2026-03-16 0001530766 srt:MaximumMember 2026-01-01 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2026-03-31 0001530766 us-gaap:StockOptionMember 2026-01-01 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2026-01-01 2026-03-31 0001530766 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001530766 STEX:ViralClearMember 2026-01-01 2026-03-31 0001530766 STEX:OptionsUnder999Member 2026-01-01 2026-03-31 0001530766 STEX:OptionsUnder999Member 2026-03-31 0001530766 STEX:Options1000To1999Member 2026-01-01 2026-03-31 0001530766 STEX:Options1000To1999Member 2026-03-31 0001530766 STEX:Options2000To4999Member 2026-01-01 2026-03-31 0001530766 STEX:Options2000To4999Member 2026-03-31 0001530766 STEX:Options5000To6999Member 2026-01-01 2026-03-31 0001530766 STEX:Options5000To6999Member 2026-03-31 0001530766 us-gaap:MeasurementInputSharePriceMember 2026-03-31 0001530766 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2026-03-31 0001530766 us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-03-31 0001530766 us-gaap:MeasurementInputExpectedDividendRateMember 2026-03-31 0001530766 us-gaap:MeasurementInputExpectedTermMember 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt03000Member 2026-03-31 0001530766 STEX:WarrantsAt03000Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt09547Member 2026-03-31 0001530766 STEX:WarrantsAt09547Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt17800Member 2026-03-31 0001530766 STEX:WarrantsAt33640Member 2026-03-31 0001530766 STEX:WarrantsAt33640Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt40660Member 2026-03-31 0001530766 STEX:WarrantsAt40660Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt44550Member 2026-03-31 0001530766 STEX:WarrantsAt44550Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt44660Member 2026-03-31 0001530766 STEX:WarrantsAt44660Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt46626Member 2026-03-31 0001530766 STEX:WarrantsAt46626Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt49252Member 2026-03-31 0001530766 STEX:WarrantsAt49252Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt49290Member 2026-03-31 0001530766 STEX:WarrantsAt49290Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt51358Member 2026-03-31 0001530766 STEX:WarrantsAt51358Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt71810Member 2026-03-31 0001530766 STEX:WarrantsAt71810Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt75020Member 2026-03-31 0001530766 STEX:WarrantsAt75020Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt79630Member 2026-03-31 0001530766 STEX:WarrantsAt79630Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt90000Member 2026-03-31 0001530766 STEX:WarrantsAt90000Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt95960Member 2026-03-31 0001530766 STEX:WarrantsAt95960Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt100992Member 2026-03-31 0001530766 STEX:WarrantsAt100992Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt102600Member 2026-03-31 0001530766 STEX:WarrantsAt102600Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt104678Member 2026-03-31 0001530766 STEX:WarrantsAt104678Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt113000Member 2026-03-31 0001530766 STEX:WarrantsAt113000Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt132800Member 2026-03-31 0001530766 STEX:WarrantsAt132800Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt480000Member 2026-03-31 0001530766 STEX:WarrantsAt480000Member 2026-01-01 2026-03-31 0001530766 STEX:WarrantsAt616000Member 2026-03-31 0001530766 STEX:WarrantsAt616000Member 2026-01-01 2026-03-31 0001530766 STEX:BioSigAIMember 2025-12-31 0001530766 STEX:BioSigAIMember 2025-01-01 2025-12-31 0001530766 STEX:BioSigAIMember 2024-12-31 0001530766 STEX:BioSigAIMember 2026-01-01 2026-03-31 0001530766 STEX:BioSigAIMember 2026-03-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember STEX:ViralClearPharmaceuticalsIncMember 2025-12-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember STEX:ViralClearPharmaceuticalsIncMember 2026-01-01 2026-03-31 0001530766 us-gaap:RestrictedStockUnitsRSUMember STEX:ViralClearPharmaceuticalsIncMember 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember STEX:OneOneTwoThousandTwentySixMember 2026-01-01 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember STEX:OneOneTwoThousandTwentySixMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 STEX:InterimExecutiveChairmanMember STEX:OneEightTwoThousandTwentySixMember 2026-01-01 2026-03-31 0001530766 STEX:InterimExecutiveChairmanMember STEX:OneEightTwoThousandTwentySixMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 STEX:ChiefExecutiveOfficierMember STEX:OneEightTwoThousandTwentySixMember 2026-01-01 2026-03-31 0001530766 STEX:ChiefExecutiveOfficierMember STEX:OneEightTwoThousandTwentySixMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember STEX:OneTwentySevenTwoThousandTwentySixMember 2026-01-01 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember STEX:OneTwentySevenTwoThousandTwentySixMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember STEX:TwoOneTwoThousandTwentySixMember 2026-01-01 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember STEX:TwoOneTwoThousandTwentySixMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember STEX:ThreeThreeTwoThousandTwentySixMember 2026-01-01 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember STEX:ThreeThreeTwoThousandTwentySixMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember STEX:ThreeSixteenTwoThousandTwentySixMember 2026-01-01 2026-03-31 0001530766 STEX:ThirdPartyConsultantMember STEX:ThreeSixteenTwoThousandTwentySixMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 srt:ChiefFinancialOfficerMember STEX:ThreeSixteenTwoThousandTwentySixMember 2026-01-01 2026-03-31 0001530766 srt:ChiefFinancialOfficerMember STEX:ThreeSixteenTwoThousandTwentySixMember us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001530766 srt:MaximumMember 2026-03-31 0001530766 srt:MinimumMember 2026-01-01 2026-03-31 0001530766 us-gaap:StockCompensationPlanMember 2026-01-01 2026-03-31 0001530766 us-gaap:PerformanceSharesMember 2025-12-31 0001530766 STEX:PerformanceSharesAndAUMMember 2025-12-31 0001530766 STEX:PerformanceSharesAndAUMMember 2026-01-01 2026-03-31 0001530766 us-gaap:PerformanceSharesMember 2026-03-31 0001530766 STEX:PerformanceSharesAndAUMMember 2026-03-31 0001530766 STEX:RangeOneMember STEX:ViralClearPharmaceuticalsIncMember 2026-01-01 2026-03-31 0001530766 STEX:BioSigAISciencesIncMember 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-12-31 0001530766 STEX:BioSigAIMember 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2026-01-01 2026-03-31 0001530766 STEX:BioSigAISciencesIncMember 2026-01-01 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-01-01 2025-03-31 0001530766 STEX:BioSigAISciencesIncMember 2025-01-01 2025-03-31 0001530766 STEX:StreamexLtdMember 2025-01-01 2025-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-12-31 0001530766 STEX:BioSigAISciencesIncMember 2025-12-31 0001530766 STEX:StreamexLtdMember 2025-12-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2026-03-31 0001530766 STEX:BioSigAISciencesIncMember 2026-03-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2024-12-31 0001530766 STEX:BioSigAISciencesIncMember 2024-12-31 0001530766 STEX:StreamexLtdMember 2024-12-31 0001530766 STEX:ViralClearPharmaceuticalsIncMember 2025-03-31 0001530766 STEX:BioSigAISciencesIncMember 2025-03-31 0001530766 STEX:StreamexLtdMember 2025-03-31 0001530766 us-gaap:CorporateMember 2026-01-01 2026-03-31 0001530766 us-gaap:CorporateMember 2025-01-01 2025-03-31 0001530766 srt:BoardOfDirectorsChairmanMember us-gaap:SubsequentEventMember 2026-04-17 2026-04-17 0001530766 STEX:ChiefInvestmentOfficerMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2026-04-06 0001530766 STEX:ChiefInvestmentOfficerMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2026-04-06 2026-04-06 0001530766 STEX:ChiefInvestmentOfficerMember STEX:PerformanceVestingRestrictedStockUnitsMember us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember 2026-05-01 0001530766 STEX:ChiefInvestmentOfficerMember us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember 2026-05-01 2026-05-01 0001530766 STEX:ChiefInvestmentOfficerMember us-gaap:ShareBasedCompensationAwardTrancheOneMember us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember 2026-05-01 2026-05-01 0001530766 STEX:ChiefInvestmentOfficerMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember 2026-05-01 2026-05-01 0001530766 STEX:ChiefInvestmentOfficerMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember 2026-05-01 2026-05-01 0001530766 STEX:ChiefInvestmentOfficerMember STEX:ShareBasedCompensationAwardTrancheFourMember us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember 2026-05-01 2026-05-01 0001530766 STEX:ChiefInvestmentOfficerMember STEX:ShareBasedCompensationAwardTrancheFiveMember us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember 2026-05-01 2026-05-01 0001530766 us-gaap:CommonStockMember us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember 2026-04-01 2026-05-14 0001530766 us-gaap:RelatedPartyMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember STEX:EmploymentAgreementMember 2026-04-01 2026-05-14 0001530766 STEX:ThirdPartyMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2026-04-10 2026-04-10 0001530766 STEX:ThirdPartyMember STEX:SixMonthAnniversariesMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2026-04-10 2026-04-10 0001530766 STEX:ThirdPartyMember STEX:TwelveMonthAnniversariesMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2026-04-10 2026-04-10 0001530766 STEX:ThirdPartyMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:SubsequentEventMember 2026-04-06 2026-04-06 0001530766 STEX:ThirdPartyMember us-gaap:RestrictedStockUnitsRSUMember us-gaap:PreferredStockMember us-gaap:SubsequentEventMember 2026-05-01 2026-05-31 iso4217:USD shares iso4217:USD shares pure STEX:Integer false Q1 --12-31 0001530766

10-Q true 2026-03-31 2026 false 001-38659 STREAMEX CORP. DE 26-4333375 2431 Aloma Avenue Suite 243 Winter Park FL 32792 (203) 409-5444 Common Stock, par value $0.001 per share STEX NASDAQ Yes Yes Non-accelerated Filer true false false 104274817 0.001

6859000

20316000

59000 51000

11000

23766000

9706000

23472000

1000000

15220000

17339000

45904000

71895000

15225000

12000

25000

42418000

44639000

69758000

70984000

127413000

115648000

173317000

187543000

907000

66000

3179000

2952000

123000

121000

38021000

1700000

3302000

42794000

10669000

11421000

13971000

54215000

0.001

1000000

4200

105

105000

123000

121000

105000

0.001

1000000

200

600

4200

1400

1000

200000

0.001

500000000

97721696

49805275

98000

50000

924802000

850447000

-1102000

814000

-764813000

-718120000

158985000

133191000

256000

32000

159241000

133223000

173317000

187543000

6000

34254000

2957000

1492000

21000

35746000

2984000

-35746000

-2984000

-12195000

2938000

484000 134000 -497000

-3057000

-119000

199000

73000

-15000

-11513000

184000

-47259000

-2800000

-565000

-46694000

-2800000

-1000

12000

-46693000

-2812000

2000

-46695000

-2814000

-0.27

-0.14

174590397

20787808

-46694000

-2800000

1916000

-48610000

-2800000

-1000

12000

-48609000

-2812000

49805275

50000

850447000

-718120000

814000

32000

133223000

6123941

6000

21455000

21461000

54647

13416667 13000 37171000 37184000

24571166

25000

-25000

3750000 4000 15756000 15760000 225000 225000

2000

-1916000 -1916000

-46693000

-1000

-46694000

97721696

98000

924802000

-764813000

-1102000

256000

159241000

17239096

17000

253784000

-255345000

17000

-1527000

17239096

17000

253784000

-255345000

17000

-1527000

1663543

2000

2072000

2074000

48996

4403166

4000

3878000

3882000

758514

1000

817000

818000

135000 189000 189000

2000

-2812000

12000

-2800000

24248315

24000

260738000

-258157000

29000

2634000

24248315

24000

260738000

-258157000

29000

2634000

-46694000

-2800000

1492000

21000

11979000

-199000

41000

2938000

484000 134000 -497000

-3057000

-119000

25370000

2074000

-565000

-11000

-17000

-9000

1934000

70000

780000

-555000

-42000

-10179000

-1115000

23900000

10190000

25000

26410000

14225000

-1500000

3882000

818000

546000

37184000

225000 38500000

-1637000

4700000

-141000

-13457000

3585000

20316000

142000

6859000

3727000

403000

189000 2000 2000 15760000

<p id="xdx_802_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zyvHyv31QSV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">NOTE 1 – NATURE OF OPERATIONS Business and organization Streamex Corp. (the “Company”, “we”, “us” and “our”) is a technology company with two principal lines of business: (i) digital infrastructure focused on the tokenization and exchange of real-world assets and other commodity-linked financial products and (ii) biomedical technology focused on advanced signal acquisition and processing solutions in electrophysiology through our PURE EP™ platform. On May 28, 2025, the Company acquired Streamex Exchange Corporation (“Streamex Exchange”), a software development company based in Vancouver, British Columbia. In connection with this strategic expansion, on September 12, 2025, the Company changed its corporate name from BioSig Technologies, Inc. to Streamex Corp., and effective September 12, 2025, the Company’s common stock began trading on The Nasdaq Capital Market under the ticker symbol “STEX” (formerly “BSGM”). On May 28, 2025, the Company completed the acquisition of Streamex Exchange pursuant to that certain Share Purchase Agreement dated as of May 23, 2025 (as amended on May 27, 2025, the “Share Purchase Agreement”) by and among the Company, BST Sub ULC, an unlimited liability company organized under the laws of the Province of British Columbia and a wholly owned subsidiary of the Company (“ExchangeCo”), 1540875 B.C. Ltd., a British Columbia company and a wholly owned subsidiary of the Company (“Callco”), the shareholders of Streamex Exchange, and 1540873 B.C. Ltd., as trustee (the “Trustee”) under the exchange rights agreement entered into among the Company, ExchangeCo, Callco, and the Trustee (the “Exchange Rights Agreement”). The Company continues to evaluate opportunities for its subsidiaries ViralClear Pharmaceuticals, Inc. (“ViralClear”) and BioSig AI Sciences, Inc. (“BioSig AI”). As of March 31, 2026 and December 31, 2025, the Company held a majority interest of approximately <span id="xdx_90B_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ViralClearMember_zNl1Ehci4I61" title="Equity method investment, ownership percentage">70% in ViralClear. As of March 31, 2026, and December 31, 2025, the Company held a majority interest of approximately <span id="xdx_903_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BioSigAIMember_z9TUhCRi7fX2" title="Equity method investment, ownership percentage">84% in BioSig AI. During the three months ended March 31, 2026, the Company, through Streamex Ltd., a Cayman Islands special-purpose entity consolidated as a variable interest entity, acquired approximately $15,225 of gold bullion to support the GLDY Token program. As of March 31, 2026, the Company held approximately <span id="xdx_903_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20260331__us-gaap--BusinessAcquisitionAxis__custom--GLDYServiceCoLLCMember_zoqMBQs5OQnh" title="Variable interest entity acquired, percentage">98.5% of outstanding GLDY Tokens. Two related party officers of the Company subscribed for an aggregate of approximately $<span id="xdx_906_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn3n3_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--GLDYServiceCoLLCMember_zud1meW3BHvf" title="Variable interest entity acquired">225 of GLDY Tokens during March 2026. The Company also formed GLDY ServiceCo, LLC, a wholly owned subsidiary that acts as servicer to Streamex Ltd. under a servicing arrangement.

0.70

0.84

15225000

0.985

225000

NOTE 2 – LIQUIDITY As of March 31, 2026, we had working capital of approximately $42,602 and cash of $6,859. For the three months ended March 31, 2026, we used $10,179 in operating activities, used $1,500 in investing activities, and used $1,637 in financing activities, primarily reflecting the repayment of the remaining outstanding balance on the secured convertible debentures of approximately $38.5 million, substantially offset by net proceeds of approximately $37.2 million from an underwritten public offering completed in January 2026. During the three months ended March 31, 2026, the Company strengthened its liquidity position through financing transactions and asset monetization activities and eliminated its outstanding convertible debt. In January 2026, the Company completed an underwritten public offering generating net proceeds of approximately $37.2 million. The Company also received approximately $10.1 million from the sale of marketable securities and approximately $26.4 million from the sale of gold bullion that had been classified as held for sale as of December 31, 2025. In February 2026, following a partial conversion of the secured convertible debentures into common stock, the Company repaid the remaining outstanding balance for an aggregate cash payment of approximately $38.5 million, and all related security interests were released. We expect to continue incurring operating losses and negative cash flows until our products, including the Streamex Exchange’s digital asset infrastructure and PURE EP™ Platform initiatives, achieve sustained commercial success. Although the PURE EP™ Platform is commercially available, revenues to date have not been material, and the timing and extent of future revenues remain uncertain. The Company launched GLDY and began accepting subscriptions; however, revenues to date have not been material. We expect to incur additional costs related to software development, regulatory compliance, and strategic partnerships prior to the commencement of any material revenue-generating activities. The timing and extent of any future revenues will depend on, among other things, continued investor adoption of GLDY, completion of development milestones, regulatory considerations, market conditions, and the successful commercialization of the Streamex Exchange platform and related offerings. Based on our existing cash and working capital position, management believes that the Company has the ability to continue as a going concern for at least one year from the issuance date of the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. The Company believes it will have sufficient liquidity to meet its anticipated working capital requirements, capital expenditures, and other liquidity needs during that period.

42602000

6859000

-10179000

-1500000

-1637000

38500000

37200000

10100000

26400000

38500000

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2025. Basis of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Streamex Corp. and its consolidated subsidiaries, including variable interest entities (“VIEs”) for which the Company is determined to be the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. Noncontrolling interests represent the portion of equity interests in consolidated subsidiaries not attributable to the Company and are reported as a separate component of stockholders’ equity. During the three months ended March 31, 2026, the Company determined that it became the primary beneficiary of Streamex Ltd., a Cayman Islands exempted company, under the VIE model in ASC 810, Consolidation. The Company became the primary beneficiary upon the formation and initial capitalization of Streamex Ltd. in February 2026, at which time the Company obtained the power to direct the activities of Streamex Ltd. that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, Streamex Ltd. has been consolidated from the date the Company became the primary beneficiary. See Note 9, Streamex Ltd. (VIE), for additional information. Use of estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Changes in circumstances could cause actual results to differ materially from these estimates. Foreign Currency Translation The functional currency of the Company’s Canadian subsidiary, ExchangeCo, is the Canadian dollar. Assets and liabilities denominated in Canadian dollars are translated into U.S. dollars at the exchange rate in effect at the balance sheet date, while revenues and expenses are translated at the average exchange rate for the period. Resulting translation adjustments are recorded in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. Marketable Securities The Company’s marketable securities consist of equity securities measured at fair value with changes in fair value recognized in earnings, in accordance with ASC 321, Investments — Equity Securities. Fair value is determined using quoted market prices in active markets (Level 1). Gold Assets The Company, through its consolidated variable interest entity Streamex Ltd., holds physical gold bullion. Gold purchased for the purpose of backing GLDY Token obligations is recorded at cost, which includes the purchase price and directly attributable transaction costs, and is classified as “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet. The Company classifies the gold as a non-current asset because the gold is acquired and held to support the long-term GLDY Token program and related leasing activities, and management does not expect to liquidate the gold within the next twelve months. The gold is accounted for as a long-lived tangible asset within the scope of ASC 360. Cost is determined on a specific identification basis. Ongoing storage, insurance, and administrative custody costs are expensed as incurred. Management evaluates the gold for impairment under ASC 360-10-35 when events or changes in circumstances indicate that the carrying amount may not be recoverable. Such events may include, among other factors, a significant decline in market prices, adverse changes in legal, regulatory, or custodial conditions, or other factors affecting the Company’s ability to access or realize economic benefits from the asset. The Company considers both market-based and asset-specific factors in assessing whether an impairment indicator exists. Once classified as held for sale, the gold is carried at the lower of carrying amount or fair value less cost to sell, with any write-downs recognized in earnings and subsequent increases recognized only to the extent of previously recognized losses. No impairment charges were recorded during the three months ended March 31, 2026. Gold that has been committed for sale or that management has committed to a plan of sale is reclassified to “Other assets held for sale” and measured at the lower of carrying amount or fair value less costs to sell in accordance with ASC 360. Concentration of Assets As of March 31, 2026, the Company’s consolidated assets totaled $173,317, of which approximately 33% ($56,387) were located in the United States and 67% ($116,930) were located in Canada. The Canadian assets are held through ExchangeCo, a wholly owned subsidiary of the Company, and relate to the Company’s Streamex Exchange business. These assets consist primarily of goodwill and intangible assets ($111,931), cash ($4,907), sales tax receivable ($59), and prepaid expenses and other assets ($33). As of March 31, 2026, the Company’s cash of $6,859 was held across the following jurisdictions: approximately $1,952 in the United States (including $60 held by Streamex Ltd., the Company’s consolidated VIE, in accounts in the United States and the Cayman Islands), and approximately $4,907 in Canada through ExchangeCo. Cash held in Canada is denominated primarily in U.S. dollars and is not subject to material repatriation restrictions. The Company evaluates geographic concentrations in accordance with ASC 275, Risks and Uncertainties, and considers potential exposure to economic, regulatory, and currency-related risks. While the Canadian-based assets represent a significant portion of consolidated assets, they are not currently subject to material operational, legal, or foreign exchange restrictions. Management believes that the Company is not exposed to heightened risk from geographic concentration, given the nature of the assets, the stability of the Canadian jurisdiction, and the strategic alignment of the Streamex Exchange business with the Company’s broader operations. Net Income (loss) Per Common Share The Company computes earnings (loss) per share in accordance with Accounting Standards Codification subtopic 260, Earnings Per Share (“ASC 260”). Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to the Company’s common stockholders by the weighted-average number of shares of common stock outstanding during the period, including exchangeable shares that are economically equivalent to the Company’s common stock. The Company has outstanding exchangeable shares issued by a consolidated subsidiary that are economically equivalent to the Company’s common stock in all material respects, including rights to dividends and participation in earnings, and are exchangeable on a one-for-one basis into shares of the Company’s common stock at the option of the holders. The exchangeable shares are classified within stockholders’ equity and are included in the weighted-average shares outstanding used in the calculation of basic earnings (loss) per common share because these shares participate equally with the Company’s common stock in undistributed net income (loss). Diluted earnings per common share is computed by giving effect to all potentially dilutive securities and other contracts to issue common stock using the treasury stock method and the if-converted method, as applicable, in accordance with ASC 260. Potentially dilutive securities may include stock options, warrants, restricted stock units, and other equity awards (treasury stock method), as well as the Company’s convertible preferred stock and convertible debt, including the secured convertible debentures (if-converted method). Under the if-converted method, convertible instruments are assumed to have been converted at the beginning of the period (or at issuance, if later), and related preferred dividends and/or interest expense (net of tax), as applicable, are adjusted in the determination of net income available to common stockholders. In periods in which the Company reports a net loss, basic and diluted loss per share are the same, as the inclusion of stock options, warrants, restricted stock units, convertible preferred stock, convertible debt and other potentially dilutive securities would be antidilutive. Accordingly, such securities are excluded from the computation of diluted loss per share. <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zyrXwBhx1Xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20260101__20260331_zEFHQy3vyYqb" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20250101__20250331_zJrIiRundIM3" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqqe5CZcLAJc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Series C convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">434,845</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">564,234</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zQd4PGjfciSe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,921,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,486,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PerformanceBasedRestrictedStockUnitMember_zMhMb6CnDzJe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Performance-based restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zIwzdbEwEys1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,647,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,577,260</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zWFtuuuvOFdj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted stock units to acquire common stock</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,583,375</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,160,830</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zr0s63fSFxNf" style="vertical-align: bottom; background-color: White"> <td>Totals</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">11,087,105</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">9,788,324</td><td style="text-align: left"> </td></tr> </table> Recently adopted accounting pronouncements In July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This standard provides all entities with a practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the current accounts receivable and current contract assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2025-05 in 2026 and the adoption had no material impact on our unaudited condensed consolidated financial statements. Recently issued accounting pronouncements not yet adopted In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 requires disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement and disclosures about selling expenses. As amended by ASU 2025-01, ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating ASU 2024-03 and does not expect it to have a material effect on the Company’s unaudited condensed consolidated financial statements. In May 2025, the FASB issued ASU No. 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity (“VIE”), which provides clarifying guidance on determining the accounting acquirer in certain transactions involving VIEs. The update aims to improve consistency and comparability in financial reporting. The guidance will be effective for annual periods beginning after December 15, 2026, including interim periods within those annual periods. Early adoption is permitted. Upon adoption, the guidance will be applied prospectively. The Company is currently evaluating the provisions of the amendments and the impact on its future financial statements. In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, to modernize the accounting guidance for internal-use software costs. The standard removes all references to software development project stages and instead requires capitalization when (i) management has authorized and committed to funding the software project and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-06.

Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2025.

Basis of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Streamex Corp. and its consolidated subsidiaries, including variable interest entities (“VIEs”) for which the Company is determined to be the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. Noncontrolling interests represent the portion of equity interests in consolidated subsidiaries not attributable to the Company and are reported as a separate component of stockholders’ equity. During the three months ended March 31, 2026, the Company determined that it became the primary beneficiary of Streamex Ltd., a Cayman Islands exempted company, under the VIE model in ASC 810, Consolidation. The Company became the primary beneficiary upon the formation and initial capitalization of Streamex Ltd. in February 2026, at which time the Company obtained the power to direct the activities of Streamex Ltd. that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, Streamex Ltd. has been consolidated from the date the Company became the primary beneficiary. See Note 9, Streamex Ltd. (VIE), for additional information.

Use of estimates The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Changes in circumstances could cause actual results to differ materially from these estimates.

Foreign Currency Translation The functional currency of the Company’s Canadian subsidiary, ExchangeCo, is the Canadian dollar. Assets and liabilities denominated in Canadian dollars are translated into U.S. dollars at the exchange rate in effect at the balance sheet date, while revenues and expenses are translated at the average exchange rate for the period. Resulting translation adjustments are recorded in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity.

Marketable Securities The Company’s marketable securities consist of equity securities measured at fair value with changes in fair value recognized in earnings, in accordance with ASC 321, Investments — Equity Securities. Fair value is determined using quoted market prices in active markets (Level 1).

Gold Assets The Company, through its consolidated variable interest entity Streamex Ltd., holds physical gold bullion. Gold purchased for the purpose of backing GLDY Token obligations is recorded at cost, which includes the purchase price and directly attributable transaction costs, and is classified as “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet. The Company classifies the gold as a non-current asset because the gold is acquired and held to support the long-term GLDY Token program and related leasing activities, and management does not expect to liquidate the gold within the next twelve months. The gold is accounted for as a long-lived tangible asset within the scope of ASC 360. Cost is determined on a specific identification basis. Ongoing storage, insurance, and administrative custody costs are expensed as incurred. Management evaluates the gold for impairment under ASC 360-10-35 when events or changes in circumstances indicate that the carrying amount may not be recoverable. Such events may include, among other factors, a significant decline in market prices, adverse changes in legal, regulatory, or custodial conditions, or other factors affecting the Company’s ability to access or realize economic benefits from the asset. The Company considers both market-based and asset-specific factors in assessing whether an impairment indicator exists. Once classified as held for sale, the gold is carried at the lower of carrying amount or fair value less cost to sell, with any write-downs recognized in earnings and subsequent increases recognized only to the extent of previously recognized losses. No impairment charges were recorded during the three months ended March 31, 2026. Gold that has been committed for sale or that management has committed to a plan of sale is reclassified to “Other assets held for sale” and measured at the lower of carrying amount or fair value less costs to sell in accordance with ASC 360. Concentration of Assets As of March 31, 2026, the Company’s consolidated assets totaled $173,317, of which approximately 33% ($56,387) were located in the United States and 67% ($116,930) were located in Canada. The Canadian assets are held through ExchangeCo, a wholly owned subsidiary of the Company, and relate to the Company’s Streamex Exchange business. These assets consist primarily of goodwill and intangible assets ($111,931), cash ($4,907), sales tax receivable ($59), and prepaid expenses and other assets ($33). As of March 31, 2026, the Company’s cash of $6,859 was held across the following jurisdictions: approximately $1,952 in the United States (including $60 held by Streamex Ltd., the Company’s consolidated VIE, in accounts in the United States and the Cayman Islands), and approximately $4,907 in Canada through ExchangeCo. Cash held in Canada is denominated primarily in U.S. dollars and is not subject to material repatriation restrictions. The Company evaluates geographic concentrations in accordance with ASC 275, Risks and Uncertainties, and considers potential exposure to economic, regulatory, and currency-related risks. While the Canadian-based assets represent a significant portion of consolidated assets, they are not currently subject to material operational, legal, or foreign exchange restrictions. Management believes that the Company is not exposed to heightened risk from geographic concentration, given the nature of the assets, the stability of the Canadian jurisdiction, and the strategic alignment of the Streamex Exchange business with the Company’s broader operations.

173317000

0.33

56387000

0.67

116930000

111931000

4907000

59000

33000

6859000

1952000

60000

4907000

Net Income (loss) Per Common Share The Company computes earnings (loss) per share in accordance with Accounting Standards Codification subtopic 260, Earnings Per Share (“ASC 260”). Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to the Company’s common stockholders by the weighted-average number of shares of common stock outstanding during the period, including exchangeable shares that are economically equivalent to the Company’s common stock. The Company has outstanding exchangeable shares issued by a consolidated subsidiary that are economically equivalent to the Company’s common stock in all material respects, including rights to dividends and participation in earnings, and are exchangeable on a one-for-one basis into shares of the Company’s common stock at the option of the holders. The exchangeable shares are classified within stockholders’ equity and are included in the weighted-average shares outstanding used in the calculation of basic earnings (loss) per common share because these shares participate equally with the Company’s common stock in undistributed net income (loss). Diluted earnings per common share is computed by giving effect to all potentially dilutive securities and other contracts to issue common stock using the treasury stock method and the if-converted method, as applicable, in accordance with ASC 260. Potentially dilutive securities may include stock options, warrants, restricted stock units, and other equity awards (treasury stock method), as well as the Company’s convertible preferred stock and convertible debt, including the secured convertible debentures (if-converted method). Under the if-converted method, convertible instruments are assumed to have been converted at the beginning of the period (or at issuance, if later), and related preferred dividends and/or interest expense (net of tax), as applicable, are adjusted in the determination of net income available to common stockholders. In periods in which the Company reports a net loss, basic and diluted loss per share are the same, as the inclusion of stock options, warrants, restricted stock units, convertible preferred stock, convertible debt and other potentially dilutive securities would be antidilutive. Accordingly, such securities are excluded from the computation of diluted loss per share. <p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zyrXwBhx1Xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20260101__20260331_zEFHQy3vyYqb" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20250101__20250331_zJrIiRundIM3" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqqe5CZcLAJc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Series C convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">434,845</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">564,234</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zQd4PGjfciSe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,921,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,486,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PerformanceBasedRestrictedStockUnitMember_zMhMb6CnDzJe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Performance-based restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zIwzdbEwEys1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,647,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,577,260</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zWFtuuuvOFdj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted stock units to acquire common stock</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,583,375</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,160,830</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zr0s63fSFxNf" style="vertical-align: bottom; background-color: White"> <td>Totals</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">11,087,105</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">9,788,324</td><td style="text-align: left"> </td></tr> </table>

<p id="xdx_891_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zyrXwBhx1Xk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49E_20260101__20260331_zEFHQy3vyYqb" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_499_20250101__20250331_zJrIiRundIM3" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zqqe5CZcLAJc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Series C convertible preferred stock</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">434,845</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">564,234</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zQd4PGjfciSe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,921,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,486,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PerformanceBasedRestrictedStockUnitMember_zMhMb6CnDzJe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Performance-based restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zIwzdbEwEys1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,647,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,577,260</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zWFtuuuvOFdj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Restricted stock units to acquire common stock</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,583,375</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,160,830</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zr0s63fSFxNf" style="vertical-align: bottom; background-color: White"> <td>Totals</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">11,087,105</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">9,788,324</td><td style="text-align: left"> </td></tr> </table>

434845

564234

2921000

2486000

1500000

1647885

5577260

4583375

1160830

11087105

9788324

Recently adopted accounting pronouncements In July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This standard provides all entities with a practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the current accounts receivable and current contract assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2025-05 in 2026 and the adoption had no material impact on our unaudited condensed consolidated financial statements.

Recently issued accounting pronouncements not yet adopted In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 requires disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement and disclosures about selling expenses. As amended by ASU 2025-01, ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating ASU 2024-03 and does not expect it to have a material effect on the Company’s unaudited condensed consolidated financial statements. In May 2025, the FASB issued ASU No. 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity (“VIE”), which provides clarifying guidance on determining the accounting acquirer in certain transactions involving VIEs. The update aims to improve consistency and comparability in financial reporting. The guidance will be effective for annual periods beginning after December 15, 2026, including interim periods within those annual periods. Early adoption is permitted. Upon adoption, the guidance will be applied prospectively. The Company is currently evaluating the provisions of the amendments and the impact on its future financial statements. In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, to modernize the accounting guidance for internal-use software costs. The standard removes all references to software development project stages and instead requires capitalization when (i) management has authorized and committed to funding the software project and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-06.

NOTE 4 – BUSINESS ACQUISITION Streamex Exchange Corporation Transaction Overview On <span id="xdx_906_eus-gaap--BusinessAcquisitionDateOfAcquisitionAgreement1_dd_c20250528__20250528__us-gaap--BusinessAcquisitionAxis__custom--StreamexExchangeCorporationMember_zStGvRIUsxxe" title="Business acquisition, date">May 28, 2025, the Company completed the acquisition of Streamex Exchange, a software development company based in Vancouver, British Columbia, specializing in digital tools for commodity trading and finance. The acquisition was effected pursuant to the Share Purchase Agreement dated May 23, 2025, as amended on May 27, 2025, by and among the Company, its wholly-owned subsidiaries ExchangeCo and Callco, the Streamex Exchange Shareholders, and 1540873 B.C. Ltd., as trustee under the Exchange Rights Agreement. Under the terms of the Share Purchase Agreement, ExchangeCo acquired all of the issued and outstanding shares of Streamex Exchange (the “Purchased Shares”) in exchange for <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250528__20250528__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zZr3BjTuXerj" title="Exchangeable shares">109,070,079 Exchangeable Shares of ExchangeCo, issued at a ratio of 2.046862 Exchangeable Shares per Purchased Share. The Exchangeable Shares are exchangeable on a one-for-one basis for shares of the Company’s common stock, subject to certain adjustments and conditions described below. The purpose of the Acquisition was to enhance shareholder value by combining with a privately held operating company and positioning the combined entity for future growth with expansion into digital commodity trading and blockchain-based financial technologies. The acquisition was undertaken to expand the Company’s technology platform into digital commodity trading and blockchain-based financial infrastructure and to obtain the assembled workforce, intellectual property, and regulatory capabilities of Streamex Exchange. In connection with the transaction, the Company evaluated the accounting under ASC 805, Business Combinations, and ASC 810, Consolidation. The Company concluded the acquired set met the definition of a business. In making this determination, the Company considered the concentration test in ASC 805 and determined that substantially all of the fair value of the gross assets acquired was not concentrated in a single identifiable asset or group of similar identifiable assets. The Company also evaluated whether the acquiree is a variable interest entity (“VIE”) and concluded Streamex Exchange is a VIE because, among other factors, it lacked sufficient equity at risk to finance its activities without additional subordinated financial support and the equity holders, as a group, did not have substantive power to direct the activities that most significantly impact economic performance at the acquisition date. The Company concluded it is the primary beneficiary because it has both (i) the power to direct the activities that most significantly impact Streamex’s economic performance through governance rights in place at closing and (ii) the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, the transaction is accounted for as a business combination with the Company as the accounting acquirer, and Streamex Exchange has been consolidated in the Company’s financial statements from the acquisition date. Shareholder Approval and Contingent Features Initially, the Exchangeable Shares were not exchangeable into more than 19.99% of the Company’s outstanding common stock on a pre-transaction basis, in accordance with Nasdaq listing rules. Following the closing, the Company sought stockholder approval for certain matters related to the transaction, including the issuance of shares of common stock exchangeable for Exchangeable Shares, the issuance of shares underlying the Convertible Debentures, increases to the authorized share count and the 2023 Long-Term Incentive Plan, and amendments to the Company’s Amended and Restated Certificate of Incorporation. At the special meeting of stockholders held on September 5, 2025, all proposals except the issuance of shares exchangeable for Exchangeable Shares (Proposal A) were approved. Proposal A was subsequently approved on November 4, 2025. Following stockholder approval of Proposal A on November 4, 2025, and subject to the terms of the Exchange Rights Agreement, the holders of Exchangeable Shares are entitled to exchange such shares for an aggregate of 109,070,079 shares of the Company’s common stock representing up to 75% of the Company’s fully diluted common stock as of the Share Purchase Agreement date. Consideration Transferred The fair value of the consideration transferred was $105,498, consisting entirely of Exchangeable Shares issued by ExchangeCo. Due to the lack of an active market for the Exchangeable Shares and the contingent nature of their conversion, a fundamentals-based valuation approach was used to estimate the fair value of the consideration. The contingent consideration related to the potential adjustment of the Exchange Ratio from 1.0 to 1.25—triggered if shareholder approval is not obtained within six months following the closing date—was not included in the purchase consideration as of May 28, 2025. As stockholder approval was obtained on November 4, 2025, within six months of the closing date, the exchange ratio adjustment was not triggered, and no additional consideration was required. For an overview of the Company’s derivative financial instruments and related disclosures required by ASC 815, see Note 11, Convertible Debentures and Related Derivative Instruments. See Note 12, Fair Value Measurements and Note 13, Stockholders’ Equity. On November 4, 2025, the Company received shareholder approval for the issuance of our shares of common stock exchangeable for Exchangeable Shares and one share of Special Voting Preferred Stock in connection with the Share Purchase Agreement. As a result, the conversion cap was removed, and Streamex Exchange shareholders may convert their Exchangeable Shares into the Company’s common stock. Concurrently, the derivative liability associated with the Exchangeable Shares was reclassified to permanent equity. As a result of the reclassification, the Exchangeable Shares are classified as permanent equity and are presented within stockholders’ equity in the consolidated balance sheet. No derivative liability related to the Exchangeable Shares remained outstanding as of March 31, 2026 or December 31, 2025. Although the Exchangeable Shares were reclassified to permanent equity upon stockholder approval on November 4, 2025, the consideration transferred for purposes of the acquisition date purchase price allocation reflects the fair value of the Exchangeable Shares as of May 28, 2025. In connection with the acquisition of Streamex Exchange, the Company incurred total acquisition-related costs of $5.9 million during the year ended December 31, 2025. These costs primarily consisted of legal, accounting, and consulting fees directly attributable to the transaction. Included in this amount was the issuance of <span id="xdx_903_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--BusinessAcquisitionAxis__custom--ThirdpartyConsultantsMember_zvz9jN0Afowh" title="Business acquisition issuance of shares">200,000 shares of the Company’s common stock to a third-party consultant, valued at $<span id="xdx_905_eus-gaap--BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_iI_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--BusinessAcquisitionAxis__custom--ThirdpartyConsultantsMember_zAplZIWVEreg" title="Business acquisition issuance of shares, value">1,010 based on the grant-date fair value and the expected issuance of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--ThirdpartyConsultantsMember_zNfvHTmFayi8" title="Number of shares issuance for acquisitions">824,052 shares of the Company’s common stock to third party consultants in connection with a finders fee, valued at $4,820. These costs were expensed as incurred and are reflected in general and administrative expenses in the Unaudited Condensed Consolidated Statements of Operations. Purchase Price Allocation The Company applied the acquisition method of accounting in accordance with ASC 805, Business Combinations (“ASC 805”) and recognized assets acquired and liabilities assumed at their estimated fair value as of the date of acquisition, with the excess purchase consideration recorded to goodwill. During the three months ended March 31, 2026, the Company completed its assessment of the fair values of the assets acquired and liabilities assumed in connection with the acquisition of Streamex Exchange. No measurement period adjustments were recorded during the three months ended March 31, 2026. The Acquisition was recorded as a business combination based on a valuation of assets acquired and liabilities assumed at their acquisition date fair values using unobservable inputs that are supported by little or no market activity and are significant to their fair value of the assets and liabilities (“Level 3” inputs). Goodwill represents the excess of the purchase price consideration over the valuation of the net assets acquired. <p id="xdx_898_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zR3nVOQQdh7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The final allocation of the purchase consideration is as follows: SCHEDULE OF TANGIBLE AND IDENTIFIABLE INTANGIBLE ASSETS ACQUIRED AND LIABILITIES ASSUMED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Amount Recognized as of the Acquisition Date (In Thousands)</td><td> </td> <td colspan="2" id="xdx_490_20250528_znzzs9dxtaCb" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Assets acquired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_maBCRIAzypu_zEuQc3q9L69i" style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: justify">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">366</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueFromRelatedParty_iI_pn3n3_maBCRIAzypu_zIAANN4bHsSa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Due from related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSalesTaxReceivable_iI_pn3n3_maBCRIAzypu_z9CrorLorNG6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Sales tax receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_pn3n3_maBCRIAzypu_zdWMoVp0uAfe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeName_iI_pn3n3_maBCRIAzypu_zBLXUoWnp5j1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trade name</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,100</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDevelopedTechnology_iI_pn3n3_maBCRIAzypu_zP9d8XV1QJnl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Developed technology</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLegalAndComplianceFramework_iI_pn3n3_maBCRIAzypu_zSC9X4N2fLQ8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Legal and compliance framework</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_iI_pn3n3_maBCRIAzypu_zCi5ZLPzaYV4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Goodwill</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">70,435</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_mtBCRIAzypu_maBCRIAzqkD_zc4Eb25HvmQa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total assets acquired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">118,348</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Liabilities assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_iNI_di_maBCRIAzdzv_zzA8tC59hedf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accounts payable and accrued expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(262</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_di_maBCRIAzdzv_zCKQaIrZKXGb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred tax liability</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,588</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNTI_pn3n3_di_mtBCRIAzdzv_msBCRIAzqkD_zNewSp05GPNk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total liabilities assumed</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,850</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pn3n3_mtBCRIAzqkD_z95rWvmwv4Qg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Net assets acquired</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">105,498</td><td style="text-align: left"> </td></tr> </table> Deferred tax liability In connection with the acquisition of Streamex Exchange, the transaction was structured as a stock acquisition for both U.S. and Canadian tax purposes. No election was made under IRC §338(g); therefore, no step-up in the tax basis of the acquired assets was obtained in either jurisdiction. The purchase price allocation created taxable temporary differences related to identifiable intangible assets, resulting in a deferred tax liability of approximately $12,588, measured using the enacted combined Canadian federal and provincial rate of 26.5%. Because these deferred tax liabilities arise in a separate foreign jurisdiction, they cannot offset deferred tax assets of the U.S. parent. The corresponding increase in goodwill was recognized as part of purchase accounting. Intangible Assets The Company identified the following finite-lived intangible assets: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Trade Name: Valued at $<span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250528__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zAWUF08TzGcf" title="Finite lived intangible assets">5,100 using the relief-from-royalty method, applying a 1.0% royalty rate and a 40.5% discount rate. The trade name is expected to be utilized over a <span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250528__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zRgjy6FXSnLa" title="Estimated useful lives">10-year period and is amortized accordingly.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Developed Technology</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Comprised of two distinct components, both valued using the multi-period excess earnings method (MPEEM) and amortized over <span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250528__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_z13MuUvLDegj" title="Estimated useful lives">8 years:</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Securitization Platform: Valued at $<span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250528__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SecuritizationPlatformMember_zuGhwkhqLQNl" title="Finite lived intangible assets">31,100, representing proprietary protocols and infrastructure enabling the tokenization of real-world assets and integration with decentralized finance platforms.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Blockchain Integration: Valued at $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250528__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--BlockchainIntegrationMember_zTuv02K8yNjh" title="Finite lived intangible assets">8,900, reflecting proprietary systems facilitating token creation and secondary market trading through blockchain-based platforms.</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Legal and Compliance Framework: Valued at $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250528__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_z8yuWhc15COl" title="Finite lived intangible assets">2,400 using the cost approach, based on the estimated cost to recreate the regulatory and legal infrastructure necessary for operations. The asset has a useful life of 7 years and is amortized accordingly. The legal and compliance framework supports the Company’s ability to operate in regulated jurisdictions and reduce legal and regulatory risk exposure.</td></tr> </table> Goodwill Goodwill of $70,435 represents the excess of the purchase consideration over the fair value of net assets acquired and was recognized in connection with the acquisition. None of the goodwill is expected to be deductible for tax purposes. The goodwill is assigned to the consolidated reporting unit, as the Company operates as a single segment. The goodwill primarily represents expected synergies, assembled workforce, and future growth potential. No goodwill arose from step acquisitions or noncontrolling interests.

2025-05-28

109070079

2.046862

109070079

105498000

5900000

200000

1010

824052

4820

<p id="xdx_898_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zR3nVOQQdh7l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The final allocation of the purchase consideration is as follows: SCHEDULE OF TANGIBLE AND IDENTIFIABLE INTANGIBLE ASSETS ACQUIRED AND LIABILITIES ASSUMED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Amount Recognized as of the Acquisition Date (In Thousands)</td><td> </td> <td colspan="2" id="xdx_490_20250528_znzzs9dxtaCb" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Assets acquired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pn3n3_maBCRIAzypu_zEuQc3q9L69i" style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: justify">Cash</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">366</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDueFromRelatedParty_iI_pn3n3_maBCRIAzypu_zIAANN4bHsSa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Due from related party</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSalesTaxReceivable_iI_pn3n3_maBCRIAzypu_z9CrorLorNG6" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Sales tax receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_pn3n3_maBCRIAzypu_zdWMoVp0uAfe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Prepaid expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradeName_iI_pn3n3_maBCRIAzypu_zBLXUoWnp5j1" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Trade name</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,100</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDevelopedTechnology_iI_pn3n3_maBCRIAzypu_zP9d8XV1QJnl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Developed technology</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLegalAndComplianceFramework_iI_pn3n3_maBCRIAzypu_zSC9X4N2fLQ8" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Legal and compliance framework</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_iI_pn3n3_maBCRIAzypu_zCi5ZLPzaYV4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Goodwill</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">70,435</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iTI_pn3n3_mtBCRIAzypu_maBCRIAzqkD_zc4Eb25HvmQa" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total assets acquired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">118,348</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Liabilities assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayableAndAccruedExpenses_iNI_di_maBCRIAzdzv_zzA8tC59hedf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accounts payable and accrued expenses</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(262</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_di_maBCRIAzdzv_zCKQaIrZKXGb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Deferred tax liability</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12,588</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_iNTI_pn3n3_di_mtBCRIAzdzv_msBCRIAzqkD_zNewSp05GPNk" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total liabilities assumed</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(12,850</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pn3n3_mtBCRIAzqkD_z95rWvmwv4Qg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Net assets acquired</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">105,498</td><td style="text-align: left"> </td></tr> </table>

366000

11000 14000

22000

5100000 40000000 2400000 70435000

118348000

262000

12588000

12850000

105498000

12588000

0.265

5100000

0.010 0.405

P10Y

P8Y

31100000

8900000

2400000

70435000

NOTE 5 – GOODWILL AND INTANGIBLE ASSETS Goodwill The following table shows the changes in the carrying amount of goodwill for the period: SCHEDULE OF CARRYING AMOUNT OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; font-weight: bold">Goodwill as of December 31, 2025 (1)</td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iS_pn3n3_c20260101__20260331_fMQ_____zZ7tJSPaGMLb" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Goodwill, beginning">70,984</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Acquisition</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--GoodwillAcquiredDuringPeriod_pn3n3_c20260101__20260331_zrbKbKyyObki" style="text-align: right" title="Acquisition">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Impairment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20260101__20260331_zt3F5RO0qUTg" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency translation adjustment</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_pn3n3_c20260101__20260331_zvyGeCjFEFjj" style="border-bottom: Black 1pt solid; text-align: right" title="Foreign currency translation adjustment">(1,226</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Goodwill as of March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--Goodwill_iE_pn3n3_c20260101__20260331_zhakhLbZJ3x7" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, ending">69,758</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Related to the acquisition of the Streamex Exchange. See Note 4 for more details. Goodwill was initially measured in the functional currency of Streamex Exchange and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in foreign exchange rates are reflected in the cumulative translation adjustment within other comprehensive loss.</td></tr> </table> During the three months ended March 31, 2026, the Company evaluated the existence of any indicators of impairment in accordance with ASC 350, Intangibles—Goodwill and Other. Based on the qualitative assessment performed, management concluded that the combination of factors considered did not result in a triggering event requiring a quantitative impairment test. Based on the assessment, there was no goodwill impairment recognized in the three months ended March 31, 2026. Intangible Assets Intangible assets consist of trade name, developed technology, legal and compliance framework, and patents, and are initially recorded at fair value. Long-lived intangible assets are amortized over their estimated useful lives in a method reflecting the pattern in which the economic benefits are consumed or amortized on a straight-line basis if such pattern cannot be reliably determined. The Company evaluates its finite-lived intangible assets for impairment in accordance with ASC 360-10-35 whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. During the three months ended March 31, 2026, the Company evaluated whether any such triggering events existed, including consideration of changes in the business environment, market conditions, and asset utilization. Based on this assessment, management concluded that no triggering events occurred and that the carrying amounts of the Company’s finite-lived intangible assets were recoverable. Accordingly, no impairment charges were recorded for the three months ended March 31, 2026 or 2025. The following summarizes the Company’s intangible assets as of March 31, 2026 and December 31, 2025: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20260331_zlvRSRbBQYog" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20251231_zHREJ85r3rd3" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zKrxjwlE70oc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Trade name (1)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,100</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,100</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zeFHpkDOPyog" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Developed technology (1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_zWxImnAGAA87" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Legal and compliance framework (1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zeIlNwlL8TCa" style="vertical-align: bottom; background-color: White"> <td>Patents</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">380</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">380</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzACZ_z1KF7T7kRNmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,880</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,880</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FiniteLivedIntangibleAssetsForeignCurrencyTranslationAdjustment_iNI_di_zdhC0dgwdKNl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency translation adjustment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(456</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">371</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated amortization:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_hus-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_msFLIANzACZ_zg0emAqtFkSj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Trade name</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(425</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(303</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_hus-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_msFLIANzACZ_zbghWeuGsN46" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Developed technology</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,162</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,975</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_hus-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__dei--LegalContactMember_msFLIANzACZ_zpJnYE72l7Sf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Legal and compliance framework</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(285</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(204</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_hus-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_msFLIANzACZ_zxY1oDdfriMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Patents</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(134</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(130</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzACZ_zgIkQUgBalT" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total accumulated amortization</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,006</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,612</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzACZ_z33aLFlUJrhl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Intangible assets, net</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,418</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">44,639</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Intangible assets acquired in connection with the Streamex Exchange acquisition were initially measured in Canadian dollars and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in exchange rates are reflected in the carrying amounts presented above and recorded in other comprehensive loss as part of the cumulative translation adjustment.</td></tr> </table> Amortization expenses for total intangible assets were $1,479 and $3 for the three months ended March 31, 2026 and 2025, respectively. Amortization expenses for trade name, developed technology, legal and compliance framework and patents was $<span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20260101__20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zbUkhW5hYLk7" title="Amortization expenses">128, $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20260101__20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zqdlODKZc5Da" title="Amortization expenses">1,260, $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20260101__20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__dei--LegalContactMember_zivZiJRDXAgc" title="Amortization expenses">86 and $<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20260101__20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zHe12PlpXb54" title="Amortization expenses">5, respectively, for the three months ended March 31, 2026. Amortization expenses for trade name, developed technology, legal and compliance framework and patents was $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250101__20250331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zVJChiDEpRvb" title="Amortization expenses">0, $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250101__20250331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zWw8krgg8sIb" title="Amortization expenses">0, $<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250101__20250331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__dei--LegalContactMember_z8e7lorYsr5g" title="Amortization expenses">0 and $<span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250101__20250331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zmxEv15BQpC8" title="Amortization expenses">3, respectively, for the three months ended March 31, 2025. The weighted-average useful lives of total intangibles, trade name, developed technology, legal and compliance framework and patents were <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zdxQBVfKqiVa" title="Finite lived intangible asset, useful life">7.4 years, <span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zosV5GmYVQ2d" title="Finite lived intangible asset, useful life">9.2 years, <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__dei--LegalContactMember_zdpHO5bAYp3" title="Finite lived intangible asset, useful life">7.2 years, <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--ComplianceFrameworkMember_zJlQl5WSfHaf" title="Finite lived intangible asset, useful life">6.2 years and <span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zqU3YLuhoweb" title="Finite lived intangible asset, useful life">13.5 years, respectively, as of March 31, 2026. <p id="xdx_892_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zEGFyDp9yFTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Expected future amortization expense of intangible assets as of March 31, 2026, is as follows: SCHEDULE OF FUTURE AMORTIZATION EXPENSE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20260331_zDWENRtqbEB8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANzCD7_zvdsnWIU6DQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Remainder 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,362</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzCD7_zxY1Kjo2KSqb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,816</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzCD7_zvpJgbjneTi4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,816</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzCD7_zlULj4abhOec" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,816</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzCD7_zQNRq8ZRvXZh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,816</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzCD7_zxbc68DOoDS1" style="vertical-align: bottom; background-color: White"> <td>Thereafter</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,792</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzCD7_zpKxNn6NGj28" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none">Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,418</td><td style="text-align: left"> </td></tr> </table>

The following table shows the changes in the carrying amount of goodwill for the period: SCHEDULE OF CARRYING AMOUNT OF GOODWILL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; font-weight: bold">Goodwill as of December 31, 2025 (1)</td><td style="width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--Goodwill_iS_pn3n3_c20260101__20260331_fMQ_____zZ7tJSPaGMLb" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Goodwill, beginning">70,984</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Acquisition</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--GoodwillAcquiredDuringPeriod_pn3n3_c20260101__20260331_zrbKbKyyObki" style="text-align: right" title="Acquisition">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Impairment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20260101__20260331_zt3F5RO0qUTg" style="text-align: right" title="Impairment">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency translation adjustment</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_pn3n3_c20260101__20260331_zvyGeCjFEFjj" style="border-bottom: Black 1pt solid; text-align: right" title="Foreign currency translation adjustment">(1,226</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Goodwill as of March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--Goodwill_iE_pn3n3_c20260101__20260331_zhakhLbZJ3x7" style="border-bottom: Black 2.5pt double; text-align: right" title="Goodwill, ending">69,758</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Related to the acquisition of the Streamex Exchange. See Note 4 for more details. Goodwill was initially measured in the functional currency of Streamex Exchange and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in foreign exchange rates are reflected in the cumulative translation adjustment within other comprehensive loss.</td></tr> </table>

70984000

-1226000

69758000

The following summarizes the Company’s intangible assets as of March 31, 2026 and December 31, 2025: SCHEDULE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20260331_zlvRSRbBQYog" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20251231_zHREJ85r3rd3" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zKrxjwlE70oc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Trade name (1)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,100</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,100</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zeFHpkDOPyog" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Developed technology (1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_zWxImnAGAA87" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Legal and compliance framework (1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zeIlNwlL8TCa" style="vertical-align: bottom; background-color: White"> <td>Patents</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">380</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">380</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzACZ_z1KF7T7kRNmi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,880</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,880</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--FiniteLivedIntangibleAssetsForeignCurrencyTranslationAdjustment_iNI_di_zdhC0dgwdKNl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Foreign currency translation adjustment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(456</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">371</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accumulated amortization:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_hus-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_msFLIANzACZ_zg0emAqtFkSj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Trade name</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(425</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(303</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_hus-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_msFLIANzACZ_zbghWeuGsN46" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Developed technology</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,162</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,975</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_hus-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__dei--LegalContactMember_msFLIANzACZ_zpJnYE72l7Sf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Legal and compliance framework</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(285</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(204</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_hus-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_msFLIANzACZ_zxY1oDdfriMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Patents</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(134</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(130</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzACZ_zgIkQUgBalT" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total accumulated amortization</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,006</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,612</td><td style="text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzACZ_z33aLFlUJrhl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Intangible assets, net</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,418</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">44,639</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Intangible assets acquired in connection with the Streamex Exchange acquisition were initially measured in Canadian dollars and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in exchange rates are reflected in the carrying amounts presented above and recorded in other comprehensive loss as part of the cumulative translation adjustment.</td></tr> </table>

5100000

40000000

2400000

380000

47880000

456000 -371000

425000

303000

4162000

2975000

285000

204000

134000

130000

5006000

3612000

42418000

44639000

1479000

3000

128000

1260000

86000

5000

3000

P7Y4M24D

P9Y2M12D

P7Y2M12D

P6Y2M12D

P13Y6M

<p id="xdx_892_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zEGFyDp9yFTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Expected future amortization expense of intangible assets as of March 31, 2026, is as follows: SCHEDULE OF FUTURE AMORTIZATION EXPENSE OF INTANGIBLE ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49B_20260331_zDWENRtqbEB8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_maFLIANzCD7_zvdsnWIU6DQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Remainder 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,362</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANzCD7_zxY1Kjo2KSqb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,816</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANzCD7_zvpJgbjneTi4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,816</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANzCD7_zlULj4abhOec" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,816</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANzCD7_zQNRq8ZRvXZh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,816</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_ecustom--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_iI_pn3n3_maFLIANzCD7_zxbc68DOoDS1" style="vertical-align: bottom; background-color: White"> <td>Thereafter</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,792</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANzCD7_zpKxNn6NGj28" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none">Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,418</td><td style="text-align: left"> </td></tr> </table>

4362000

5816000

14792000

42418000

NOTE 6 – PROPERTY AND EQUIPMENT Property and equipment as of March 31, 2026, and December 31, 2025 is summarized as follows: SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_499_20260331_zm65YTUuCqLl" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_495_20251231_zTimaUi7BmWh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2026</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z1xW2oikiNp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">531</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">531</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zVLYycvDfMde" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">109</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">109</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TestingAndDemoEquipmentMember_zUDk2gk3tzqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Testing/Demo equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">312</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">312</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zl6UuBIM2yO6" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">84</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">84</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzbNh_zqZCkuzlAjDk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,036</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,036</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzbNh_zmCQjJ8t5nNf" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,024</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,011</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzbNh_z54XRo1N2tsa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">25</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> As of March 31, 2026, the Company evaluated whether any events or changes in circumstances indicated that the carrying amounts of its property and equipment may not be recoverable. Based on this assessment, no impairment indicators were identified and no impairment charges were recorded during the three months ended March 31, 2026 or 2025. Depreciation expenses were $13 and $18 for the three months ended March 31, 2026 and 2025, respectively.

Property and equipment as of March 31, 2026, and December 31, 2025 is summarized as follows: SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 12pt Arial, Helvetica, Sans-Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_499_20260331_zm65YTUuCqLl" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_495_20251231_zTimaUi7BmWh" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: center"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2026</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2025</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_z1xW2oikiNp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">531</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">531</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zVLYycvDfMde" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">109</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">109</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TestingAndDemoEquipmentMember_zUDk2gk3tzqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Testing/Demo equipment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">312</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">312</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zl6UuBIM2yO6" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">84</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">84</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzbNh_zqZCkuzlAjDk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,036</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,036</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzbNh_zmCQjJ8t5nNf" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,024</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,011</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzbNh_z54XRo1N2tsa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">25</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

531000

109000

312000

84000

1036000

1024000

1011000

12000

25000

13000

18000

NOTE 7 – MARKETABLE SECURITIES Exchange-Traded Funds The Company’s marketable securities consist of exchange-traded funds (“ETFs”) holding short-term U.S. Treasury securities and investment-grade corporate debt instruments. As of March 31, 2026, the portfolio was composed of four ETFs: iShares 0-3 Month Treasury Bond ETF (SGOV), SPDR Portfolio Short-Term Treasury ETF (SPTS), Vanguard Short-Term Treasury Index ETF (VGSH), and Vanguard Short-Term Corporate Bond ETF (VCSH), each representing approximately 25% of the total portfolio. These securities are held in a brokerage account and are classified as equity securities measured at fair value with changes in fair value recognized in earnings, in accordance with ASC 321, Investments — Equity Securities. Fair value is determined using quoted market prices in active markets and, accordingly, all marketable securities are classified within Level 1 of the ASC 820 fair value hierarchy. During the three months ended March 31, 2026, the Company purchased approximately $23,900 of marketable securities on February 26, 2026. No ETF securities were sold during the period; therefore, no realized gains or losses were recognized. As of March 31, 2026, the aggregate fair value of the ETF portfolio was approximately $23,766 against a cost basis of $23,900, resulting in a net unrealized loss of approximately $(134), which related entirely to equity securities still held as of March 31, 2026 and is included in “Change in fair value of marketable securities” in the unaudited condensed consolidated statements of operations. No impairment charges were recognized during the period. During the three months ended March 31, 2026, the Company earned dividend income and interest income on sweep balances totaling approximately $71, which is included in “Other income (expense), net” in the unaudited condensed consolidated statements of operations. As of December 31, 2025, the Company held no ETF investments. Empress Royalty Corp. On December 9, 2025, the Company entered into a share purchase agreement with Terra Capital Natural Resources Fund Pty Ltd to acquire <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20251209__20251209__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zM5O3mbo70y6" title="Issuance of shares acquired">12,671,297 common shares of Empress Royalty Corp. (“Empress”), representing approximately <span id="xdx_909_ecustom--EquityMethodInvestmentOutstandingPercentage_iI_pid_dp_uPure_c20251209__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z8HpkDnPwrz1" title="Outstanding percentage">9.9% of Empress’s outstanding common shares. Empress is listed on the TSX Venture Exchange and OTCQX. As consideration, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_c20251209__20251209__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_zB8MwEcG4XWc" title="Issuance of restricted shares">2,443,750 restricted shares of its common stock on December 12, 2025, the date ownership transferred. The investment was initially recognized at $10,533, based on the fair value of 2,443,750 Streamex shares issued at $4.31 per share on December 12, 2025. The Company does not have significant influence over Empress. As of December 31, 2025, the fair value of the Empress investment was approximately $9,706, with the resulting unrealized loss of $<span id="xdx_901_eus-gaap--UnrealizedGainLossOnInvestments_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--SharePurchaseAgreementMember_z3crFcNrrZy6" title="Unrealized loss of investment">(827) recognized in earnings during the year ended December 31, 2025. In January 2026, the Company sold all of its shares in Empress Royalty Corp. for gross proceeds of approximately $10,190, resulting in a realized gain of $484 measured from the December 31, 2025 fair value. The realized gain is included in “Realized gain on marketable securities” in other income (expense) in the unaudited condensed consolidated statements of operations. As the investment was disposed of prior to March 31, 2026, no unrealized gains or losses on the Empress investment were recognized during the three months ended March 31, 2026, and no impairment charges were recorded during any period in which the investment was held. As of March 31, 2026, the Company held no investment in Empress Royalty Corp.

0.25

23900000

23766000

23900000 -134000

71000

12671297

0.099

2443750

10533000

2443750

4.31

9706000

-827000

10190000

484000

NOTE 8 – GOLD ASSETS Gold Bullion — Held for Sale (Sold February 2026) As of December 31, 2025, the Company held LBMA Good Delivery gold bullion (the “Gold”) on an allocated, physically segregated basis in secure vaults operated by Brink’s Global Services USA, Inc. (“Brink’s”) and maintained the Gold in a securities account with Gold Bullion International, LLC (“GBI”). The aggregate carrying value of the Gold as of December 31, 2025 was approximately $24,472, of which approximately $23,472 was restricted and approximately $1,000 was unrestricted. The restricted portion of the Gold and related account rights were pledged as collateral under the Company’s secured financing arrangements, including the Secured Convertible Debenture Purchase Agreement dated July 7, 2025 and the Guaranty and Security Agreement dated November 4, 2025. Pursuant to the Securities Account Control Agreement dated November 4, 2025, GBI is required to comply with entitlement orders issued by YA II PN, LTD., acting as collateral agent (the “Collateral Agent”), and GBI will not follow Company instructions unless accompanied by the Collateral Agent’s express written consent. Upon receipt of a notice of sole control following an event of default, GBI would terminate the Company’s access to the securities account and take instructions solely from the Collateral Agent as the entitlement holder with respect to the account and property therein. Pursuant to the Brink’s Bailee Agreement dated November 4, 2025, Brink’s acts solely as bailee of the Gold, acknowledges no property interest in the Gold, and any statutory or possessory liens are subordinated to the Collateral Agent’s first-priority security interest. Brink’s maximum liability amount under its arrangements with GBI is $<span id="xdx_900_eus-gaap--OtherLiabilities_iI_pn6n6_c20251104__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--BrinksBaileeAgreementMember_z3TTxtbm7Kge" title="Other liabilities">125 million. No entitlement orders or notices of sole control were issued during the three months ended March 31, 2026. On December 29, 2025, management committed to a plan to sell the Gold in connection with the Company’s plan to resolve and repay its secured convertible debentures. The Company determined that all criteria for classification as held for sale under ASC 360-10-45-9 were met as of December 29, 2025. Accordingly, as of December 31, 2025, the Gold was classified as held for sale and measured at the lower of its carrying amount or fair value less cost to sell. Because fair value less cost to sell exceeded the carrying amount, no write-down was recorded prior to sale. In February 2026, the Company transferred approximately $1,000 of unrestricted gold bullion at cost to Streamex Ltd. in connection with the establishment of the GLDY Token program. The transferred gold is included in “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet as of March 31, 2026 (see Note 9). On February 5, 2026, the Company completed the sale of the remaining LBMA Good Delivery gold bullion previously classified as held for sale, with a carrying amount of approximately $23,472. The transaction was executed through the Company’s securities intermediary and resulted in cash proceeds of approximately $26,410. The Company recognized a gain of approximately $2,938 on the sale, which is included in “Realized gain on sale of gold” in other income (expense) in the unaudited condensed consolidated statements of operations. The proceeds were used to fund the repayment of the Yorkville Debentures (see Note 11). As of March 31, 2026, no gold bullion classified as held for sale remained on the unaudited condensed consolidated balance sheet. Upon completion of the sale and settlement of the Convertible Debentures, all related security interests, liens, and custodial arrangements described above were terminated. Gold Assets Held at Cost — Streamex Ltd. (VIE) During the three months ended March 31, 2026, Streamex Ltd. (the Company’s consolidated VIE) acquired gold bullion consisting of (i) the approximately $1,000 of unrestricted gold transferred from the Company as described above, and (ii) approximately $14,225 of gold purchased directly by Streamex Ltd. with cash funded by the Company. As of March 31, 2026, the aggregate carrying amount of gold held by Streamex Ltd. was $15,225, classified as “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet. The gold is held to support the long-term GLDY Token program and related leasing activities and is accounted for as a long-lived tangible asset within the scope of ASC 360 (see Note 3). As of March 31, 2026, the Company evaluated whether any events or changes in circumstances indicated that the carrying amount of its gold assets held at cost may not be recoverable. Based on this assessment, including consideration of gold market prices as of the balance sheet date, management concluded that no triggering events existed and no impairment charges were recorded during the three months ended March 31, 2026. See Note 9 for additional information regarding Streamex Ltd.

24472000

23472000

1000000

125000000

1000000

23472000

26410000

2938000

1000000

14225000

15225000

NOTE 9 – STREAMEX LTD. (VIE) Overview Streamex Ltd. (“Streamex Ltd.” or the “VIE”) is a special-purpose entity organized in the Cayman Islands and formed to purchase and hold physical gold and to issue digital GLDY Tokens designed to provide tokenholders exposure to gold and gold-denominated leasing returns. Streamex Ltd. may also lease its gold holdings to generate gold-denominated yield. The Company is involved with Streamex Ltd. through its governance rights and through its economic interests in GLDY Tokens. Streamex Ltd. began operations during the three months ended March 31, 2026. Variable Interest Entity Consideration The Company evaluated Streamex Ltd. under the variable interest entity (“VIE”) model in ASC 810, Consolidation. A legal entity is a VIE if, among other conditions, the holders of the equity investment at risk, as a group, lack the power, through voting rights or similar rights, to direct the activities that most significantly impact the entity’s economic performance. Streamex Ltd. is considered a VIE because the holders of GLDY Tokens (which represent non-voting participating equity interests) lack substantive voting rights and do not have the power to direct the activities that most significantly impact Streamex Ltd.’s economic performance. Voting control resides with the single voting management share, which controls shareholder-level decisions including the appointment and removal of directors, and day-to-day operating authority has been delegated to GLDY ServiceCo, LLC, a consolidated subsidiary of the Company, pursuant to a services agreement. Because Streamex Ltd. is a VIE, the Company evaluated whether it is the primary beneficiary and therefore required to consolidate Streamex Ltd., as discussed below. Primary Beneficiary Conclusion and Consolidation The Company evaluated its involvement with Streamex Ltd. under ASC 810, Consolidation, and concluded it is the primary beneficiary and is required to consolidate Streamex Ltd. Under ASC 810-10-25-38, a reporting entity is the primary beneficiary of a VIE only if it has both (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Company concluded both criteria are met as of March 31, 2026 because it has the power to direct the activities that most significantly impact Streamex Ltd.’s economic performance through its control of the VIE’s governance structure (including the voting management share and related decision rights, as applicable) and the servicer arrangement, and has the obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE due to its economic interest in the GLDY Tokens. As of March 31, 2026, the Company held approximately 98.5% of the outstanding GLDY Tokens issued by Streamex Ltd. (approximately $15,000 invested by the Company out of $15,225 total tokens issued). Two related party investors subscribed for an aggregate of approximately $<span id="xdx_901_eus-gaap--OtherAssetsNoncurrent_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--TwoRelatedPartyMember_zTgZvs7P9L37" title="Other assets held at cost - gold">225 in GLDY Tokens during March 2026, representing approximately <span id="xdx_902_ecustom--VariableInterestPercentage_pid_dp_uPure_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zBCvPBKsvo82" title="Variable interest percentage">1.5% of total tokens outstanding. Accordingly, the Company has consolidated Streamex Ltd. from the date of its formation in the unaudited condensed consolidated financial statements. Carrying Amounts of Assets and Liabilities of Consolidated VIE The following table presents the carrying amounts and balance sheet classifications of the significant assets and liabilities of Streamex Ltd. included in the Company’s unaudited condensed consolidated balance sheet as of March 31, 2026. The assets of Streamex Ltd. are generally restricted and can be used only to settle obligations of Streamex Ltd. Streamex Ltd. assets and liabilities included in the unaudited condensed consolidated balance sheet as of March 31, 2026: SCHEDULE OF VAIABLE INTEREST ENTITY ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2" id="xdx_49F_20260331__srt--ConsolidatedEntitiesAxis__custom--StreamexLtdMember_zIrg9wUFQYIj"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--AssetsAbstract_iB_zMJwzJvBUUy7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--OtherAssetsNoncurrent_iI_zjFsfZ0JEob3" style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Other assets held at cost – gold</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">15,225</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--Cash_iI_zeP9NqEpG9Kf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cash</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">60</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Assets_iI_zBhlAHPTD7G1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Total assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,285</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LiabilitiesAbstract_iB_zCMTSUHgSo62" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_zAnKO1XW7Arj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts payable and accrued expenses</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">33</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--Liabilities_iI_z8cpNK98euhd" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Total liabilities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33</td><td style="text-align: left"> </td></tr> </table> During the three months ended March 31, 2026, Streamex Ltd. incurred a net loss of approximately $155, primarily consisting of operating expenses including bank fees, custody-related charges, and digital asset transaction costs. The net loss was funded by capital contributions from the Company and its affiliates (see Note 8 for additional information regarding the gold assets held by Streamex Ltd.). During March 2026, two officers of the Company subscribed for GLDY Tokens directly with Streamex Ltd.: (i) the Company’s Chief Investment Officer, subscribed for approximately $<span id="xdx_90D_eus-gaap--NoncontrollingInterestInVariableInterestEntity_iI_pn3n3_c20260331__srt--ConsolidatedEntitiesAxis__custom--StreamexLtdMember__srt--TitleOfIndividualAxis__custom--ChiefInvestOfficerMember_zFNu8QZY6ga8" title="Variable interst entity">200 of GLDY Tokens on March 17, 2026, and (ii) the Company’s General Counsel, subscribed for approximately $<span id="xdx_908_eus-gaap--NoncontrollingInterestInVariableInterestEntity_iI_pn3n3_c20260331__srt--ConsolidatedEntitiesAxis__custom--StreamexLtdMember__srt--TitleOfIndividualAxis__custom--GeneralCounselOfficersMember_zqoX2FmWy5Lc" title="Variable interst entity">25 of GLDY Tokens on March 27, 2026. These subscriptions were made on the same terms and at the same per-token price as the Company’s own subscriptions and are related party transactions (see Note 18, Related Party Transactions). Lack of Recourse / Restrictions The assets of Streamex Ltd. are generally not available to satisfy the obligations of the Company or its other subsidiaries, and the creditors and tokenholders of Streamex Ltd. generally do not have recourse to the general credit of the Company beyond the assets of Streamex Ltd., except to the limited extent of intercompany balances eliminated in consolidation. The liabilities recognized as a result of consolidating Streamex Ltd. do not represent additional claims on the Company’s general assets. Maximum Exposure to Loss / Financial Support The Company’s maximum exposure to loss associated with its involvement with Streamex Ltd. as of March 31, 2026 is limited to the carrying amount of its approximately 98.5% economic interest in the GLDY Tokens and its net interest in Streamex Ltd.’s net assets, which totaled approximately $15,000 at the date of investment. The Company has no arrangements that legally obligate it to provide additional financial support to Streamex Ltd., such as guarantees or liquidity facilities, beyond its role as an investor and service provider. However, the Company funded approximately $158 of Streamex Ltd.’s operating expenses during Q1 2026 through capital contributions from the Company and its affiliates, which are eliminated in consolidation. Related Party Considerations / Intercompany Eliminations Streamex Ltd. pays servicing fees to GLDY ServiceCo, LLC, a consolidated subsidiary of the Company, under the applicable servicing arrangement. Because the servicer is a consolidated subsidiary, these servicing fees and related intercompany balances are eliminated in consolidation. Noncontrolling Interest As of March 31, 2026, noncontrolling interests in Streamex Ltd. consisted of (i) the single voting management share held by the VIE’s director, which carries governance rights but no material economic interest, and (ii) GLDY Tokens held by two officers of the Company who subscribed as related party investors during March 2026. In aggregate, related party tokenholders held approximately <span id="xdx_90F_eus-gaap--VariableInterestEntityOwnershipPercentage_pid_dp_uPure_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zF2ggjIodUW" title="Interest percentage">1.5% of the outstanding GLDY Tokens as of March 31, 2026. The noncontrolling interest attributable to Streamex Ltd. as of March 31, 2026 was approximately $224, consisting of related party token subscriptions described above, net of the noncontrolling interest’s proportionate share of the VIE’s net loss for the period. The noncontrolling interest is presented within noncontrolling interest on the unaudited condensed consolidated balance sheet and in the unaudited condensed consolidated statements of operations. See Note 15 for the noncontrolling interest rollforward and attribution tables. Ongoing Assessment The Company reassesses its primary beneficiary conclusion on an ongoing basis in accordance with ASC 810 whenever changes in facts and circumstances occur that could affect the determination of whether either criterion under ASC 810 continues to be met. Changes that could affect the primary beneficiary assessment include, but are not limited to, changes in GLDY Token ownership (including issuance, redemption, or transfer of GLDY Tokens to unrelated third parties that could affect the significance of the Company’s economic exposure to the VIE), modifications of governing documents or fee arrangements, changes in ownership of the management share, or replacement of the affiliated servicer by an unrelated party. As of March 31, 2026, no changes in facts or circumstances have occurred that would alter the Company’s conclusion.

0.985

15000000

15225000

225000

0.015

Streamex Ltd. assets and liabilities included in the unaudited condensed consolidated balance sheet as of March 31, 2026: SCHEDULE OF VAIABLE INTEREST ENTITY ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold"> </td><td> </td> <td colspan="2" id="xdx_49F_20260331__srt--ConsolidatedEntitiesAxis__custom--StreamexLtdMember_zIrg9wUFQYIj"> </td><td> </td></tr> <tr id="xdx_403_eus-gaap--AssetsAbstract_iB_zMJwzJvBUUy7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets</td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--OtherAssetsNoncurrent_iI_zjFsfZ0JEob3" style="vertical-align: bottom; background-color: White"> <td style="width: 80%; text-align: left">Other assets held at cost – gold</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">15,225</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--Cash_iI_zeP9NqEpG9Kf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Cash</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">60</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--Assets_iI_zBhlAHPTD7G1" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Total assets</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,285</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LiabilitiesAbstract_iB_zCMTSUHgSo62" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_zAnKO1XW7Arj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accounts payable and accrued expenses</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">33</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--Liabilities_iI_z8cpNK98euhd" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Total liabilities</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">33</td><td style="text-align: left"> </td></tr> </table>

15225000

60000

15285000

33000

155000

200000

25000

0.985

15000000

158000

0.015

224000

NOTE 10 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses as of March 31, 2026, and December 31, 2025, consist of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20260331_ztLfyIySEJc8" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20251231_zoEwTIk1K0D" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maAPAALzKpF_zcWbbL0ORSrk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued accounting and legal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">725</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">705</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedConsultingCurrent_iI_pn3n3_maAPAALzKpF_zE51Mzxy8HPa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued consulting</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">406</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AccruedInterestCurrent_iI_pn3n3_maAPAALzKpF_zYdObERClEKb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedResearchAndDevelopmentExpenses_iI_pn3n3_maAPAALzKpF_zdy524xEbkY2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedOfficeExpenseAndOtherExpense_iI_pn3n3_maAPAALzKpF_zf9eBHSeBugh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued office and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AccruedInsurancePremiumFinancing_iI_pn3n3_maAPAALzKpF_zEQ8CtbnoO2a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued insurance premium financing(1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">370</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">916</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maAPAALzKpF_zJopCIwYphS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Accrued payroll(2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">512</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maAPAALzKpF_zUOLL1hwZ3Uj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other accrued expenses</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">132</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALzKpF_zamE1ra6N159" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Accounts payable and accrued expenses </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,179</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,952</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On August 27, 2025, the Company entered into a premium finance agreement for the policy period beginning August 3, 2025. The total premium was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zP67bXzmnQxg" title="Total Premium">2,172, of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zIPrm8oJvDaj" title="Paid as down payment">544 was paid as a down payment and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_pn3n3_c20250827__20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_znk2WQ6IPgSi" title="Financed paid">1,600 was financed. The agreement includes a finance charge of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PaymentsToAcquireFinanceReceivables_pn3n3_c20250827__20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zS3y6Op22h4k" title="Finance charge">51, resulting in total payments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--AccountsPayableOtherCurrentAndNoncurrent_iI_pn3n3_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_z4fDSBD9BKni">1,700 payable in nine monthly installments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_ecustom--AccountsPayableMonthlyInstallments_iI_pn3n3_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_z7f52GWRQAa5" title="Accounts payable, monthly installments">187 through May 2026 at an annual percentage rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_ecustom--AnnualPercentageRate_iI_pid_dp_uPure_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zFIpg7ZtRiVl" title="Annual percentage rate">7.48%. The financing obligation is secured by unearned premiums under the financed policies. As of March 31, 2026, the amount included in prepaid insurance is approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PrepaidInsurance_iI_pn3n3_c20260331_zoySqjqm2NWc" title="Prepaid insurance">570 and AFCO loan payable of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_ecustom--AccruedInsurancePremiumFinancing_iI_pn3n3_c20260331_zzYBHTnXJGW" title="Prepaid insurance premium financing">370. Prepaid insurance is amortized over the policy term, and the financing liability is reduced as payments are made. Interest expense is recognized using the effective interest method.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_ecustom--OtherSeparationrelatedObligations_iI_pn3n3_c20260331_zQ7SE5WXUtse" title="Other separation-related obligations">779 related to severance and other separation-related obligations associated with the Company’s former Chief Financial Officer pursuant to a Separation and General Release Agreement entered into in March 2026. The accrued amount includes cash severance, pro rata bonus components, and other related obligations expected to be paid in accordance with the terms of the agreement.</td></tr> </table>

Accounts payable and accrued expenses as of March 31, 2026, and December 31, 2025, consist of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20260331_ztLfyIySEJc8" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20251231_zoEwTIk1K0D" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-weight: bold; text-align: center"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maAPAALzKpF_zcWbbL0ORSrk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accrued accounting and legal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">725</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">705</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedConsultingCurrent_iI_pn3n3_maAPAALzKpF_zE51Mzxy8HPa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued consulting</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">406</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AccruedInterestCurrent_iI_pn3n3_maAPAALzKpF_zYdObERClEKb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--AccruedResearchAndDevelopmentExpenses_iI_pn3n3_maAPAALzKpF_zdy524xEbkY2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">167</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">169</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--AccruedOfficeExpenseAndOtherExpense_iI_pn3n3_maAPAALzKpF_zf9eBHSeBugh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued office and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AccruedInsurancePremiumFinancing_iI_pn3n3_maAPAALzKpF_zEQ8CtbnoO2a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued insurance premium financing(1)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">370</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">916</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maAPAALzKpF_zJopCIwYphS8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Accrued payroll(2)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,180</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">512</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maAPAALzKpF_zUOLL1hwZ3Uj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other accrued expenses</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">132</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iTI_pn3n3_mtAPAALzKpF_zamE1ra6N159" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Accounts payable and accrued expenses </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,179</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,952</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On August 27, 2025, the Company entered into a premium finance agreement for the policy period beginning August 3, 2025. The total premium was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_pn3n3_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zP67bXzmnQxg" title="Total Premium">2,172, of which $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_eus-gaap--AccountsPayableOtherCurrent_iI_pn3n3_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zIPrm8oJvDaj" title="Paid as down payment">544 was paid as a down payment and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_pn3n3_c20250827__20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_znk2WQ6IPgSi" title="Financed paid">1,600 was financed. The agreement includes a finance charge of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_904_eus-gaap--PaymentsToAcquireFinanceReceivables_pn3n3_c20250827__20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zS3y6Op22h4k" title="Finance charge">51, resulting in total payments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--AccountsPayableOtherCurrentAndNoncurrent_iI_pn3n3_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_z4fDSBD9BKni">1,700 payable in nine monthly installments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_903_ecustom--AccountsPayableMonthlyInstallments_iI_pn3n3_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_z7f52GWRQAa5" title="Accounts payable, monthly installments">187 through May 2026 at an annual percentage rate of <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_901_ecustom--AnnualPercentageRate_iI_pid_dp_uPure_c20250827__us-gaap--TypeOfArrangementAxis__custom--PremiumFinanceAgreementMember_zFIpg7ZtRiVl" title="Annual percentage rate">7.48%. The financing obligation is secured by unearned premiums under the financed policies. As of March 31, 2026, the amount included in prepaid insurance is approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_eus-gaap--PrepaidInsurance_iI_pn3n3_c20260331_zoySqjqm2NWc" title="Prepaid insurance">570 and AFCO loan payable of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90A_ecustom--AccruedInsurancePremiumFinancing_iI_pn3n3_c20260331_zzYBHTnXJGW" title="Prepaid insurance premium financing">370. Prepaid insurance is amortized over the policy term, and the financing liability is reduced as payments are made. Interest expense is recognized using the effective interest method.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">(2)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEFDQ09VTlRTIFBBWUFCTEUgQU5EIEFDQ1JVRUQgRVhQRU5TRSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90D_ecustom--OtherSeparationrelatedObligations_iI_pn3n3_c20260331_zQ7SE5WXUtse" title="Other separation-related obligations">779 related to severance and other separation-related obligations associated with the Company’s former Chief Financial Officer pursuant to a Separation and General Release Agreement entered into in March 2026. The accrued amount includes cash severance, pro rata bonus components, and other related obligations expected to be paid in accordance with the terms of the agreement.</td></tr> </table>

725000

705000

564000 406000 200000 167000 169000 41000 38000 370000 916000

1180000

512000

132000

6000

3179000

2952000

2172000

544000

1600000

51000

1700000

187000 0.0748

570000

370000 779000

NOTE 11 – CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS On November 4, 2025 and December 17, 2025, the Company issued two tranches of senior secured convertible debentures to YA II PN, Ltd. (“Yorkville”) (collectively, the “Convertible Debentures”) with aggregate principal of $50,000 (each tranche with principal of $25,000). The Convertible Debentures were issued as part of the Company’s capital-raising strategy to fund operations and growth initiatives. Each debenture was issued at a purchase price of 96% of principal, bore interest at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20271104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ziAIb5YEL02a" title="Interest rate effective percentage"><span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20271217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1ygmunn6WP3" title="Interest rate effective percentage">4.0% per annum (increasing to <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20271104__20271104__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFdoIqjJsx34" title="Interest rate for basic"><span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20271217__20271217__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zb7B31jSgJv3" title="Interest rate for basic">18.0% upon an event of default), and had a contractual maturity date that was 24 months from issuance (November 4, 2027 and December 17, 2027, respectively). The Convertible Debentures were secured by first-priority liens on substantially all assets of the Company and were guaranteed by certain subsidiaries. Upon settlement in February 2026, all related security interests and liens were released. Conversion Features Yorkville could convert all or any portion of the outstanding principal and accrued interest into shares of the Company’s common stock at a conversion price equal to the lower of: (i) a fixed price of $6.016 per share, subject to a one-time downward-only reset following registration effectiveness, and (ii) 97% of the lowest daily volume-weighted average price (“VWAP”) during the three trading days immediately preceding conversion, subject to a $4.00 per share floor price, in each case subject to customary anti-dilution adjustments. Conversions were also subject to a beneficial ownership limitation (generally 4.99%) and an exchange cap tied to Nasdaq rules, unless stockholder approval was obtained or the limitation was otherwise waived pursuant to the debenture terms. If fully converted at the $4.00 floor price, the $50,000 principal amount of the Convertible Debentures would have been convertible into a maximum of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20260101__20260331__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zpqIHUeVbfY1" title="Conversion of convertible shares">12,500,000 shares of the Company’s common stock, exclusive of any shares issuable for accrued interest or premiums. The Company did not register any shares for issuance under the Convertible Debentures and elected to utilize its optional cash settlement provisions in February 2026. Embedded Derivative Liability – Conversion Option The Company determined that the holder’s optional conversion feature requires bifurcation as an embedded derivative under ASC 815, Derivatives and Hedging, because (i) the economic characteristics of the conversion feature were not clearly and closely related to the host debt instrument and (ii) the conversion feature did not qualify for equity classification due to its variable conversion pricing mechanics, including VWAP-based pricing, floor price provisions, and reset features. Accordingly, the embedded conversion option was accounted for separately as a derivative liability measured at fair value, with changes in fair value recognized in earnings each reporting period. At issuance, the Company allocated proceeds between the host debt and the embedded derivative based on relative fair value, with the derivative recorded as a liability and a corresponding amount recorded as a debt discount on the host debenture. This debt discount was amortized to interest expense using the effective interest method over the estimated term of the debenture. As of March 31, 2026, the embedded derivative liability was fully settled and no balance remained outstanding. See Note 12, Fair Value Measurements, for information regarding the valuation methodology, significant unobservable inputs, sensitivity considerations, changes in fair value, the tabular presentation of gains and losses on derivative instruments recognized in earnings as required by ASC 815, and the Level 3 rollforward of the embedded derivative liability. The Company does not designate any derivative instruments as hedging instruments for accounting purposes and does not apply hedge accounting. Debt Carrying Amount and Interest Expense As of March 31, 2026, the carrying value of the Convertible Debentures, net of unamortized original issue discount, debt issuance costs, and bifurcation-related discounts, was $0 on a combined basis. Interest expense recognized for the three months ended March 31, 2026 includes stated coupon interest and amortization of debt discounts and issuance costs under the effective interest method. For the three months ended March 31, 2026, the Company recognized total interest expense of approximately $12,182 related to the Convertible Debentures, consisting of approximately $203 of contractual interest and approximately $11,979 of non-cash interest expense from the amortization of discounts and issuance costs. Interest expense is included in “Interest expense, net” in the unaudited condensed consolidated statements of operations. The effective interest rate on the Convertible Debentures substantially exceeded the 4.0% stated coupon rate. On December 29, 2025, management committed to a plan to settle the Convertible Debentures in early 2026, which constituted a change in the estimated life of the instruments. The Company prospectively recalculated the effective interest rates based on the revised expected settlement date of February 6, 2026. The resulting effective interest rates for the November 4, 2025 tranche and the December 17, 2025 tranche were approximately 393.7% and 228.9%, respectively, reflecting the accelerated amortization of unamortized discounts and issuance costs over a significantly shortened expected term. These revised rates were applied from December 29, 2025 through the settlement date of February 6, 2026, and are the basis for the non-cash interest expense from the accelerated amortization of discounts and issuance costs described above. Upon settlement, all remaining unamortized discounts and issuance costs were fully amortized and the net carrying value of the Convertible Debentures was reduced to zero. Had the Convertible Debentures been held to their contractual maturity dates of November 4, 2027 and December 17, 2027, respectively, the effective interest rates would have been approximately 17.6% and 26.5%, respectively, still materially higher than the stated coupon due to the substantial original issue discount. Outstanding Principal As of March 31, 2026, and December 31, 2025, the outstanding principal balance of the Convertible Debentures was $0 and $50,000, respectively. Settlement and Extinguishment On January 22, 2026, the Company delivered an irrevocable optional prepayment notice with respect to the Convertible Debentures. On February 6, 2026, the Company settled the Convertible Debentures, which had an aggregate outstanding principal of $50,000 and a net carrying value of $38,021 (after unamortized debt discounts of $11,979 as of December 31, 2025), through a combination of (i) a cash payoff of approximately $38,903, consisting of $35,000 of principal, a $3,500 prepayment premium, and approximately $403 of accrued interest, and (ii) conversion of $15,000 of principal, with no accrued interest, at a conversion price of $4.00 per share, resulting in the issuance of 3,750,000 shares of the Company’s common stock. The remaining unamortized debt discounts of $11,979 were fully amortized to interest expense upon settlement during the three months ended March 31, 2026, and are included in “Interest expense, net” in the unaudited condensed consolidated statements of operations. In connection with the settlement, the Company recognized the following: SCHEDULE OF SETTLEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20260101__20260331_zqmxawIimbw8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ExtinguishmentOfDebtAmount_iN_pn3n3_di_zU0gQcoBOOQb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Loss on extinguishment of convertible debentures — prepayment premium</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,500</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--EmbeddedDerivativeGainOnEmbeddedDerivative_pn3n3_zGAhp1RXkk04" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Gain on derecognition of embedded derivative at settlement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">443</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtSecuritiesRealizedGainLoss_iN_pn3n3_di_zyS3IYTeqzZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Realized loss on extinguishment of convertible debentures</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(3,057</td><td style="text-align: left">)</td></tr> </table> Upon payment in full, the Convertible Debentures were satisfied and terminated, and all related security interests and liens were released. We also entered into a SEPA with Yorkville that provided the Company with the right, but not the obligation, to sell shares of common stock during the commitment period. We terminated the SEPA effective January 29, 2026, and did not sell any shares under the SEPA. Cross-references to related disclosures Derivative-related qualitative, quantitative, and tabular disclosures are included in more than one note to the unaudited condensed consolidated financial statements. Accordingly, the Company provides the following cross-references: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 4 — Business Acquisition (Exchangeable Shares issued as consideration and related acquisition disclosures)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 12 — Fair Value Measurements (fair value hierarchy and valuation inputs for Level 3 instruments, as applicable)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 13 — Stockholders’ Equity (Exchangeable Shares and Special Voting Preferred Stock; reclassification to equity)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note 14 — Options, Restricted Stock Units and Warrants (warrant terms and Fundamental Transaction cash settlement / repurchase activity)</td></tr> </table>

50000000

25000000

0.96

0.040

0.180

6.016

4.00

50000000

12500000

12182000

203000

11979000

0.040

3.937

2.289

0.176

50000000

38021000

11979000

38903000

35000000

3500000

403000

15000000

4.00

3750000

11979000

In connection with the settlement, the Company recognized the following: SCHEDULE OF SETTLEMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_493_20260101__20260331_zqmxawIimbw8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ExtinguishmentOfDebtAmount_iN_pn3n3_di_zU0gQcoBOOQb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Loss on extinguishment of convertible debentures — prepayment premium</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(3,500</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--EmbeddedDerivativeGainOnEmbeddedDerivative_pn3n3_zGAhp1RXkk04" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Gain on derecognition of embedded derivative at settlement</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">443</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtSecuritiesRealizedGainLoss_iN_pn3n3_di_zyS3IYTeqzZ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Realized loss on extinguishment of convertible debentures</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(3,057</td><td style="text-align: left">)</td></tr> </table>

3500000

443000

3057000

NOTE 12 – FAIR VALUE MEASUREMENTS The Company measures certain financial instruments at fair value on a recurring basis in accordance with ASC 820, Fair Value Measurement. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value on a nonrecurring basis relate primarily to tangible property and equipment, goodwill and other intangible assets, which are remeasured when the derived fair value is below carrying value in the consolidated balance sheets. For these assets, the Company does not periodically adjust carrying value to fair value except in the event of impairment. If it is determined that impairment has occurred, the carrying value of the asset is reduced to fair value and the difference is included in impairments and other charges, net in the consolidated statements of operations. Nonrecurring Level 3 Fair Value Measurements Assets that are measured at fair value and classified as level 3 on a nonrecurring basis are as follows: SCHEDULE OF ASSETS MEASURED AT FAIR VALUE ON NONRECURRING BASIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Description</td><td> </td> <td colspan="2" id="xdx_495_20250528__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zBLmz1NGTpok" style="border-bottom: Black 1pt solid; text-align: center">May 28, 2025</td><td> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zbNLTawyxKUf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Trade name</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,100</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedTechnologyMember_z1wMaFF3M5we" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Developed technology</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">40,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_zCE2sXQRd2z9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Legal and compliance framework</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_zjEw54KIm4r7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value of intangible assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_zg7QV7M8HnKe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Goodwill</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">70,435</td><td style="text-align: left"> </td></tr> </table> All these assets were measured at the acquisition dates in conjunction with the Streamex Exchange acquisition. See Note 4, Business Acquisition, for additional information regarding the purchase price allocation and valuation methodologies. Derivative Liabilities – Recurring Fair Value Measurements (Embedded Conversion Options) The embedded conversion options associated with the Company’s secured convertible debentures were bifurcated and accounted for as derivative liabilities under ASC 815. The derivative liabilities were measured at fair value upon issuance of each debenture tranche (November 4, 2025 and December 17, 2025) and subsequently remeasured at fair value on a recurring basis through settlement on February 6, 2026. See Note 11, Convertible Debentures and Related Derivative Instruments, for information regarding the terms of the Convertible Debentures, the bifurcation analysis, settlement mechanics, and extinguishment accounting. The Company estimated the fair value of the embedded conversion options using a Monte Carlo simulation model within a “with-and-without” framework, which isolates the value of the holder’s conversion option by comparing the fair value of the debentures with and without the embedded conversion feature. The Monte Carlo model was designed to capture the path-dependent and non-linear features of the conversion option, including variable conversion pricing, contractual floor prices, amortization mechanics, optional prepayment features, and management’s expectations regarding conversion and repayment behavior. Because the valuation utilized significant unobservable inputs, the derivative liabilities were classified as Level 3 within the fair value hierarchy. Prior to settlement on February 6, 2026, the embedded conversion derivative was valued using a Monte Carlo simulation model incorporating the following significant unobservable inputs (Level 3): SCHEDULE OF UNOBSERVABLE INPUT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2/6/2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">12/31/2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unobservable / key assumption</td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Remeasurement</td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remeasurement</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Common stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260206__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputCommonStockPriceMember_z60P27mcviO6" title="Derivative liability measurement input">3.28</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputCommonStockPriceMember_z1bla3o3dBRi" title="Derivative liability measurement input">3.03</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Indicated conversion price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260206__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIndicatedConversionPriceMember_zszF5wCOT2nk" title="Derivative liability measurement input">4.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIndicatedConversionPriceMember_zRWFKOCnWDL8" title="Derivative liability measurement input">4.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Floor price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260206__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFloorPriceMember_zilw4VeGtofa" title="Derivative liability measurement input">4.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFloorPriceMember_z5BXo8Z8wUt9" title="Derivative liability measurement input">4.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepayment probability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260206__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPrepaymentRateMember_zhnoOKm12efl" title="Derivative liability measurement input">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPrepaymentRateMember_zSE8oY0Ykkxb" title="Derivative liability measurement input">70</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Prepayment premium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260206__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputPrepaymentPremiumMember_zDuJk6kxytzl" title="Derivative liability measurement input">10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputPrepaymentPremiumMember_zx3bGH45TPSg" title="Derivative liability measurement input">10</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Registration probability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260206__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRegistrationProbabilityMember_z0r23J9WjIY6" title="Derivative liability measurement input">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRegistrationProbabilityMember_z5rAtREAEGii" title="Derivative liability measurement input">0</td><td style="text-align: left">%</td></tr> </table> The February 6, 2026, valuation incorporated management’s assessment that optional prepayment was the most likely outcome and weighted prepayment and non-prepayment scenarios accordingly. Registration-dependent conversion scenarios were assigned a zero probability, as registration effectiveness was not expected. The fair value of the derivative liabilities is most sensitive to changes in the Company’s stock price, expected volatility, and assumptions regarding the timing and likelihood of prepayment. An increase in expected volatility or stock price would generally increase the fair value of the derivative liability, while an increase in the probability of early prepayment would generally decrease the fair value. Due to the path-dependent nature of the valuation, quantitative sensitivity analyses are not presented. During the three months ended March 31, 2026, the Company recognized a gain of $497 related to changes in the fair value of the embedded derivative liabilities prior to settlement on February 6, 2026. On settlement, the Company derecognized the remaining embedded derivative liability of $1,203, resulting in a gain on derecognition of $443 included in “Realized loss on extinguishment of convertible debentures” in the unaudited condensed consolidated statements of operations. See Note 11 for the complete extinguishment accounting. <p id="xdx_89C_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zcaYk1ykSACb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents the impact of the Company’s derivative instruments on earnings for the three months ended March 31, 2026: SCHEDULE OF DERIVATIVE INSTRUMENTS ON EARNINGS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260101__20260331_zjwNJ0HbwUU6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_ecustom--EmbeddedDerivativeGainOnEmbeddedDerivatives_pn3n3_zYgOPwk4iJtc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Change in fair value of embedded derivative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">497</td><td style="width: 1%; text-align: left"> </td></tr> </table> Rollforward of Level 3 Recurring Fair Value Measurements – Embedded Derivative Liabilities: SCHEDULE OF FAIR VALUE MEASUREMENTS EMBEDDED DERIVATIVE LIABILITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260101__20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5miZQnZolU1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3n3_zzT9ye0jLiLc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance as of December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--ChangeInFairValueOfEmbeddedDerivativeLiability_pn3n3_z8cqS93ycvp5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(497</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--EmbeddedDerivativeLiabilitySettlements_iI_pn3n3_z7VX06dmKoF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Settlements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,203</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3n3_zkDVFDn3zAe" style="vertical-align: bottom; background-color: White"> <td>Balance as of March 31, 2026</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table> Investment in Empress Royalty Corp. The Company’s investment in Empress Royalty Corp. is measured at fair value each reporting period based on quoted market prices in active markets. This represents a Level 1 measurement within the fair value hierarchy. The fair value is based on quoted prices on the TSX Venture Exchange (principal market), translated into U.S. dollars using the spot exchange rate at the measurement date. In January 2026, the Company sold all of its shares in Empress Royalty Corp. for gross proceeds of approximately $10,190, resulting in a realized gain on marketable securities of $484, which is included in other income (expense) in the unaudited condensed consolidated statements of operations. As of March 31, 2026, the Company held no investment in Empress Royalty Corp. See Note 7, Marketable Securities, for additional information. Exchange-Traded Funds The Company’s investments in exchange-traded funds (“ETFs”) holding short-term U.S. Treasury securities and investment-grade corporate debt instruments are measured at fair value each reporting period based on quoted market prices in active markets. This represents a Level 1 measurement within the fair value hierarchy. Recurring Fair Value Measurements The following table presents information about the Company’s financial instruments measured at fair value on a recurring basis as of March 31, 2026 (in thousands): SCHEDULE OF RECURRING BASIS FAIR VALUE MEASUREMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Description</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_493_20260331_z61JGyj4Gspj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20251231_zIvMBLGEbvtj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_pn3n3_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6Jc1oG3qKEf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Embedded derivative liabilities – Yorkville Debentures</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: center">3</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zyyjc1UKIHqf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">23,766</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9,706</td><td style="text-align: left"> </td></tr> </table>

Assets that are measured at fair value and classified as level 3 on a nonrecurring basis are as follows: SCHEDULE OF ASSETS MEASURED AT FAIR VALUE ON NONRECURRING BASIS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: justify">Description</td><td> </td> <td colspan="2" id="xdx_495_20250528__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsNonrecurringMember_zBLmz1NGTpok" style="border-bottom: Black 1pt solid; text-align: center">May 28, 2025</td><td> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TradeNamesMember_zbNLTawyxKUf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Trade name</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,100</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DevelopedTechnologyMember_z1wMaFF3M5we" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Developed technology</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">40,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_zCE2sXQRd2z9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Legal and compliance framework</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsFairValueDisclosure_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LegalAndComplianceFrameWorkMember_zjEw54KIm4r7" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value of intangible assets</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">2,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GoodwillFairValueDisclosure_iI_pn3n3_zg7QV7M8HnKe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Goodwill</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">70,435</td><td style="text-align: left"> </td></tr> </table>

5100000

40000000

2400000

70435000

Prior to settlement on February 6, 2026, the embedded conversion derivative was valued using a Monte Carlo simulation model incorporating the following significant unobservable inputs (Level 3): SCHEDULE OF UNOBSERVABLE INPUT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2/6/2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">12/31/2025</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Unobservable / key assumption</td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Remeasurement</td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Remeasurement</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Common stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_903_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260206__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputCommonStockPriceMember_z60P27mcviO6" title="Derivative liability measurement input">3.28</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputCommonStockPriceMember_z1bla3o3dBRi" title="Derivative liability measurement input">3.03</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Indicated conversion price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260206__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIndicatedConversionPriceMember_zszF5wCOT2nk" title="Derivative liability measurement input">4.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputIndicatedConversionPriceMember_zRWFKOCnWDL8" title="Derivative liability measurement input">4.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Floor price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260206__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFloorPriceMember_zilw4VeGtofa" title="Derivative liability measurement input">4.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputFloorPriceMember_z5BXo8Z8wUt9" title="Derivative liability measurement input">4.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepayment probability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260206__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPrepaymentRateMember_zhnoOKm12efl" title="Derivative liability measurement input">100</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPrepaymentRateMember_zSE8oY0Ykkxb" title="Derivative liability measurement input">70</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Prepayment premium</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260206__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputPrepaymentPremiumMember_zDuJk6kxytzl" title="Derivative liability measurement input">10</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputPrepaymentPremiumMember_zx3bGH45TPSg" title="Derivative liability measurement input">10</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Registration probability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260206__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRegistrationProbabilityMember_z0r23J9WjIY6" title="Derivative liability measurement input">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRegistrationProbabilityMember_z5rAtREAEGii" title="Derivative liability measurement input">0</td><td style="text-align: left">%</td></tr> </table>

3.28

3.03

4.00

100

497000

1203000

443000

<p id="xdx_89C_eus-gaap--ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_zcaYk1ykSACb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents the impact of the Company’s derivative instruments on earnings for the three months ended March 31, 2026: SCHEDULE OF DERIVATIVE INSTRUMENTS ON EARNINGS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260101__20260331_zjwNJ0HbwUU6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_ecustom--EmbeddedDerivativeGainOnEmbeddedDerivatives_pn3n3_zYgOPwk4iJtc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Change in fair value of embedded derivative</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">497</td><td style="width: 1%; text-align: left"> </td></tr> </table>

497000

Rollforward of Level 3 Recurring Fair Value Measurements – Embedded Derivative Liabilities: SCHEDULE OF FAIR VALUE MEASUREMENTS EMBEDDED DERIVATIVE LIABILITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260101__20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5miZQnZolU1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--DerivativeLiabilitiesCurrent_iS_pn3n3_zzT9ye0jLiLc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance as of December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--ChangeInFairValueOfEmbeddedDerivativeLiability_pn3n3_z8cqS93ycvp5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in fair value</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(497</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_ecustom--EmbeddedDerivativeLiabilitySettlements_iI_pn3n3_z7VX06dmKoF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Settlements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,203</td><td style="text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--DerivativeLiabilitiesCurrent_iE_pn3n3_zkDVFDn3zAe" style="vertical-align: bottom; background-color: White"> <td>Balance as of March 31, 2026</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table>

1700000

-497000 -1203000

10190000

484000

The following table presents information about the Company’s financial instruments measured at fair value on a recurring basis as of March 31, 2026 (in thousands): SCHEDULE OF RECURRING BASIS FAIR VALUE MEASUREMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Description</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_493_20260331_z61JGyj4Gspj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_49F_20251231_zIvMBLGEbvtj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_pn3n3_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6Jc1oG3qKEf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Embedded derivative liabilities – Yorkville Debentures</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: center">3</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,700</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--MarketableSecurities_iI_pn3n3_hus-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zyyjc1UKIHqf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">23,766</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">9,706</td><td style="text-align: left"> </td></tr> </table>

1700000

23766000

9706000

NOTE 13 – STOCKHOLDERS’ EQUITY Preferred stock The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of March 31, 2026 and December 31, 2025, the Company has designated 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock, 1,000 shares of Series E Preferred Stock, 200,000 shares of Series F Preferred Stock and 1 Special Voting Preferred Stock. As of March 31, 2026 and December 31, 2025, there were no issued or outstanding shares of Series A, Series B, Series D, Series E and Series F preferred stock. Special Voting Preferred Stock In connection with the issuance of Exchangeable Shares, the Company designated one share of Special Voting Preferred Stock, par value $0.001 per share. One share of Special Voting Preferred Stock was issued and outstanding as of March 31, 2026, and December 31, 2025. The Special Voting Preferred Stock was issued to a trustee and does not have any economic rights, including rights to dividends or participation in liquidation, other than a nominal liquidation preference of $<span id="xdx_90C_eus-gaap--TemporaryEquityLiquidationPreferencePerShare_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember_z3RnJYkh4y6" title="Temporary equity, liquidation preference">1.00. The Special Voting Preferred Stock is not convertible into common stock. The sole purpose of the Special Voting Preferred Stock is to provide voting rights to holders of Exchangeable Shares on an equivalent basis with holders of the Company’s common stock. The holder of the Special Voting Preferred Stock is entitled to cast a number of votes equal to the aggregate number of votes that the holders of Exchangeable Shares would be entitled to cast if such Exchangeable Shares were exchanged for shares of the Company’s common stock, in accordance with the Exchange Rights Agreement. The voting rights associated with the Special Voting Preferred Stock terminate automatically upon the exchange or cancellation of all outstanding Exchangeable Shares, at which time the Special Voting Preferred Stock is automatically cancelled for no consideration. Series C Preferred Stock Series C Preferred Stock (“Series C”) issued and outstanding totaled <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zDwPmJxcna4h" title="Preferred stock, shares outstanding"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_z2mDZZEIfw3g" title="Preferred stock, shares outstanding">105 shares as of March 31, 2026, and December 31, 2025. As of March 31, 2026, and December 31, 2025, the Company has accrued $123 and $121 dividends payable on the Series C, respectively. As of March 31, 2026, and December 31, 2025, the cumulative dividend per share payable on the Series C was approximately $1,175 and $1,153, respectively. Each share of Series C is convertible at the holder’s option into shares of common stock at a conversion price of $<span id="xdx_900_eus-gaap--CommonStockConvertibleConversionPriceDecrease_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zPlHWBo9mZt" title="Common stock conversion price">0.3197 per share, based on the stated value of $1,000 per preferred share. As of March 31, 2026, the outstanding Series C shares were convertible into an aggregate of 434,845 shares of common stock, which includes <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zxjPxyeZlnMj" title="Shares issued for services">106,412 shares issuable for accrued dividends at a conversion rate of $1.1593 per share. The Series C is subject to full ratchet anti-dilution price protection upon issuance of equity or equity-linked securities at an effective price below $0.3197 per share, as well as customary anti-dilution adjustments for stock splits and similar events. Common stock The Company is authorized to issue 500,000,000 shares of $0.001 par value common stock. As of March 31, 2026, and December 31, 2025, the Company had 97,721,696 and 49,805,275 shares issued and outstanding, respectively. Exchangeable Shares During the three months ended March 31, 2026, holders of Exchangeable Shares converted a total of 24,571,166 Exchangeable Shares into an equal number of shares of the Company’s common stock. As of March 31, 2026 and December 31, 2025, the Company had 83,420,765 and 107,991,931 Exchangeable Shares outstanding, respectively, each of which is exchangeable on a one-for-one basis for a share of the Company’s common stock, subject to the terms of the exchange agreement. Sale of Common Stock. On January 22, 2026, the Company entered into an underwriting agreement with Needham & Company, LLC, as representative of the several underwriters, in connection with an underwritten public offering of the Company’s common stock. The Company issued <span id="xdx_90E_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240112__20240112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zf7l29ZpLhU3" title="Sold to investors">11,666,667 shares of common stock at a public offering price of $3.00 per share. The underwriters fully exercised their over-allotment option, resulting in the issuance of an additional <span id="xdx_903_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_pid_c20260122__20260122__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z9QcSRLwAaNf" title="Adjustments to addtional paid issuance costs">1,750,000 shares of common stock. Aggregate gross proceeds from the offering, including the over-allotment option, were approximately $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pid_c20260122__20260122__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zgwvpwUlbPoc" title="Gross proceed for stock offering">40,250. The Company incurred transaction costs of approximately $3,066, including underwriting discounts, commissions, and other offering expenses, resulting in net proceeds of approximately $37,184. ATM Sales Agreement 2024 As of March 31, 2026, the Company had approximately $4,500 of remaining capacity under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, dated December 18, 2024. No shares were sold under the ATM Offering during the three months ended March 31, 2026. Equity Line of Credit As of March 31, 2026, the Company had approximately $<span id="xdx_906_eus-gaap--CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zietAzhccVzj" title="Subscription amount">5,000 of remaining capacity under its Equity Subscription Agreement with Lind Global Fund III, LP, dated February 28, 2025, subject to the filing and effectiveness of a registration statement. No advances have been made under the Subscription Agreement as of March 31, 2026.

1000000

0.001

200

600

4200

1400

1000

200000

0.001

1.00

105

123000

121000

1175000 1153000

0.3197

1000

434845

106412

1.1593

0.3197

500000000

0.001

97721696

49805275

24571166

83420765

107991931

11666667

3.00

1750000

40250

3066

37184

4500000

5000000

NOTE 14 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS Streamex Corp. 2023 Long-Term Incentive Plan Stockholders approved the Third Amendment to the Company’s 2023 Long-Term Incentive Plan (the “Incentive Plan Amendment”) on September 5, 2025, increasing the total number of shares authorized for issuance under the plan by <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250905__20250905__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeLongTermIncentivePlanMember_zChOHMCVoBTk" title="Shares issued">10,359,211 shares, from <span id="xdx_903_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20250904__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeLongTermIncentivePlanMember_zzXrWapuhFc2" title="Shares authorized">4,376,595 shares to <span id="xdx_90A_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20250905__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeLongTermIncentivePlanMember_zHDasftb4i5c" title="Shares authorized">14,735,806 shares. Stockholders approved the Fourth Amendment to the Company’s 2023 Long-Term Incentive Plan on December 30, 2025, increasing the total number of shares authorized for issuance under the plan by <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20251230__20251230__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeLongTermIncentivePlanMember_zbIYqrzgvbK" title="Shares issued">22,494,324 shares, from <span id="xdx_904_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20251229__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeLongTermIncentivePlanMember_zr1TzCt17old" title="Shares authorized">14,735,806 shares to <span id="xdx_908_eus-gaap--CapitalUnitsAuthorized_iI_pid_c20251230__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeLongTermIncentivePlanMember_zzxQz3oshbNb" title="Shares authorized">37,230,130 shares. As of March 31, 2026, there were <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260331__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyThreeLongTermIncentivePlanMember_z4NqVjm5eiN5" title="Shares issued">18,109,340 shares available under the 2023 Long-Term Incentive Plan. Options Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from historical stock prices of the Company. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. <p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRQmRSyRgB74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents information related to stock options as of March 31, 2026: SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="9" style="border-bottom: Black 1pt solid; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center">Exercise</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average Remaining Life</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercisable Number of</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Options</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">In Years</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td style="width: 21%; text-align: right">Under <span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zJUBjI1fdCs1" title="Options Outstanding, Exercise Price">9.99</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zDl2Fp2tgHFi" style="width: 22%; text-align: right" title="Number of Options Outstanding">2,900,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zzWsmO5rFbu8" style="width: 22%; text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">8.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zaT16DIQ49n3" style="width: 22%; text-align: right" title="Number of Options Outstanding Options Exercisable">2,900,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zFOX8HM2vmZ7" title="Options Outstanding, Exercise Price">10.00-<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zHoiYZdTpLTi" title="Options Outstanding, Exercise Price">19.99</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zZsFaXXZgDOa" style="text-align: right" title="Number of Options Outstanding">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_z52R6XM6Sl4d" style="text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">7.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zlwkTcWSRGSl" style="text-align: right" title="Number of Options Outstanding Options Exercisable">15,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zplXG429kpPg" title="Options Outstanding, Exercise Price">20.00-<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zT2u2aJg3gch" title="Options Outstanding, Exercise Price">49.99</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zsFbj7llpWgg" style="text-align: right" title="Number of Options Outstanding">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_z75Q6yGMfNv3" style="text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">3.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_z2rDY58Gw0mb" style="text-align: right" title="Number of Options Outstanding Options Exercisable">3,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_z22LnohoifH1" title="Options Outstanding, Exercise Price">50.00-<span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_zuSlNT5rDDDd" title="Options Outstanding, Exercise Price">69.99</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_zQCR0aQNqAs9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_z4whnaEGgMk4" style="text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">3.8</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_zL5NHol5LYe5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding Options Exercisable">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td></td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20260331_zUWDkjt7s6hj" style="text-align: right" title="Number of Options Outstanding">2,921,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zPYDSlDNtGUl" title="Number of Options Outstanding Weighted Average Remaining Life">8.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20260331_zE41Xa7psPr3" style="text-align: right" title="Number of Options Outstanding Options Exercisable">2,921,000</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3NbEZJaQEYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of the stock option activity and related information for the Plan for the three months ended March 31, 2026 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Remaining Contractual Term</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260331_zCwlmCszOucj" style="width: 11%; text-align: right" title="Outstanding shares">2,736,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20260101__20260331_zgkFnOSz4onb" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding">0.78</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zx9ttiqxYcze" style="width: 11%; text-align: right" title="Weighted-Average Remaining Contractual Term">8.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331_za9cIC2q83rd" style="width: 11%; text-align: right" title="Outstanding Aggregate Intrinsic Value">6,744,540</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykA" id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIssued_pid_c20260101__20260331_zSSwPbglVhIb" style="text-align: right" title="Grants">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykA" id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20260101__20260331_zIH72xWCEDW2" style="text-align: right" title="Weighted Average Exercise Price Grants">3.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zrvoE65hyxh8" style="text-align: right" title="Weighted-Average Remaining Contractual Term">9.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited/expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20260101__20260331_zbxdM8oVTrT7" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited/expired">(65,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20260101__20260331_zRPCN7MTljnj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited/expired">5.01</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260101__20260331_zXbrTTV43Qm5" style="text-align: right" title="Outstanding shares">2,921,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20260101__20260331_zhgezoQ0sVn8" style="text-align: right" title="Weighted Average Exercise Price Outstanding">0.89</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zue6gLLtqIde" style="text-align: right" title="Weighted-Average Remaining Contractual Term">8.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331_zjqJry38RW3a" style="text-align: right" title="Outstanding Aggregate Intrinsic Value">1,709,540</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20260331_zPc7rmIZczwa" style="text-align: right" title="Outstanding shares Exercisable">2,921,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20260101__20260331_z1x6xs6enfu2" style="text-align: right" title="Weighted Average Exercise Price Outstanding">0.89</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20260101__20260331_zotNZV5u7LBb" style="text-align: right" title="Weighted-Average Remaining Contractual Term">8.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260331_zxl7sSeRHS58" style="text-align: right" title="Outstanding Exercisable Aggregate Intrinsic Value">1,709,540</td><td style="text-align: left"> </td></tr> </table> The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on options with an exercise price less than the stock price of the Company of $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_pid_uUSDPShares_c20260101__20260331_zHpchMsL4Llj" title="Exercise price">1.13 as of March 31, 2026, which would have been received by the option holders had those option holders exercised their options as of that date. During the three months ended March 31, 2026, the Company granted an aggregate of 250,000 options to purchase the Company’s common stock at a weighted average exercise price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20260101__20260331_zPMCgZDyLbW7" title="Weighted average exercise price">3.21 per share for a term of <span id="xdx_901_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dc_c20260101__20260331_zNcWixerepre" title="Weighted average remaining contractual term">ten years. The options vested immediately upon grant and the full grant-date fair value of approximately $770 was recognized as stock-based compensation expense during the three months ended March 31, 2026. Stock based compensation expense related to stock options recognized during the three months ended March 31, 2026 and 2025, was $770 and $40, respectively, which is presented within general and administrative expenses in the unaudited Condensed Consolidated Statements of Operations. As of March 31, 2026, there was no unrecognized compensation expense related to stock options. On May 23, 2025, in connection with the Company’s acquisition of Streamex Exchange, the Company entered into an amendment to the Executive Employment Agreement with the Company’s former Chief Executive Officer and Chairman of the Board. Pursuant to the amendment, all previously granted equity awards to the former Chief Executive Officer and Chairman of the Board including vested and unvested stock options were accelerated and deemed fully vested and nonforfeitable as of May 28, 2025. In addition, the post-resignation exercise period for all vested options was extended to the later of the original expiration date or 36 months following the transaction closing. <p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zKYh80d1diPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">During the three months ended March 31, 2026, the Company granted options to purchase shares of its common stock, which were valued using the Black-Scholes option pricing model. The following assumptions were used to calculate the fair value of the options granted during the three months ended March 31, 2026: SCHEDULE OF OPTIONS GRANTED ASSUMPTIONS USING BLACK-SCHOLES OPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assumption</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Weighted average grant date fair value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zzQx6EDqEx16" title="Derivative liability">3.08</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zQwUZu6X24U" title="Derivative liability">124.17</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zUaKEjFsxoV3" title="Derivative liability">4.15</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_ztlrlB2l2Tac" title="Derivative liability">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected Term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DerivativeTermOfContract_dtY_c20260101__20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z7iwjzdhC8b9" title="Derivative liability, measurement input, expected life">5.0</td><td style="text-align: left"> </td></tr> </table> Warrants <p id="xdx_892_ecustom--ScheduleOfWarrantsOrRightsSharesAuthorizedExercisePriceRangeTableTextBlock_zvZ3WZgk747a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information with respect to outstanding warrants to purchase common stock of Streamex Corp. as of March 31, 2026: SCHEDULE OF INFORMATION RELATED TO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 70%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Warrants</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Expiration Date</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%">$</td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt03000Member_zSjo4kqacV0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 30%; text-align: right" title="Exercise price">0.3000</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"> </td> <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt03000Member_zAhSvBw4Orud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%; text-align: right" title="Number Outstanding">11,982</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"> </td> <td id="xdx_98A_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt03000Member_zyPjrwpg3Nk8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center" title="Expiration date">Nov-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt09547Member_zT02YMRS5hlc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">0.9547</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt09547Member_zyOKGZwiMvEc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">577,916</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98E_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt09547Member_zAVkKUK0CN63" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Sep-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt17800Member_ziJV0ayV3mbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">3.3640</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt33640Member_zrmdwfIFKyLk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">117,828</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_988_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt33640Member_zFuB2CPcpu6f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jul-29</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt40660Member_zsLJbb9JuxJg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">4.0660</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt40660Member_zZZwy87bv5Wf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">25,000</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_984_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt40660Member_zb4RErB2fgKj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Nov-32</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44550Member_zUJW9s3Bp2p9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">4.4550</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44550Member_zMau7uqx7D8i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">107,483</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98A_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44550Member_zRfZ5f9bBe0a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jun-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44660Member_zD3D4aBtGsXe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">4.4660</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44660Member_zjqlv1kEOKca" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">5,580</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_987_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44660Member_zEzl64AKlP82" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Apr-29</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt46626Member_zf3ehvSIa0q8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">4.6626</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt46626Member_zV7l0EdVp3o7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">49,550</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt46626Member_zIUmN1m4Ump3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Mar-29</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49252Member_zqsP07naO3B" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">4.9252</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49252Member_ztWgi9w4ItX6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">71,593</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49252Member_zByctZqsfxs7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Mar-29</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49290Member_z4pq77QMsKhg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">4.9290</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49290Member_zUdU2zwwfCy3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">99,243</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_985_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49290Member_zrS5vfwrOMvb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jul-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt51358Member_z2GSys3IYLHf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">5.1358</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt51358Member_zSnWpSN9MEWk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">83,270</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_983_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt51358Member_zAM58d3t3bQ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jul-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt71810Member_zu9crszAgqLh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">7.1810</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt71810Member_z0Gop4iLd0u3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">9,846</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98F_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt71810Member_zxTf8BsC2Kvb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jul-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt75020Member_zF8n2ItHCLzk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">7.5020</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt75020Member_zaWore382wd5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">21,369</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt75020Member_zBThlererZZ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Aug-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt79630Member_zmKmSnBTf0T8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">7.9630</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt79630Member_zXIcNTnM614c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">21,709</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_984_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt79630Member_z9oaMfar8UU9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jun-27</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt90000Member_zzwpUlpGRkK2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">9.0000</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt90000Member_z4GOvLzzJOZ8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">84,390</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt90000Member_ztaKU7AfNps" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jan-29</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt95960Member_zhknhVPSlke4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">9.5960</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt95960Member_zc4uWKLExDLl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">19,118</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98F_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt95960Member_zkmw5ijlN6Zh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Aug-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt100992Member_zoG7rRAhf2pi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">10.0992</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt100992Member_zPljZFF4Dh4c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">51,705</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98A_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt100992Member_zDpyw1exQJak" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Sep-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt102600Member_zn8W5xG6Qw94" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">10.2600</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt102600Member_znsTeXoOdHF2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">84,296</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98C_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt102600Member_ziSfopg839tl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Sep-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt104678Member_zbzOlk5u3BWf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">10.4678</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt104678Member_ze1zWMAm4F7l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">40,417</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98E_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt104678Member_zGNlTSbM8nSk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Oct-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt113000Member_zZ15zGYIrSn9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">11.3000</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt113000Member_zYXCBKFgKQf1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">96,198</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_983_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt113000Member_zkHqHHfXGF0k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Nov-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt132800Member_zGzKFldPFW03" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">13.2800</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt132800Member_zAV7tbybloif" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">12,500</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_980_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt132800Member_zsjj1vHkE16" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jul-26</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt480000Member_zPuOaY2pAuMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">48.0000</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt480000Member_zVCZD44Meu78" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">56,892</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98C_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt480000Member_z9sUydU50n0f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Nov-27</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt616000Member_zVIjXO0bZkE5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">61.6000</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt616000Member_zoHCkwn6qcTh" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">11,982</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98B_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt616000Member_zujd1soxEde5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Nov-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331_zk0c0xvzB9ma" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number outstanding">1,647,885</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> During the three months ended March 31, 2026, the Company issued <span id="xdx_907_ecustom--StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAAWNP891rN7" title="Shares of its common stock, warrants">54,647 shares of its common stock upon cashless exercise of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNeoVdDl7aA2" title="Warrants to purchase common stock">87,984 warrants to purchase shares of common stock, pursuant to the formula set forth in such warrants. A summary of the warrant activity for three months ended March 31, 2026 is as follows: SCHEDULE OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Remaining Contractual Term</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zQNuGYaGPo7b" style="width: 11%; text-align: right" title="Outstanding shares">1,735,869</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_904_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding_iS_pid_uUSDPShares_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_z5aCPpJQw2Ff" title="Weighted-Average Exercise Price ending">6.94</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90B_ecustom--WarrantsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_z8DmWS9N5qj2" title="Weighted-Average Remaining Contractual Term, Outstanding">2.8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zm72oyJomJO7" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value">1,414,626</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantsOrRightIssued_pid_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zlDAB4jRpJU1" style="text-align: right" title="Issued">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited/expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantsOrRightExpried_pid_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zKplsDAnhtgg" style="text-align: right" title="Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantsOrRightExercised_iN_pid_di_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_z2c7GSMjaqx5" style="border-bottom: Black 1pt solid; text-align: right" title="Exercised">(87,984</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_pid_uUSDPShares_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zzEZHsVFX5j8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price Exercised">0.95</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zWEEIjpMRomg" style="text-align: right" title="Outstanding shares">1,647,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding_iE_pid_uUSDPShares_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_ze8c3sCM2j8" title="Weighted-Average Exercise Price ending">7.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--WarrantsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zrIdLQrEKpN7" title="Weighted-Average Remaining Contractual Term, Outstanding">2.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zAyaM6alNug" style="text-align: right" title="Aggregate Intrinsic Value">111,231</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and expected to vest at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightsVestedAndExpectedToVestOutstanding_iE_pid_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zLN1QuEswKn9" style="text-align: right" title="Warrants Vested and expected to vest, Shares">1,647,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsVestedAndExpectedToVestOutstanding_iE_pid_uUSDPShares_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zENI6VPlqV73" style="text-align: right" title="Weighted-Average Exercise Price Vested and expected to vest">7.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--WarrantsWeightedAverageRemainingContractualTermExercised_dtY_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zAisHnGpH4fj" title="Weighted-Average Remaining Contractual Term, Exercised">2.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20260101__20260331_zJXHJVd3mx58" style="text-align: right" title="Warrants Vested and expected to vest, Aggregate Intrinsic Value">111,231</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightsExercisable_iE_pid_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zL5ckJbs5yz6" style="text-align: right" title="Warrants Exercisable, Shares">1,647,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable_iE_pid_uUSDPShares_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zTybZwZa838g" style="text-align: right" title="Weighted-Average Exercise Price Exercisable">7.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--WarrantsExercisableWeightedAverageRemainingContractualTerm_dtY_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_za0hcYvkD0rf" title="Weighted-Average Remaining Contractual Term Exercisable">2.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20260101__20260331_zEVPLvNrKFEl" style="text-align: right" title="Warrants Exercisable, Aggregate Intrinsic Value">111,231</td><td style="text-align: left"> </td></tr> </table> The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the company’s stock price of $1.13 as of March 31, 2026, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date. Restricted Stock Units <p id="xdx_890_eus-gaap--NonvestedRestrictedStockSharesActivityTableTextBlock_hdei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zqLWmb65h9zj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the restricted stock activity for the three months ended March 31, 2026: SCHEDULE OF RESTRICTED STOCK ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Grant Date Fair Value Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Restricted shares issued as of January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zU6yAPm9GDp7" style="width: 16%; text-align: right" title="Total restricted shares outstanding">2,037,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zW6chHOBrx89" style="width: 16%; text-align: right" title="Weighted average grant date fair value">5.36</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zqwBQ0THaL88" style="text-align: right" title="Granted">8,868,316</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zgEcM6CkxKoj" style="text-align: right" title="Granted">2.91</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_z2aG27nG54Kc" style="text-align: right" title="Vested">(6,123,941</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zkCAcM9smBH3" style="text-align: right" title="Vested">3.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zU7jhaBrRk7d" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">(198,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zu6yZlHhwgrg" style="text-align: right" title="Forfeited">3.21</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zVIDfB03hEZ2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total restricted shares outstanding">4,583,375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zTSqH1QJpEzb" style="text-align: right" title="Total">3.86</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Comprised of:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested restricted shares as of March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumberOfShares_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_za2A3AUILo29" style="text-align: right" title="Vested restricted shares">301,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDate_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_z9lBR4SABb72" style="text-align: right" title="Vested restricted shares, Weighted-Average Grant Date Fair Value Per Share">3.21</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Unvested restricted shares as of March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumberOfShares_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zJgNT8XFgsQc" style="text-align: right" title="Unvested restricted shares">4,281,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDate_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zgItdmW7sI7f" style="text-align: right" title="Unvested restricted, Weighted-Average Grant Date Fair Value Per Share">3.90</td><td style="text-align: left"> </td></tr> </table> Stock based compensation expense related to RSU grants was $24,545 and $2,236 for the three months ended March 31, 2026 and 2025, respectively, which is included in general and administrative expenses in the unaudited condensed consolidated statements of operations. As of March 31, 2026, total unrecognized stock-based compensation cost related to unvested RSUs was approximately $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTFq2M5X6nv8" title="Unrecognized stock-based compensation cost">24,545, which is expected to be recognized over a weighted-average period of approximately 1.33 years. The following table summarizes the terms of individual RSU grants issued during the three months ended March 31, 2026 that were subject to vesting conditions extending beyond the grant date: <p id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zYtGE20XIgfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> SCHEDULE OF RESTRICTED STOCK UNITS GRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Recipient</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RSUs Granted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vesting Terms</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">GDFV1</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 16%; text-align: center">1/1/2026</td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center">Third-party consultant</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneOneTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zQmybD9ElbVa" style="width: 12%; text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 30%; text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneOneTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zpfJywxR75wk" title="Share based compensation arrangement by share-based payment award, award vesting rights">25,000 immediately; remainder quarterly</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneOneTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zq8UNcQjSrP2" style="width: 12%; text-align: right" title="Stock issued during the period, value">758</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">1/8/2026</td><td> </td> <td style="text-align: center">Interim Executive Chairman</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneEightTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--InterimExecutiveChairmanMember_zCds9XWqV4C" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneEightTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--InterimExecutiveChairmanMember_znYUUedKgtxi" title="Share based compensation arrangement by share-based payment award, award vesting rights">4 equal quarterly installments over 1 year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneEightTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--InterimExecutiveChairmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zlK6asSdaz8h" style="text-align: right" title="Stock issued during the period, value">321</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">1/8/2026</td><td> </td> <td style="text-align: center">Chief Executive Officer</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneEightTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficierMember_zR4FTTXqJsK8" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneEightTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficierMember_zE9f8cqnrxJ6" title="Share based compensation arrangement by share-based payment award, award vesting rights">100,000 on May 15, 2026; 900,000 in 16 quarterly installments over 4 years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneEightTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficierMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zUKxEPuYzms9" style="text-align: right" title="Stock issued during the period, value">3,210</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">1/27/2026</td><td> </td> <td style="text-align: center">Third-party consultant</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneTwentySevenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zz98jtNILia3" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">125,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneTwentySevenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zNccOaAJ5r1g" title="Share based compensation arrangement by share-based payment award, award vesting rights">16 quarterly installments over 4 years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneTwentySevenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zqEmX0LKZpj3" style="text-align: right" title="Stock issued during the period, value">456</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">2/1/2026</td><td> </td> <td style="text-align: center">Third-party consultant</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--TwoOneTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_z7sJDU2rzvfb" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--TwoOneTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zxSJFUVEYqpi" title="Share based compensation arrangement by share-based payment award, award vesting rights">300,000 immediately; 200,000 in 4 quarterly installments over 12 months</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--TwoOneTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zKnyGr2OW89j" style="text-align: right" title="Stock issued during the period, value">1,790</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">3/3/2026</td><td> </td> <td style="text-align: center">Third-party consultant</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeThreeTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zUWZ9hwEyM0i" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">425,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeThreeTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zDhYQLgNuuZ9" title="Share based compensation arrangement by share-based payment award, award vesting rights">212,500 immediately; 125,000 on Jun 3; 87,500 on Sep 3, 2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeThreeTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zYjhYZdjLM95" style="text-align: right" title="Stock issued during the period, value">876</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3/16/2026</td><td> </td> <td style="text-align: center">Third-party consultant</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeSixteenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zfDfsmAuqYd7" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">65,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeSixteenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_z7G9BEMAp0B8" title="Share based compensation arrangement by share-based payment award, award vesting rights">5,000 immediately; remainder monthly</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeSixteenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_z8UHCf1dAVw7" style="text-align: right" title="Stock issued during the period, value">119</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">3/16/2026</td><td> </td> <td style="text-align: center">Chief Financial Officer</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeSixteenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zKNoNtU3ehQ7" style="border-bottom: Black 1pt solid; text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeSixteenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z6Yr0g4aWIL" title="Share based compensation arrangement by share-based payment award, award vesting rights">16 quarterly installments over 4 years</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeSixteenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zectv6UzqAkl" style="border-bottom: Black 1pt solid; text-align: right" title="Stock issued during the period, value">915</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331_zDp4dGN5Sec6" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">2,965,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zCXXwSjJUGOa" style="text-align: right" title="Stock issued during the period, value">8,445</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Grant-date fair value (“GDFV”)</td></tr></table> The table above includes only RSU grants issued during the three months ended March 31, 2026 that were subject to vesting conditions extending beyond the grant date. During the same period, the Company also granted an aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331_zXIK3OT2jSvg" title="Share based compensation, granted">5,903,316 RSUs that vested immediately upon grant and are therefore excluded from this table. The total RSUs granted during the three months ended March 31, 2026 were <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJRr1ka6HlG2" title="Share based compensation, granted">8,868,316, as reflected in the RSU activity table above. Performance-Based Restricted Stock Units During the three months ended March 31, 2026, the Company granted performance-vesting restricted stock units (“PSUs”) to certain consultants. The PSUs represent the right to receive shares of the Company’s common stock upon the achievement of specified performance conditions or market conditions, and satisfaction of service requirements, subject to certification by the Company’s Board of Directors or its Compensation Committee (the “Committee”). The PSUs are equity-classified awards and settle solely in shares of the Company’s common stock. No cash settlement alternative exists. Stock Price-Based PSUs On February 1, 2026, the Company granted <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260201__20260201__dei--LegalEntityAxis__custom--ThirdPartyConsultantMember_zhXA7vfr39D8" title="Share based compensation, granted">500,000 PSUs to a third-party consultant, under a consulting agreement effective February 1, 2026. The PSUs vest in five tranches upon the achievement of specified stock price milestones, measured by the closing price of the Company’s common stock on a U.S. national securities exchange, as follows: <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260201__20260201__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_zfxu861zb1ff" title="Share based compensation, granted">100,000 shares at $5.00; <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260201__20260201__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember_zx1bJWNmkK32" title="Share based compensation, granted">100,000 shares at $6.00; <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260201__20260201__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_zBWjLCkvibR4" title="Share based compensation, granted">100,000 shares at $8.00; <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260201__20260201__us-gaap--StatementEquityComponentsAxis__custom--CommonStockFourMember_zmRpMmr3OOxd" title="Share based compensation, granted">100,000 shares at $10.00; and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260201__20260201__us-gaap--StatementEquityComponentsAxis__custom--CommonStockFiveMember_zExwy8rpgyDa" title="Share based compensation, granted">100,000 shares at $12.00. Each milestone is certified by the Committee in good faith, and the consultant must be providing continuous service through the certification date. All unvested PSUs are forfeited immediately upon cessation of service. The stock price milestones and shares issuable per tranche are subject to equitable adjustment for stock splits, reverse stock splits, and similar events under the Company’s 2023 Long-Term Incentive Plan. The stock price targets represent market conditions because they relate to the achievement of specified stock prices of the Company’s equity instruments. In accordance with ASC 718, the effect of the market conditions is reflected in the estimate of the grant-date fair value of the awards. The Company estimated the grant-date fair value of each tranche using a Monte Carlo simulation model, which incorporated the following significant assumptions: <p id="xdx_899_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_zaPUEBWO13W6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">SCHEDULE OF ESTIMATED GRANT DATE FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assumption</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Grant-date stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"></td><td style="width: 16%; text-align: center">$3.58</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Stock price milestones</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">$5.00 – $12.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20260101__20260331_za2YNFr4KcB1" style="text-align: center" title="Expected volatility">152.9%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20260101__20260331_zAkMHFOIFSi7" style="text-align: center" title="Interest rate">3.72%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20260101__20260331_zg9p7YoRWWKg" style="text-align: center" title="Dividend yield">0.00%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Derived service periods (range)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20260101__20260331__srt--RangeAxis__srt--MinimumMember_zON3qEU3oFfl" title="Derived service period">3.43 – <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20260101__20260331__srt--RangeAxis__srt--MaximumMember_zYY9GhTjVsQ9" title="Derived service period">7.41 years</td><td style="text-align: left"> </td></tr> </table> The following table summarizes the grant-date fair value by tranche (in thousands, except per unit data and units): <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Tranche</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Milestone</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">GDFV1/Unit</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Units</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Agg FV2</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">DSP3 (yrs)</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Q1 2026 Expense</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 6%; text-align: center">1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zODFydbMopW8" style="width: 10%; text-align: right" title="Other than options grants, milestone">5.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_fKDEp_zigEr7mpLXC1" style="width: 12%; text-align: right" title="Other than options grants, GDFV">3.56</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zGGIgjFu6kpl" style="width: 12%; text-align: right" title="Weighted average grant date fair value">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn3n3_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKDIp_zcdridUBfNjg" style="width: 12%; text-align: right" title="Other than options vested in period Agg">356</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKDMp_zuJu60982IBf" style="width: 12%; text-align: right" title="Weighted average remaining contractual term">3.43</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensation_pn3n3_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zG4x3MJceSMl" style="width: 12%; text-align: right" title="Share based compensation, expense">17</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z0WTqEkQx4v2" style="text-align: right" title="Other than options grants, milestone">6.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_fKDEp_zXXtf0dR24Rf" style="text-align: right" title="Other than options grants, GDFV">3.55</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zcbLzsuO5lz3" style="text-align: right" title="Weighted average grant date fair value">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn3n3_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKDIp_z6gVlbDUmiB6" style="text-align: right" title="Other than options vested in period Agg">355</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKDMp_zkKzhpVIBXt8" style="text-align: right" title="Weighted average remaining contractual term">4.58</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensation_pn3n3_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zKVRqX26k3Hg" style="text-align: right" title="Share based compensation, expense">12</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zWBn0hdKb2Pb" style="text-align: right" title="Other than options grants, milestone">8.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_fKDEp_zcvsW0MMnsTd" style="text-align: right" title="Other than options grants, GDFV">3.57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zGz55570KAV8" style="text-align: right" title="Weighted average grant date fair value">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn3n3_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKDIp_z2vMm7YvBoN" style="text-align: right" title="Other than options vested in period Agg">357</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKDMp_zrzaGAgVaDcj" style="text-align: right" title="Weighted average remaining contractual term">5.99</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensation_pn3n3_c20260101__20260331__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zT0ZYTmcStJj" style="text-align: right" title="Share based compensation, expense">9</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">4</td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20260101__20260331__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z4ccg3rWzUHb" style="text-align: right" title="Other than options grants, milestone">10.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20260101__20260331__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember_fKDEp_zmCjqfcT5ys" style="text-align: right" title="Other than options grants, GDFV">3.56</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zmbjHrRT0sXj" style="text-align: right" title="Weighted average grant date fair value">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn3n3_c20260101__20260331__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKDIp_zQzQEeybyCCf" style="text-align: right" title="Other than options vested in period Agg">356</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260101__20260331__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKDMp_znggXYVj2bO9" style="text-align: right" title="Weighted average remaining contractual term">6.84</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensation_pn3n3_c20260101__20260331__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFourMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zwOxc9L08Wlc" style="text-align: right" title="Share based compensation, expense">8</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: center">5</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_pid_c20260101__20260331__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFiveMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zerCunUjrDBl" style="padding-bottom: 1pt; text-align: right" title="Other than options grants, milestone">12.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20260101__20260331__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFiveMember_fKDEp_zseJ3e4zaRf2" style="padding-bottom: 1pt; text-align: right" title="Other than options grants, GDFV">3.54</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFiveMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_z4yDu4O7CiZb" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average grant date fair value">100,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn3n3_c20260101__20260331__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFiveMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKDIp_zvGYaPqNfhL6" style="border-bottom: Black 1pt solid; text-align: right" title="Other than options vested in period Agg">354</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260101__20260331__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFiveMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKDMp_ziGOdQCVSsEd" style="padding-bottom: 1pt; text-align: right" title="Weighted average remaining contractual term">7.41</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensation_pn3n3_c20260101__20260331__us-gaap--VestingAxis__custom--ShareBasedCompensationAwardTrancheFiveMember__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zFImXREPyby" style="border-bottom: Black 1pt solid; text-align: right" title="Share based compensation, expense">8</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zXK8qoFdaPu2" style="font-weight: bold; text-align: right" title="Weighted average grant date fair value">500,000</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn3n3_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_fKDIp_z3IDbYSuhgG4" style="font-weight: bold; text-align: right" title="Other than options vested in period Agg">1,778</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensation_pn3n3_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zsniSnB3odjd" style="font-weight: bold; text-align: right" title="Share based compensation, expense">54</td><td style="font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">GDFV per unit, determined using a Monte Carlo simulation model. The weighted-average grant-date fair value per unit for the stock price-based PSUs was $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIEVTVElNQVRFRCBHUkFOVCBEQVRFIEZBSVIgVkFMVUUgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zk41kZO6Mdnk" title="Share based compensation, price per share">3.56.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">(2)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Aggregate fair value (“Agg FV”)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">(3)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Derived service period (“DSP”)</td></tr></table> The aggregate grant-date fair value of the 500,000 stock price-based PSUs was approximately $1,778. In accordance with ASC 718-10-25-8, compensation cost is recognized on a straight-line basis over the derived service period for each tranche, regardless of whether the stock price milestones are ultimately achieved. Previously recognized compensation cost is not reversed if a market condition is not satisfied, provided that all necessary service has been rendered. During the three months ended March 31, 2026, the Company recognized stock-based compensation expense of approximately $54 related to the stock price-based PSUs, which is included in general and administrative expenses in the unaudited condensed consolidated statements of operations. As of March 31, 2026, unrecognized compensation cost related to the stock price-based PSUs was approximately $1,724, however, following the consultant’s resignation in April 2026, the remaining unrecognized compensation cost associated with the unvested stock price-based PSUs will not be recognized in future periods because the requisite service condition will no longer be satisfied. The consultant is also entitled to 500,000 time-based RSUs (<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20260331__us-gaap--AwardTypeAxis__custom--RestrictedStockOneMember_z5FgdotMLbm4" title="Stock issued grant fair shares vesting">300,000 vesting on the effective date and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20260331__us-gaap--AwardTypeAxis__custom--RestrictedStockTwoMember_z95it3fcSib2" title="Stock issued grant fair shares vesting">200,000 vesting quarterly over 12 months), which are separately disclosed in the RSU section above. AUM-Based PSUs On March 16, 2026, the Company granted up to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260316__20260316__dei--LegalEntityAxis__custom--ThirdPartyConsultantMember_zSeOudYoIFJ1" title="Stock issued during the period, shares">1,000,000 PSUs to a third-party consultant, vesting upon the achievement of assets under management (“AUM”) milestones related to the Company’s rare earth elements (“REE”) Fund (a planned commodity-linked investment product): (i) 50,000 units upon launch of the REE Fund (subject to a dollar cap of $150); (ii) 100,000 units when AUM exceeds $500 million (subject to a dollar cap of $350); and (iii) 850,000 units when AUM exceeds $1 billion (subject to a dollar cap of $3,000). The number of shares issuable under each tranche is the lesser of the fixed share amount or the dollar cap divided by the fair value per share at each vesting date. Although the number of shares is variable, the dollar caps function as a ceiling on value deliverable to the consultant and do not require delivery of a fixed monetary amount; the consultant bears downside stock price risk. The Company evaluated the award under ASC 480 and ASC 815 and concluded it does not meet the criteria for liability classification or derivative accounting. The award is equity-classified and indexed to the Company’s own stock. These PSUs contain performance conditions under ASC 718. The grant-date fair value per unit was determined based on the closing price of the Company’s common stock of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pn4n6_c20260316__20260316__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfSf68cfIAT1" title="Stock issued during the period, conversion">1.83 on the grant date of March 16, 2026. At the grant-date stock price of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pn4n6_c20260316__20260316__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zovwxQ9Ydvg9" title="Stock issued during the period, conversion">1.83, none of the dollar caps were binding (the lowest implied cap price is $3.00 for Tranche 1), and accordingly the grant-date fair value per unit equals $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pn4n6_c20260316__20260316__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztgoRo8wGtAb" title="Stock issued during the period, conversion">1.83 for all tranches. The aggregate grant-date fair value of the AUM-based PSUs is approximately $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pn3n3_c20260316__20260316__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zPnA0CRTVhi9" title="Stock issued during the period, conversion">1,830 (based on the grant-date stock price of $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_pn4n6_c20260316__20260316__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNTYKsdy96Ak" title="Stock issued during the period, conversion">1.83 applied to <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pn3n3_c20260316__20260316__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zzIfzV0sNGV7" title="Stock issued during the period, conversion shares">1,000,000 units at the maximum fixed share amounts), subject to a maximum aggregate dollar cap of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueOther_pn3n3_c20260316__20260316__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zV3pS3pjdma" title="Stock issued during the period, other">3,500 (consisting of $150 for the first tranche, $350 for the second tranche, and $3,000 for the third tranche). The dollar caps limit the maximum value deliverable to the consultant regardless of the stock price at vesting. As of March 31, 2026, management assessed the probability of achieving each AUM-based performance condition on a tranche-by-tranche basis and concluded that no condition is probable. The launch of a REE Fund would require, among other things, formation of a legal entity, preparation of offering documents, establishment of custody and pricing infrastructure for rare earth elements, and satisfaction of applicable regulatory requirements — none of which had been initiated as of the reporting date. The AUM-based milestones ($500 million and $1 billion) are sequentially dependent on fund launch and were assessed as remote. Accordingly, no stock-based compensation expense was recognized during the three months ended March 31, 2026. The Company recognizes compensation cost only when achievement of the applicable performance condition is considered probable, on a straight-line basis over the requisite service period. Summary of PSU Awards As of March 31, 2026, total stock-based compensation expense recognized for PSU awards during the three months ended March 31, 2026 was approximately $54, consisting entirely of expense related to the stock price-based PSUs. For the AUM-based PSUs, management assessed the probability of achieving each performance condition on a tranche-by-tranche basis and concluded that no condition met the “probable” threshold under ASC 718; accordingly, no expense was recognized. Total unrecognized compensation cost related to outstanding PSUs was approximately $1,724 as of March 31, 2026, consisting of $1,724 related to stock price-based PSUs (to be recognized over a weighted-average period of approximately <span id="xdx_90D_ecustom--WarrantsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zYvB8uRZTgDd" title="Weighted average Years">5.5 years) and $<span id="xdx_90C_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn3n3_do_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zQnqt8fPT3Y1" title="Employee share based compensation">0 related to AUM-based PSUs (to be recognized when achievement becomes probable, with an aggregate grant-date fair value of approximately $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn3n3_c20260101__20260331_zUf79fTzFdk1" title="Grant-date fair value">1,830, subject to a maximum dollar cap of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn3n3_c20260101__20260331__srt--RangeAxis__srt--MaximumMember_zjzhK0e6nzl1" title="Grant-date fair value">3,500). The Company accounts for forfeitures as they occur. No forfeitures of PSUs were recognized during the three months ended March 31, 2026. <p id="xdx_895_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zuzSJho9pwri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes PSU activity for the three months ended March 31, 2026: SCHEDULE OF NON VESTED RESTRICTED ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4B1_us-gaap--AwardTypeAxis_us-gaap--PerformanceSharesMember_zmVhOf67ATpc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PSUs – Stock Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4B1_us-gaap--AwardTypeAxis_custom--PerformanceSharesAndAUMMember_z4M9IspbpBcf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PSUs - AUM</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4B7_z6gdl80meDdd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total PSUs</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_431_c20260101__20260331_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_zqJeF6E5PlEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Nonvested as of December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_zlfSnGWzuy9f" style="vertical-align: bottom; background-color: White"> <td style="width: 46%">Granted</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">1,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">1,500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_zFlsgXvEjeK" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_zhugbnZoxcKg" style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_43A_c20260101__20260331_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_zHUZCuapVqAa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Nonvested as of March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,500,000</td><td style="text-align: left"> </td></tr> </table> The table above excludes (i) performance-based restricted stock units tied to Organic Gross Revenue Growth targets, under which certain consultants may earn additional units annually based on achievement of annual revenue growth targets established and certified by the Compensation Committee, as the number of units issuable is not determinable until the applicable targets are set, and (ii) PSU grants to four third-party consultants, involving an aggregate of up to approximately 910,000 units tied to cumulative gross revenue and token-related performance milestones, that have not been approved by the Board of Directors or the Compensation Committee as of March 31, 2026 and are therefore not considered granted under ASC 718. ViralClear Pharmaceuticals, Inc. 2019 Long-Term Incentive Plan There are <span id="xdx_906_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20260331__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zJQRCPZVXUp9" title="Shares available for future issuance">2,915,071 shares remaining available for future issuance of awards under the terms of the ViralClear Plan. Warrants (ViralClear) <p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpX4hFRI9LE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of the warrant activity for three months ended March 31, 2026 is as follows: SUMMARY OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Term</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260101__20260331_zMUWSSHZ60y1" style="width: 14%; text-align: right" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, beginning">473,772</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331_zJOpuHe9bgya" style="width: 14%; text-align: right" title="Weighted-Average Exercise Price, Outstanding">5.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_ecustom--WarrantsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20260101__20260331_z6kNw9IeuABi" style="width: 14%; text-align: right" title="Weighted-Average Remaining Contractual Term, Outstanding">1.9</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited/expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20260101__20260331_ztZfOl86hde4" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited Expired">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331_zQfmA9N8pbD3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Forfeited/expired">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260101__20260331_zrROZBxHOfgg" style="text-align: right" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Ending">473,772</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331_zsm08wGtl3Mf" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--WarrantsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260101__20260331_zffUanhqhkRi" style="text-align: right" title="Weighted-Average Remaining Contractual Term, Outstanding">1.6</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantsOrRightsExercisable_iE_pid_c20260101__20260331_zktKLDI0XCGb" style="text-align: right" title="Exercisable warrants">473,772</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantOrRightsExercisable_iE_pid_c20260101__20260331_zShhHfvSZcbh" style="text-align: right" title="Weighted-Average Exercise Price, Exercisable">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--WarrantsExercisableWeightedAverageRemainingContractualTerms_dtY_c20260101__20260331_zauYXbkU8RA7" style="text-align: right" title="Weighted-Average Remaining Contractual Term, Exercisable">1.6</td><td style="text-align: left"> </td></tr> </table> The following table presents information related to warrants (ViralClear) at March 31, 2026: SCHEDULE OF RELATED TO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Expiration</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331_zhrbgUyyRDcg" style="width: 30%; text-align: right" title="Warrants exercise price">5.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantsOrRightOutstanding_iI_pid_c20260331_zwbifDezf6Ed" style="width: 30%; text-align: right" title="Warrants rights outstanding">473,772</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_ecustom--WarrantsExpirationDateDescription_c20260101__20260331__us-gaap--AwardTypeAxis__custom--RangeOneMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zauwJIPVBbS7" style="width: 30%; text-align: center" title="Expiration date">November 2027</td><td style="width: 1%; text-align: left"> </td></tr> </table> Restricted stock units (ViralClear) <p id="xdx_893_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_hdei--LegalEntityAxis__custom--ViralClearMember_zGs6eDquXa0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the restricted stock activity for the three months ended March 31, 2026: SCHEDULE OF NON VESTED RESTRICTED ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Restricted shares outstanding at January 1, 2026:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionNonvestedNumberOfShares_iS_pid_c20260101__20260331_z6gvvtaiQRdi" style="width: 16%; text-align: right" title="Restricted shares outstanding beginning balance">678,679</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20260101__20260331_zF6KK5PgfD99" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total restricted shares outstanding at March 31, 2026:</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionNonvestedNumberOfShares_iE_pid_c20260101__20260331_zexmS4bHtVh8" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted shares outstanding ending balance">678,679</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Comprised of:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested restricted shares as of March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_iI_pid_c20260331_zy6xQR5h2Vwh" style="text-align: right" title="Vested restricted shares">678,679</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested restricted shares as of March 31, 2026</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionUnvestedNumberOfShares_iI_pid_c20260331_zXl1vbEkbYYb" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested restricted shares">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionUnvestedTotalNumberOfShares_iI_pid_c20260331_zrQDItqJiYQl" style="border-bottom: Black 2.5pt double; text-align: right" title="Vested and unvested restricted shares total">678,679</td><td style="text-align: left"> </td></tr> </table> BioSig AI Sciences, Inc. Warrants (BioSig AI) The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at March 31, 2026: SCHEDULE OF OUTSTANDING TO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Expiration</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__dei--LegalEntityAxis__custom--BioSigAISciencesIncMember_zOvN11BGlm1k" style="width: 30%; text-align: right" title="Warrants exercise price">1.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantsOrRightOutstanding_iI_pid_c20260331__dei--LegalEntityAxis__custom--BioSigAISciencesIncMember_zXBc2m0KPdK9" style="width: 30%; text-align: right" title="Warrants rights outstanding">130,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 30%; text-align: right">June-July 2028</td><td style="width: 1%; text-align: left"> </td></tr> </table>

10359211

4376595

14735806

22494324

14735806

37230130

18109340

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zRQmRSyRgB74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents information related to stock options as of March 31, 2026: SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="9" style="border-bottom: Black 1pt solid; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center">Exercise</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted Average Remaining Life</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Exercisable Number of</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Options</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">In Years</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td style="width: 21%; text-align: right">Under <span id="xdx_908_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zJUBjI1fdCs1" title="Options Outstanding, Exercise Price">9.99</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zDl2Fp2tgHFi" style="width: 22%; text-align: right" title="Number of Options Outstanding">2,900,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zzWsmO5rFbu8" style="width: 22%; text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">8.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--OptionsUnder999Member_zaT16DIQ49n3" style="width: 22%; text-align: right" title="Number of Options Outstanding Options Exercisable">2,900,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zFOX8HM2vmZ7" title="Options Outstanding, Exercise Price">10.00-<span id="xdx_90A_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zHoiYZdTpLTi" title="Options Outstanding, Exercise Price">19.99</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zZsFaXXZgDOa" style="text-align: right" title="Number of Options Outstanding">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_z52R6XM6Sl4d" style="text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">7.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options1000To1999Member_zlwkTcWSRGSl" style="text-align: right" title="Number of Options Outstanding Options Exercisable">15,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zplXG429kpPg" title="Options Outstanding, Exercise Price">20.00-<span id="xdx_90D_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zT2u2aJg3gch" title="Options Outstanding, Exercise Price">49.99</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_zsFbj7llpWgg" style="text-align: right" title="Number of Options Outstanding">3,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_z75Q6yGMfNv3" style="text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">3.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options2000To4999Member_z2rDY58Gw0mb" style="text-align: right" title="Number of Options Outstanding Options Exercisable">3,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$</td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_z22LnohoifH1" title="Options Outstanding, Exercise Price">50.00-<span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_uUSDPShares_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_zuSlNT5rDDDd" title="Options Outstanding, Exercise Price">69.99</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_zQCR0aQNqAs9" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_z4whnaEGgMk4" style="text-align: right" title="Number of Options Outstanding Weighted Average Remaining Life">3.8</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--Options5000To6999Member_zL5NHol5LYe5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options Outstanding Options Exercisable">3,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td></td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20260331_zUWDkjt7s6hj" style="text-align: right" title="Number of Options Outstanding">2,921,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zPYDSlDNtGUl" title="Number of Options Outstanding Weighted Average Remaining Life">8.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_pid_c20260331_zE41Xa7psPr3" style="text-align: right" title="Number of Options Outstanding Options Exercisable">2,921,000</td><td style="text-align: left"> </td></tr> </table>

9.99

2900000

P8Y7M6D

2900000

10.00

19.99

15000

P7Y1M6D

15000

20.00

49.99

3000

P3Y

3000

50.00

69.99

3000

P3Y9M18D

3000

2921000

P8Y7M6D

2921000

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z3NbEZJaQEYl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of the stock option activity and related information for the Plan for the three months ended March 31, 2026 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Remaining Contractual Term</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260331_zCwlmCszOucj" style="width: 11%; text-align: right" title="Outstanding shares">2,736,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20260101__20260331_zgkFnOSz4onb" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Outstanding">0.78</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231_zx9ttiqxYcze" style="width: 11%; text-align: right" title="Weighted-Average Remaining Contractual Term">8.7</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331_za9cIC2q83rd" style="width: 11%; text-align: right" title="Outstanding Aggregate Intrinsic Value">6,744,540</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykA" id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIssued_pid_c20260101__20260331_zSSwPbglVhIb" style="text-align: right" title="Grants">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykA" id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20260101__20260331_zIH72xWCEDW2" style="text-align: right" title="Weighted Average Exercise Price Grants">3.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zrvoE65hyxh8" style="text-align: right" title="Weighted-Average Remaining Contractual Term">9.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited/expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20260101__20260331_zbxdM8oVTrT7" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited/expired">(65,000</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20260101__20260331_zRPCN7MTljnj" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Forfeited/expired">5.01</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Outstanding at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260101__20260331_zXbrTTV43Qm5" style="text-align: right" title="Outstanding shares">2,921,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20260101__20260331_zhgezoQ0sVn8" style="text-align: right" title="Weighted Average Exercise Price Outstanding">0.89</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331_zue6gLLtqIde" style="text-align: right" title="Weighted-Average Remaining Contractual Term">8.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331_zjqJry38RW3a" style="text-align: right" title="Outstanding Aggregate Intrinsic Value">1,709,540</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20260331_zPc7rmIZczwa" style="text-align: right" title="Outstanding shares Exercisable">2,921,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20260101__20260331_z1x6xs6enfu2" style="text-align: right" title="Weighted Average Exercise Price Outstanding">0.89</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_dtY_c20260101__20260331_zotNZV5u7LBb" style="text-align: right" title="Weighted-Average Remaining Contractual Term">8.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260331_zxl7sSeRHS58" style="text-align: right" title="Outstanding Exercisable Aggregate Intrinsic Value">1,709,540</td><td style="text-align: left"> </td></tr> </table>

2736000

0.78

P8Y8M12D

6744540000

250000

3.21

P9Y9M18D

65000

5.01

2921000

0.89

P8Y7M6D

1709540000

2921000

0.89

P8Y7M6D

1709540000

1.13

250000

3.21

P10Y

770000

40000

<p id="xdx_896_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zKYh80d1diPe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">During the three months ended March 31, 2026, the Company granted options to purchase shares of its common stock, which were valued using the Black-Scholes option pricing model. The following assumptions were used to calculate the fair value of the options granted during the three months ended March 31, 2026: SCHEDULE OF OPTIONS GRANTED ASSUMPTIONS USING BLACK-SCHOLES OPTION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assumption</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Weighted average grant date fair value</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zzQx6EDqEx16" title="Derivative liability">3.08</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zQwUZu6X24U" title="Derivative liability">124.17</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zUaKEjFsxoV3" title="Derivative liability">4.15</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_ztlrlB2l2Tac" title="Derivative liability">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected Term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--DerivativeTermOfContract_dtY_c20260101__20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z7iwjzdhC8b9" title="Derivative liability, measurement input, expected life">5.0</td><td style="text-align: left"> </td></tr> </table>

3.08

124.17

4.15

0.00

P5Y

<p id="xdx_892_ecustom--ScheduleOfWarrantsOrRightsSharesAuthorizedExercisePriceRangeTableTextBlock_zvZ3WZgk747a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information with respect to outstanding warrants to purchase common stock of Streamex Corp. as of March 31, 2026: SCHEDULE OF INFORMATION RELATED TO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 70%; border-collapse: collapse; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Warrants</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Expiration Date</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%">$</td> <td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt03000Member_zSjo4kqacV0e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 30%; text-align: right" title="Exercise price">0.3000</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"> </td> <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt03000Member_zAhSvBw4Orud" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30%; text-align: right" title="Number Outstanding">11,982</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"> </td> <td id="xdx_98A_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt03000Member_zyPjrwpg3Nk8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center" title="Expiration date">Nov-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt09547Member_zT02YMRS5hlc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">0.9547</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt09547Member_zyOKGZwiMvEc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">577,916</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98E_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt09547Member_zAVkKUK0CN63" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Sep-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt17800Member_ziJV0ayV3mbi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">3.3640</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt33640Member_zrmdwfIFKyLk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">117,828</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_988_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt33640Member_zFuB2CPcpu6f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jul-29</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt40660Member_zsLJbb9JuxJg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">4.0660</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt40660Member_zZZwy87bv5Wf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">25,000</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_984_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt40660Member_zb4RErB2fgKj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Nov-32</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44550Member_zUJW9s3Bp2p9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">4.4550</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44550Member_zMau7uqx7D8i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">107,483</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98A_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44550Member_zRfZ5f9bBe0a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jun-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44660Member_zD3D4aBtGsXe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">4.4660</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44660Member_zjqlv1kEOKca" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">5,580</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_987_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt44660Member_zEzl64AKlP82" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Apr-29</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt46626Member_zf3ehvSIa0q8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">4.6626</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt46626Member_zV7l0EdVp3o7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">49,550</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt46626Member_zIUmN1m4Ump3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Mar-29</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49252Member_zqsP07naO3B" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">4.9252</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49252Member_ztWgi9w4ItX6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">71,593</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49252Member_zByctZqsfxs7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Mar-29</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49290Member_z4pq77QMsKhg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">4.9290</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49290Member_zUdU2zwwfCy3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">99,243</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_985_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt49290Member_zrS5vfwrOMvb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jul-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt51358Member_z2GSys3IYLHf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">5.1358</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt51358Member_zSnWpSN9MEWk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">83,270</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_983_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt51358Member_zAM58d3t3bQ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jul-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt71810Member_zu9crszAgqLh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">7.1810</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt71810Member_z0Gop4iLd0u3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">9,846</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98F_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt71810Member_zxTf8BsC2Kvb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jul-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt75020Member_zF8n2ItHCLzk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">7.5020</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt75020Member_zaWore382wd5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">21,369</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt75020Member_zBThlererZZ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Aug-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt79630Member_zmKmSnBTf0T8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">7.9630</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt79630Member_zXIcNTnM614c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">21,709</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_984_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt79630Member_z9oaMfar8UU9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jun-27</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt90000Member_zzwpUlpGRkK2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">9.0000</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt90000Member_z4GOvLzzJOZ8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">84,390</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt90000Member_ztaKU7AfNps" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jan-29</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt95960Member_zhknhVPSlke4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">9.5960</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt95960Member_zc4uWKLExDLl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">19,118</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98F_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt95960Member_zkmw5ijlN6Zh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Aug-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt100992Member_zoG7rRAhf2pi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">10.0992</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt100992Member_zPljZFF4Dh4c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">51,705</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98A_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt100992Member_zDpyw1exQJak" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Sep-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt102600Member_zn8W5xG6Qw94" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">10.2600</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt102600Member_znsTeXoOdHF2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">84,296</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98C_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt102600Member_ziSfopg839tl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Sep-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt104678Member_zbzOlk5u3BWf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">10.4678</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt104678Member_ze1zWMAm4F7l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">40,417</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98E_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt104678Member_zGNlTSbM8nSk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Oct-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt113000Member_zZ15zGYIrSn9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">11.3000</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt113000Member_zYXCBKFgKQf1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">96,198</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_983_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt113000Member_zkHqHHfXGF0k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Nov-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt132800Member_zGzKFldPFW03" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">13.2800</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt132800Member_zAV7tbybloif" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">12,500</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_980_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt132800Member_zsjj1vHkE16" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Jul-26</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt480000Member_zPuOaY2pAuMd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">48.0000</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt480000Member_zVCZD44Meu78" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">56,892</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98C_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt480000Member_z9sUydU50n0f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Nov-27</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt616000Member_zVIjXO0bZkE5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Exercise price">61.6000</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt616000Member_zoHCkwn6qcTh" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right" title="Number Outstanding">11,982</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td id="xdx_98B_ecustom--WarrantsExpirationDateDescription_pid_c20260101__20260331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--WarrantsAt616000Member_zujd1soxEde5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center" title="Expiration date">Nov-28</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331_zk0c0xvzB9ma" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number outstanding">1,647,885</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

0.3000

11982

Nov-28

0.9547

577916

Sep-28

3.3640

117828

Jul-29

4.0660

25000

Nov-32

4.4550

107483

Jun-28

4.4660

5580

Apr-29

4.6626

49550

Mar-29

4.9252

71593

Mar-29

4.9290

99243

Jul-28

5.1358

83270

Jul-28

7.1810

9846

Jul-28

7.5020

21369

Aug-28

7.9630

21709

Jun-27

9.0000

84390

Jan-29

9.5960

19118

Aug-28

10.0992

51705

Sep-28

10.2600

84296

Sep-28

10.4678

40417

Oct-28

11.3000

96198

Nov-28

13.2800

12500

Jul-26

48.0000

56892

Nov-27

61.6000

11982

Nov-28

1647885

54647

87984

A summary of the warrant activity for three months ended March 31, 2026 is as follows: SCHEDULE OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Exercise Price</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Remaining Contractual Term</td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zQNuGYaGPo7b" style="width: 11%; text-align: right" title="Outstanding shares">1,735,869</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_904_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding_iS_pid_uUSDPShares_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_z5aCPpJQw2Ff" title="Weighted-Average Exercise Price ending">6.94</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90B_ecustom--WarrantsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_z8DmWS9N5qj2" title="Weighted-Average Remaining Contractual Term, Outstanding">2.8</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20250101__20251231__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zm72oyJomJO7" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value">1,414,626</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantsOrRightIssued_pid_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zlDAB4jRpJU1" style="text-align: right" title="Issued">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Forfeited/expired</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantsOrRightExpried_pid_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zKplsDAnhtgg" style="text-align: right" title="Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercised</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantsOrRightExercised_iN_pid_di_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_z2c7GSMjaqx5" style="border-bottom: Black 1pt solid; text-align: right" title="Exercised">(87,984</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_pid_uUSDPShares_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zzEZHsVFX5j8" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price Exercised">0.95</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zWEEIjpMRomg" style="text-align: right" title="Outstanding shares">1,647,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_906_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding_iE_pid_uUSDPShares_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_ze8c3sCM2j8" title="Weighted-Average Exercise Price ending">7.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--WarrantsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zrIdLQrEKpN7" title="Weighted-Average Remaining Contractual Term, Outstanding">2.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zAyaM6alNug" style="text-align: right" title="Aggregate Intrinsic Value">111,231</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and expected to vest at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightsVestedAndExpectedToVestOutstanding_iE_pid_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zLN1QuEswKn9" style="text-align: right" title="Warrants Vested and expected to vest, Shares">1,647,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsVestedAndExpectedToVestOutstanding_iE_pid_uUSDPShares_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zENI6VPlqV73" style="text-align: right" title="Weighted-Average Exercise Price Vested and expected to vest">7.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_ecustom--WarrantsWeightedAverageRemainingContractualTermExercised_dtY_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zAisHnGpH4fj" title="Weighted-Average Remaining Contractual Term, Exercised">2.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20260101__20260331_zJXHJVd3mx58" style="text-align: right" title="Warrants Vested and expected to vest, Aggregate Intrinsic Value">111,231</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightsExercisable_iE_pid_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zL5ckJbs5yz6" style="text-align: right" title="Warrants Exercisable, Shares">1,647,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable_iE_pid_uUSDPShares_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_zTybZwZa838g" style="text-align: right" title="Weighted-Average Exercise Price Exercisable">7.26</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--WarrantsExercisableWeightedAverageRemainingContractualTerm_dtY_c20260101__20260331__us-gaap--BusinessAcquisitionAxis__custom--BioSigAIMember_za0hcYvkD0rf" title="Weighted-Average Remaining Contractual Term Exercisable">2.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20260101__20260331_zEVPLvNrKFEl" style="text-align: right" title="Warrants Exercisable, Aggregate Intrinsic Value">111,231</td><td style="text-align: left"> </td></tr> </table>

1735869

6.94 P2Y9M18D

1414626000

87984 0.95

1647885

7.26 P2Y7M6D

111231000

1647885 7.26 P2Y7M6D

111231000

1647885 7.26 P2Y7M6D

111231000

1.13

<p id="xdx_890_eus-gaap--NonvestedRestrictedStockSharesActivityTableTextBlock_hdei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zqLWmb65h9zj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the restricted stock activity for the three months ended March 31, 2026: SCHEDULE OF RESTRICTED STOCK ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Grant Date Fair Value Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Restricted shares issued as of January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zU6yAPm9GDp7" style="width: 16%; text-align: right" title="Total restricted shares outstanding">2,037,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zW6chHOBrx89" style="width: 16%; text-align: right" title="Weighted average grant date fair value">5.36</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zqwBQ0THaL88" style="text-align: right" title="Granted">8,868,316</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zgEcM6CkxKoj" style="text-align: right" title="Granted">2.91</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_z2aG27nG54Kc" style="text-align: right" title="Vested">(6,123,941</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zkCAcM9smBH3" style="text-align: right" title="Vested">3.01</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zU7jhaBrRk7d" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">(198,500</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zu6yZlHhwgrg" style="text-align: right" title="Forfeited">3.21</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zVIDfB03hEZ2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total restricted shares outstanding">4,583,375</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zTSqH1QJpEzb" style="text-align: right" title="Total">3.86</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Comprised of:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested restricted shares as of March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedNumberOfShares_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_za2A3AUILo29" style="text-align: right" title="Vested restricted shares">301,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDate_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_z9lBR4SABb72" style="text-align: right" title="Vested restricted shares, Weighted-Average Grant Date Fair Value Per Share">3.21</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Unvested restricted shares as of March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnvestedNumberOfShares_iE_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zJgNT8XFgsQc" style="text-align: right" title="Unvested restricted shares">4,281,875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDate_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zgItdmW7sI7f" style="text-align: right" title="Unvested restricted, Weighted-Average Grant Date Fair Value Per Share">3.90</td><td style="text-align: left"> </td></tr> </table>

2037500

5.36

8868316000

2.91

6123941000

3.01

198500000

3.21

4583375

3.86

301500000 3.21 4281875000 3.90

24545

2236

24545

P1Y3M29D

<p id="xdx_892_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zYtGE20XIgfd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> SCHEDULE OF RESTRICTED STOCK UNITS GRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Grant Date</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Recipient</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RSUs Granted</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Vesting Terms</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">GDFV1</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 16%; text-align: center">1/1/2026</td><td style="width: 2%"> </td> <td style="width: 18%; text-align: center">Third-party consultant</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneOneTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zQmybD9ElbVa" style="width: 12%; text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 30%; text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneOneTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zpfJywxR75wk" title="Share based compensation arrangement by share-based payment award, award vesting rights">25,000 immediately; remainder quarterly</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneOneTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zq8UNcQjSrP2" style="width: 12%; text-align: right" title="Stock issued during the period, value">758</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">1/8/2026</td><td> </td> <td style="text-align: center">Interim Executive Chairman</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneEightTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--InterimExecutiveChairmanMember_zCds9XWqV4C" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneEightTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--InterimExecutiveChairmanMember_znYUUedKgtxi" title="Share based compensation arrangement by share-based payment award, award vesting rights">4 equal quarterly installments over 1 year</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneEightTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--InterimExecutiveChairmanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zlK6asSdaz8h" style="text-align: right" title="Stock issued during the period, value">321</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">1/8/2026</td><td> </td> <td style="text-align: center">Chief Executive Officer</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneEightTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficierMember_zR4FTTXqJsK8" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneEightTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficierMember_zE9f8cqnrxJ6" title="Share based compensation arrangement by share-based payment award, award vesting rights">100,000 on May 15, 2026; 900,000 in 16 quarterly installments over 4 years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneEightTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficierMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zUKxEPuYzms9" style="text-align: right" title="Stock issued during the period, value">3,210</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">1/27/2026</td><td> </td> <td style="text-align: center">Third-party consultant</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneTwentySevenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zz98jtNILia3" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">125,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneTwentySevenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zNccOaAJ5r1g" title="Share based compensation arrangement by share-based payment award, award vesting rights">16 quarterly installments over 4 years</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--OneTwentySevenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zqEmX0LKZpj3" style="text-align: right" title="Stock issued during the period, value">456</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">2/1/2026</td><td> </td> <td style="text-align: center">Third-party consultant</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--TwoOneTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_z7sJDU2rzvfb" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--TwoOneTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zxSJFUVEYqpi" title="Share based compensation arrangement by share-based payment award, award vesting rights">300,000 immediately; 200,000 in 4 quarterly installments over 12 months</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--TwoOneTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zKnyGr2OW89j" style="text-align: right" title="Stock issued during the period, value">1,790</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">3/3/2026</td><td> </td> <td style="text-align: center">Third-party consultant</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeThreeTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zUWZ9hwEyM0i" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">425,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeThreeTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zDhYQLgNuuZ9" title="Share based compensation arrangement by share-based payment award, award vesting rights">212,500 immediately; 125,000 on Jun 3; 87,500 on Sep 3, 2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeThreeTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zYjhYZdjLM95" style="text-align: right" title="Stock issued during the period, value">876</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">3/16/2026</td><td> </td> <td style="text-align: center">Third-party consultant</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeSixteenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_zfDfsmAuqYd7" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">65,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeSixteenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember_z7G9BEMAp0B8" title="Share based compensation arrangement by share-based payment award, award vesting rights">5,000 immediately; remainder monthly</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeSixteenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__custom--ThirdPartyConsultantMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_z8UHCf1dAVw7" style="text-align: right" title="Stock issued during the period, value">119</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">3/16/2026</td><td> </td> <td style="text-align: center">Chief Financial Officer</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeSixteenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_zKNoNtU3ehQ7" style="border-bottom: Black 1pt solid; text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeSixteenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z6Yr0g4aWIL" title="Share based compensation arrangement by share-based payment award, award vesting rights">16 quarterly installments over 4 years</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardDateAxis__custom--ThreeSixteenTwoThousandTwentySixMember__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zectv6UzqAkl" style="border-bottom: Black 1pt solid; text-align: right" title="Stock issued during the period, value">915</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260331_zDp4dGN5Sec6" style="text-align: right" title="Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted">2,965,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_fKDEp_zCXXwSjJUGOa" style="text-align: right" title="Stock issued during the period, value">8,445</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Grant-date fair value (“GDFV”)</td></tr></table> The table above includes only RSU grants issued during the three months ended March 31, 2026 that were subject to vesting conditions extending beyond the grant date. During the same period, the Company also granted an aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331_zXIK3OT2jSvg" title="Share based compensation, granted">5,903,316 RSUs that vested immediately upon grant and are therefore excluded from this table. The total RSUs granted during the three months ended March 31, 2026 were <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zJRr1ka6HlG2" title="Share based compensation, granted">8,868,316, as reflected in the RSU activity table above.

250000000

25,000 immediately; remainder quarterly

758000

100000000

4 equal quarterly installments over 1 year

321000

1000000000

100,000 on May 15, 2026; 900,000 in 16 quarterly installments over 4 years

3210000

125000000

16 quarterly installments over 4 years

456000

500000000

300,000 immediately; 200,000 in 4 quarterly installments over 12 months

1790000

425000000

212,500 immediately; 125,000 on Jun 3; 87,500 on Sep 3, 2026

876000

65000000

5,000 immediately; remainder monthly

119000

500000000

16 quarterly installments over 4 years

915000

2965000000

8445000

5903316

8868316

500000

100000

5.00

100000

6.00

100000

8.00

100000

10.00

100000

12.00

<p id="xdx_899_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_zaPUEBWO13W6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">SCHEDULE OF ESTIMATED GRANT DATE FAIR VALUE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Assumption</td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Grant-date stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"></td><td style="width: 16%; text-align: center">$3.58</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Stock price milestones</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center">$5.00 – $12.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20260101__20260331_za2YNFr4KcB1" style="text-align: center" title="Expected volatility">152.9%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20260101__20260331_zAkMHFOIFSi7" style="text-align: center" title="Interest rate">3.72%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20260101__20260331_zg9p7YoRWWKg" style="text-align: center" title="Dividend yield">0.00%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Derived service periods (range)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20260101__20260331__srt--RangeAxis__srt--MinimumMember_zON3qEU3oFfl" title="Derived service period">3.43 – <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_pid_dtY_c20260101__20260331__srt--RangeAxis__srt--MaximumMember_zYY9GhTjVsQ9" title="Derived service period">7.41 years</td><td style="text-align: left"> </td></tr> </table>

3.58

5000.00

12000.00

1.529

0.0372

0.0000

P3Y5M4D

P7Y4M28D

5.00

3.56

100000

356000

P3Y5M4D

17000

6.00

3.55

100000

355000

P4Y6M29D

12000

8.00

3.57

100000

357000

P5Y11M26D

9000

10.00

3.56

100000

356000

P6Y10M2D

8000

12.00

3.54

100000

354000

P7Y4M28D

8000

500000

1778000

54000

3.56

500000

1778000

1724000

500000

300000

200000

1000000

i) 50,000 units upon launch of the REE Fund (subject to a dollar cap of $150); (ii) 100,000 units when AUM exceeds $500 million (subject to a dollar cap of $350); and (iii) 850,000 units when AUM exceeds $1 billion (subject to a dollar cap of $3,000)

1830000

3.00

1830000

1000000000

3500000

150

350

3000

The dollar caps limit the maximum value deliverable to the consultant regardless of the stock price at vesting. As of March 31, 2026, management assessed the probability of achieving each AUM-based performance condition on a tranche-by-tranche basis and concluded that no condition is probable. The launch of a REE Fund would require, among other things, formation of a legal entity, preparation of offering documents, establishment of custody and pricing infrastructure for rare earth elements, and satisfaction of applicable regulatory requirements — none of which had been initiated as of the reporting date. The AUM-based milestones ($500 million and $1 billion) are sequentially dependent on fund launch and were assessed as remote. Accordingly, no stock-based compensation expense was recognized during the three months ended March 31, 2026. The Company recognizes compensation cost only when achievement of the applicable performance condition is considered probable, on a straight-line basis over the requisite service period.

1724000

P5Y6M

1830000

3500000

<p id="xdx_895_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zuzSJho9pwri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes PSU activity for the three months ended March 31, 2026: SCHEDULE OF NON VESTED RESTRICTED ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4B1_us-gaap--AwardTypeAxis_us-gaap--PerformanceSharesMember_zmVhOf67ATpc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PSUs – Stock Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4B1_us-gaap--AwardTypeAxis_custom--PerformanceSharesAndAUMMember_z4M9IspbpBcf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">PSUs - AUM</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_4B7_z6gdl80meDdd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total PSUs</td><td style="font-weight: bold"> </td></tr> <tr id="xdx_431_c20260101__20260331_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iS_zqJeF6E5PlEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Nonvested as of December 31, 2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_zlfSnGWzuy9f" style="vertical-align: bottom; background-color: White"> <td style="width: 46%">Granted</td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">500,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">1,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right">1,500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_zFlsgXvEjeK" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Vested and issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_zhugbnZoxcKg" style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_43A_c20260101__20260331_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_zHUZCuapVqAa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Nonvested as of March 31, 2026</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,500,000</td><td style="text-align: left"> </td></tr> </table>

500000000

1000000000

1500000000

500000000

1000000000

1500000000

2915071

<p id="xdx_896_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zpX4hFRI9LE6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of the warrant activity for three months ended March 31, 2026 is as follows: SUMMARY OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Term</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260101__20260331_zMUWSSHZ60y1" style="width: 14%; text-align: right" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, beginning">473,772</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331_zJOpuHe9bgya" style="width: 14%; text-align: right" title="Weighted-Average Exercise Price, Outstanding">5.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_ecustom--WarrantsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20260101__20260331_z6kNw9IeuABi" style="width: 14%; text-align: right" title="Weighted-Average Remaining Contractual Term, Outstanding">1.9</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited/expired</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20260101__20260331_ztZfOl86hde4" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited Expired">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331_zQfmA9N8pbD3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Forfeited/expired">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260101__20260331_zrROZBxHOfgg" style="text-align: right" title="Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Ending">473,772</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331_zsm08wGtl3Mf" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--WarrantsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerms_dtY_c20260101__20260331_zffUanhqhkRi" style="text-align: right" title="Weighted-Average Remaining Contractual Term, Outstanding">1.6</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable at March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantsOrRightsExercisable_iE_pid_c20260101__20260331_zktKLDI0XCGb" style="text-align: right" title="Exercisable warrants">473,772</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantOrRightsExercisable_iE_pid_c20260101__20260331_zShhHfvSZcbh" style="text-align: right" title="Weighted-Average Exercise Price, Exercisable">5.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--WarrantsExercisableWeightedAverageRemainingContractualTerms_dtY_c20260101__20260331_zauYXbkU8RA7" style="text-align: right" title="Weighted-Average Remaining Contractual Term, Exercisable">1.6</td><td style="text-align: left"> </td></tr> </table>

473772

5.00

P1Y10M24D

473772

5.00

P1Y7M6D 473772 5.00 P1Y7M6D The following table presents information related to warrants (ViralClear) at March 31, 2026: SCHEDULE OF RELATED TO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Expiration</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331_zhrbgUyyRDcg" style="width: 30%; text-align: right" title="Warrants exercise price">5.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantsOrRightOutstanding_iI_pid_c20260331_zwbifDezf6Ed" style="width: 30%; text-align: right" title="Warrants rights outstanding">473,772</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_ecustom--WarrantsExpirationDateDescription_c20260101__20260331__us-gaap--AwardTypeAxis__custom--RangeOneMember__dei--LegalEntityAxis__custom--ViralClearPharmaceuticalsIncMember_zauwJIPVBbS7" style="width: 30%; text-align: center" title="Expiration date">November 2027</td><td style="width: 1%; text-align: left"> </td></tr> </table>

5.00

473772 November 2027

<p id="xdx_893_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_hdei--LegalEntityAxis__custom--ViralClearMember_zGs6eDquXa0b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the restricted stock activity for the three months ended March 31, 2026: SCHEDULE OF NON VESTED RESTRICTED ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Restricted shares outstanding at January 1, 2026:</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionNonvestedNumberOfShares_iS_pid_c20260101__20260331_z6gvvtaiQRdi" style="width: 16%; text-align: right" title="Restricted shares outstanding beginning balance">678,679</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Forfeited</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20260101__20260331_zF6KK5PgfD99" style="border-bottom: Black 1pt solid; text-align: right" title="Forfeited">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Total restricted shares outstanding at March 31, 2026:</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionNonvestedNumberOfShares_iE_pid_c20260101__20260331_zexmS4bHtVh8" style="border-bottom: Black 2.5pt double; text-align: right" title="Restricted shares outstanding ending balance">678,679</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Comprised of:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vested restricted shares as of March 31, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentOutstandingNumber_iI_pid_c20260331_zy6xQR5h2Vwh" style="text-align: right" title="Vested restricted shares">678,679</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested restricted shares as of March 31, 2026</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionUnvestedNumberOfShares_iI_pid_c20260331_zXl1vbEkbYYb" style="border-bottom: Black 1pt solid; text-align: right" title="Unvested restricted shares">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionUnvestedTotalNumberOfShares_iI_pid_c20260331_zrQDItqJiYQl" style="border-bottom: Black 2.5pt double; text-align: right" title="Vested and unvested restricted shares total">678,679</td><td style="text-align: left"> </td></tr> </table>

678679 678679 678679 678679 The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at March 31, 2026: SCHEDULE OF OUTSTANDING TO WARRANTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Expiration</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Date</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__dei--LegalEntityAxis__custom--BioSigAISciencesIncMember_zOvN11BGlm1k" style="width: 30%; text-align: right" title="Warrants exercise price">1.00</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantsOrRightOutstanding_iI_pid_c20260331__dei--LegalEntityAxis__custom--BioSigAISciencesIncMember_zXBc2m0KPdK9" style="width: 30%; text-align: right" title="Warrants rights outstanding">130,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 30%; text-align: right">June-July 2028</td><td style="width: 1%; text-align: left"> </td></tr> </table>

1.00

130500

NOTE 15 – NON-CONTROLLING INTEREST As of March 31, 2026 and December 31, 2025, the Company had a majority interest in ViralClear of approximately <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_uPure_c20260331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ViralClearPharmaceuticalsIncMember_zBSLbvsrlDxj" title="Majority interest"><span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ViralClearPharmaceuticalsIncMember_zIzzHDaCbNN9" title="Majority interest">70% for both periods. As of March 31, 2026, and December 31, 2025, the Company had a majority interest in BioSig AI of approximately <span id="xdx_905_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20260331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BioSigAIMember_zc3mjiBTTbTf" title="Majority interest"><span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20251231__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--BioSigAIMember_zBhe0ATFeTTc" title="Majority interest">84% for both periods. As of March 31, 2026, the Company consolidated Streamex Ltd. as a variable interest entity, with noncontrolling interest holders (consisting of two related party officers) holding approximately <span id="xdx_90F_ecustom--VariableInterestPercentage_pid_dp_uPure_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zUrj1i2g5uil" title="Variable interest percentage">1.5% of the outstanding GLDY Tokens. See Note 9, Streamex Ltd. (VIE), for additional information. A reconciliation of ViralClear Pharmaceuticals, Inc., BioSig AI Sciences, Inc. and Streamex Ltd. non-controlling loss attributable to the Company: Net loss attributable to the non-controlling interest for the three months ended March 31, 2026: SCHEDULE OF NON-CONTROLLING INTEREST <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_498_20260101__20260331__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_z7tXHVxJQF26" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">ViralClear Pharmaceuticals, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_499_20260101__20260331__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zuWCZl6LTKQa" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">BioSig AI Sciences, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_495_20260101__20260331__srt--ConsolidatedEntitiesAxis__custom--StreamexLtdMember_zUiRisbdQ5aj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Streamex Ltd</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_492_20260101__20260331_zG902pX0lfei" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_403_ecustom--NetIncomeLossOfNonControllingInterest_pn3n3_zmZlvwOe1r6e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Net Income (loss)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-*</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">(155</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">(155</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--AverageNoncontrollingInterestPercentageOfProfitlosses_pid_dp_uPure_zHz94wcMfan4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Noncontrolling interest’s weighted-average ownership percentage</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">30.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net income (loss) attributable to non-controlling interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20260101__20260331__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_fKg_____z4wrnUwb32B7" title="Net loss attributable to non-controlling interest">-*</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20260101__20260331__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_fKg_____zaec1LuuqWgj" title="Net loss attributable to non-controlling interest">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20260101__20260331__srt--ConsolidatedEntitiesAxis__custom--StreamexLtdMember_fKg_____zmwIYJLET4C1" title="Net loss attributable to non-controlling interest">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table> Net loss attributable to the non-controlling interest for the three months ended March 31, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_492_20250101__20250331__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_ztZlWZuFyXhh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">ViralClear Pharmaceuticals, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_499_20250101__20250331__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zBLPOT9e1gzj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">BioSig AI Sciences, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_495_20250101__20250331__srt--ConsolidatedEntitiesAxis__custom--StreamexLtdMember_zlRyeVhHDg67" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Streamex Ltd</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_495_20250101__20250331_zqWXRsV1DF81" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_403_ecustom--NetIncomeLossOfNonControllingInterest_pn3n3_zrQSI2lzluy4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-* </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">75</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">75</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AverageNoncontrollingInterestPercentageOfProfitlosses_pid_dp_uPure_zFXc3UTmzhq" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Noncontrolling interest’s weighted-average ownership percentage</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss attributable to non-controlling interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20250331__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_fKg_____zWMPhZGKdl0d" title="Net loss attributable to non-controlling interest">-* </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20250331__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_fKg_____zmBm4LuaZVm1" title="Net loss attributable to non-controlling interest">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20250331__srt--ConsolidatedEntitiesAxis__custom--StreamexLtdMember_fKg_____zC561Bpbt411" title="Net loss attributable to non-controlling interest">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">*</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Less than $0.5 thousand</td></tr> </table> <p id="xdx_890_eus-gaap--ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_zInCOSdx3ih6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2026: SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4BE_srt--ConsolidatedEntitiesAxis_custom--ViralClearPharmaceuticalsIncMember_zZ2Kqw79ti9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">ViralClear Pharmaceuticals, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4BB_srt--ConsolidatedEntitiesAxis_custom--BioSigAISciencesIncMember_zZe7AT7Pb4We" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">BioSig AI Sciences, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4BA_srt--ConsolidatedEntitiesAxis_custom--StreamexLtdMember_zKQLZ0ATZl9g" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Streamex Ltd</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4B5_zHEDqXqoUV5l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_43E_c20260101__20260331_eus-gaap--MinorityInterest_iS_pn3n3_zbuzX5jByxlc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%">Balance, January 1, 2026</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">(171</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">203</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">32</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--IssuanceOfEquityToNoncontrollingInterestHolders_zPpJj9lpRu3a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of equity to noncontrolling interest holders</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">225</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">225</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_zixcxg84dSP9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net income (loss) attributable to non-controlling interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_430_c20260101__20260331_eus-gaap--MinorityInterest_iE_pn3n3_z9Xi1SCJ8wLa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, March 31, 2026</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(171</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">203</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">224</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">256</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4BE_srt--ConsolidatedEntitiesAxis_custom--ViralClearPharmaceuticalsIncMember_zJtrwur6DEVe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">ViralClear Pharmaceuticals, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4BB_srt--ConsolidatedEntitiesAxis_custom--BioSigAISciencesIncMember_zxrU3aX0opa7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">BioSig AI Sciences, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4BA_srt--ConsolidatedEntitiesAxis_custom--StreamexLtdMember_z6JtdyxAVd61" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Streamex Ltd</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4B5_zqsMxKQcTFHf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_430_c20250101__20250331_eus-gaap--MinorityInterest_iS_pn3n3_zzjV25u1cjTk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%">Balance, January 1, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">(171</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">188</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">17</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_z28hxYY9ooki" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net income (loss) attributable to non-controlling interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_43B_c20250101__20250331_eus-gaap--MinorityInterest_iE_pn3n3_zjX5NqXiPynk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, March 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(171</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">200</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">29</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

0.70

0.84

0.015 Net loss attributable to the non-controlling interest for the three months ended March 31, 2026: SCHEDULE OF NON-CONTROLLING INTEREST <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_498_20260101__20260331__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_z7tXHVxJQF26" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">ViralClear Pharmaceuticals, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_499_20260101__20260331__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zuWCZl6LTKQa" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">BioSig AI Sciences, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_495_20260101__20260331__srt--ConsolidatedEntitiesAxis__custom--StreamexLtdMember_zUiRisbdQ5aj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Streamex Ltd</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_492_20260101__20260331_zG902pX0lfei" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_403_ecustom--NetIncomeLossOfNonControllingInterest_pn3n3_zmZlvwOe1r6e" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Net Income (loss)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-*</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">(155</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">(155</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr> <tr id="xdx_40E_ecustom--AverageNoncontrollingInterestPercentageOfProfitlosses_pid_dp_uPure_zHz94wcMfan4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Noncontrolling interest’s weighted-average ownership percentage</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">30.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.01</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net income (loss) attributable to non-controlling interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20260101__20260331__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_fKg_____z4wrnUwb32B7" title="Net loss attributable to non-controlling interest">-*</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20260101__20260331__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_fKg_____zaec1LuuqWgj" title="Net loss attributable to non-controlling interest">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20260101__20260331__srt--ConsolidatedEntitiesAxis__custom--StreamexLtdMember_fKg_____zmwIYJLET4C1" title="Net loss attributable to non-controlling interest">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table> Net loss attributable to the non-controlling interest for the three months ended March 31, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_492_20250101__20250331__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_ztZlWZuFyXhh" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">ViralClear Pharmaceuticals, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_499_20250101__20250331__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_zBLPOT9e1gzj" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">BioSig AI Sciences, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_495_20250101__20250331__srt--ConsolidatedEntitiesAxis__custom--StreamexLtdMember_zlRyeVhHDg67" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Streamex Ltd</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_495_20250101__20250331_zqWXRsV1DF81" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_403_ecustom--NetIncomeLossOfNonControllingInterest_pn3n3_zrQSI2lzluy4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-* </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">75</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">75</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--AverageNoncontrollingInterestPercentageOfProfitlosses_pid_dp_uPure_zFXc3UTmzhq" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Noncontrolling interest’s weighted-average ownership percentage</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net loss attributable to non-controlling interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20250331__srt--ConsolidatedEntitiesAxis__custom--ViralClearPharmaceuticalsIncMember_fKg_____zWMPhZGKdl0d" title="Net loss attributable to non-controlling interest">-* </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20250331__srt--ConsolidatedEntitiesAxis__custom--BioSigAISciencesIncMember_fKg_____zmBm4LuaZVm1" title="Net loss attributable to non-controlling interest">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_c20250101__20250331__srt--ConsolidatedEntitiesAxis__custom--StreamexLtdMember_fKg_____zC561Bpbt411" title="Net loss attributable to non-controlling interest">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">*</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Less than $0.5 thousand</td></tr> </table> -155000 -155000 0.300 0.160 0.002 0.0001

-1000

75000 75000 0.32 0.16 0.16

12000

<p id="xdx_890_eus-gaap--ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock_zInCOSdx3ih6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2026: SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4BE_srt--ConsolidatedEntitiesAxis_custom--ViralClearPharmaceuticalsIncMember_zZ2Kqw79ti9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">ViralClear Pharmaceuticals, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4BB_srt--ConsolidatedEntitiesAxis_custom--BioSigAISciencesIncMember_zZe7AT7Pb4We" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">BioSig AI Sciences, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4BA_srt--ConsolidatedEntitiesAxis_custom--StreamexLtdMember_zKQLZ0ATZl9g" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Streamex Ltd</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4B5_zHEDqXqoUV5l" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_43E_c20260101__20260331_eus-gaap--MinorityInterest_iS_pn3n3_zbuzX5jByxlc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%">Balance, January 1, 2026</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">(171</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">203</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">32</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--IssuanceOfEquityToNoncontrollingInterestHolders_zPpJj9lpRu3a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of equity to noncontrolling interest holders</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">225</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">225</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_zixcxg84dSP9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net income (loss) attributable to non-controlling interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr id="xdx_430_c20260101__20260331_eus-gaap--MinorityInterest_iE_pn3n3_z9Xi1SCJ8wLa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, March 31, 2026</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(171</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">203</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">224</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">256</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2025: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4BE_srt--ConsolidatedEntitiesAxis_custom--ViralClearPharmaceuticalsIncMember_zJtrwur6DEVe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">ViralClear Pharmaceuticals, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4BB_srt--ConsolidatedEntitiesAxis_custom--BioSigAISciencesIncMember_zxrU3aX0opa7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">BioSig AI Sciences, Inc.</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4BA_srt--ConsolidatedEntitiesAxis_custom--StreamexLtdMember_z6JtdyxAVd61" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Streamex Ltd</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" id="xdx_4B5_zqsMxKQcTFHf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif"> </td></tr> <tr id="xdx_430_c20250101__20250331_eus-gaap--MinorityInterest_iS_pn3n3_zzjV25u1cjTk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%">Balance, January 1, 2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">(171</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">188</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">17</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_pn3n3_z28hxYY9ooki" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net income (loss) attributable to non-controlling interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_43B_c20250101__20250331_eus-gaap--MinorityInterest_iE_pn3n3_zjX5NqXiPynk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Balance, March 31, 2025</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(171</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">200</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">29</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

-171000

203000

32000

225000 225000

-1000

-171000

203000

224000

256000

-171000

188000

17000

12000

-171000

200000

29000

NOTE 16 — COMMITMENTS AND CONTINGENCIES Tokenized Yield Partnership Agreement Overview On September 8, 2025, the Company entered into a Tokenized Yield Partnership Agreement (the “Token Agreement”) with Monetary Metals & Co. (“MM”), a Delaware corporation, establishing an exclusive, multi-year strategic partnership to design, launch, and distribute blockchain-based financial products that tokenize the yield generated from MM’s precious-metal lease and bond programs. The Token Agreement commenced on September 8, 2025 and continues for an initial term of three years, subject to automatic one-year renewal periods unless terminated in accordance with its terms. For additional information regarding the gold assets held by Streamex Ltd. and the related VIE disclosures, see Notes 8 and 9. Exclusivity and Performance Conditions For at least three years, MM agreed not to engage with any other party to tokenize the yield or other financial attributes of its precious-metal lease or bond products, and the Company agreed not to partner with any third party to tokenize yield derived from precious-metal leases, in each case subject to specified volume-based performance conditions. To maintain exclusivity, the Company must supply at least 10% of the total leased ounces presented by MM each quarter that meet defined criteria, including minimum insurance standards, a net yield of at least 3% per annum after origination fees, and compliance with restrictions on counterparties and jurisdictions. Failure to meet these thresholds, after a 90-day cure period, results in loss of exclusivity but does not obligate the Company to commit capital or continue participation. Consulting Services Agreement On February 4, 2026, the Company entered into a consulting agreement with an independent third party to provide advisory and capital markets related services in connection with the Company’s GLDY Token program. The agreement has an initial term of six months and provides for a fixed consulting fee of $4,000, as well as potential transaction-based fees contingent upon the completion of certain activities during the term. The full $4,000 base fee was paid during the three months ended March 31, 2026. As of March 31, 2026, the unamortized portion of $2,785 is included in prepaid expenses and other assets on the unaudited condensed consolidated balance sheet and is being recognized ratably over the service period. No transaction-based fees were earned or payable during the period. Litigation We may be subject at times to other legal proceedings and claims, which arise in the ordinary course of our business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity. In November 2025, a former advisor filed a Notice of Civil Claim in the Supreme Court of British Columbia against the Company, its wholly owned subsidiary Streamex Exchange Corporation, and certain current officers and directors. The claim alleges, among other things, breach of contract, unjust enrichment, and civil conspiracy in connection with alleged agreements relating to equity interests in Streamex Exchange Corporation prior to the Company’s acquisition of that entity. The plaintiff seeks, among other relief, specific performance, equitable compensation, and damages. The Company disputes the claims and intends to defend the matter vigorously. As of March 31, 2026, no liability has been recorded in the unaudited condensed consolidated financial statements related to this matter, as management, after consultation with legal counsel, believes that a loss is not probable. The matter is in a preliminary stage and, as a result, the Company is unable to reasonably estimate the possible loss or range of loss, if any, associated with this matter at this time.

4000000 4000000

2785000

NOTE 17 – SEGMENT REPORTING Chief Operating Decision Maker (CODM) and Segment Evaluation On May 28, 2025, in connection with the acquisition of Streamex Exchange, the Company appointed Henry McPhie, former co-founder and CEO of Streamex Exchange, as its new Chief Executive Officer and a member of the Board of Directors. As a result of this leadership change, Mr. McPhie was designated as the Company’s new Chief Operating Decision Maker (“CODM”), replacing Anthony Amato, the Company’s former CEO and director. Following this change, the Company re-evaluated its operating and reportable segments based on the internal financial information reviewed by the CODM for purposes of performance assessment and resource allocation. Although the acquisition of Streamex Exchange introduced a new line of business focused on digital asset infrastructure, the CODM has not yet begun reviewing Streamex Exchange’s operating results separately for purposes of performance assessment or resource allocation. As of March 31, 2026, the CODM continues to evaluate the Company’s financial performance on a consolidated basis, and the internal reporting structure has not been modified to reflect discrete segment-level financial information. Management believes that a transitional period is appropriate given the timing of the acquisition, the pre-revenue status of Streamex Exchange, and the pending financing and shareholder approvals necessary to operationalize the Streamex Exchange platform. Accordingly, the Company has concluded that no change in reportable segments has occurred as of March 31, 2026. The Company will continue to monitor the CODM’s review practices and internal reporting structure and will update its segment disclosures in future periods if and when discrete financial information is regularly reviewed at the segment level. In accordance with ASC 280-10-50-34, if a change in reportable segments occurs in a future period, the Company will recast prior-period segment disclosures retrospectively to reflect the new segment structure. Basis of Segmentation The Company’s CODM evaluates financial performance and allocates resources on a consolidated basis. The Company manages its operations as one integrated business, and the CODM does not receive or review separate financial information for Streamex Exchange or any other business unit. This approach reflects the manner in which the CODM: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Assesses performance against budgeted targets;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Forecasts future financial results;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Makes strategic and operational decisions;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocates resources across the organization.</td></tr> </table> Accordingly, the Company has determined that it operates as one reportable and operating segment as of March 31, 2026. Management continues to evaluate whether the Streamex Exchange business may become a separate reportable segment in future periods, depending on the scale and financial significance, and the CODM’s review of discrete operating results. Segment Performance Measures The primary measure used by the CODM to assess performance is consolidated net loss, which is reviewed in conjunction with other consolidated financial metrics. The CODM also evaluates actual results against budgeted amounts and considers consolidated operating results in making decisions about research and development investments and other strategic initiatives. Segment assets are not separately reported to or reviewed by the CODM. Therefore, the Company does not disclose segment asset information. All assets are managed on a consolidated basis and are reported in the Company’s unaudited condensed consolidated balance sheets. The Company does not currently disclose geographic revenue or customer concentration by segment, as such information is not reviewed by the CODM. However, this will be reassessed as operations evolve. Revenue and Expense Information Information concerning the operations of the Company’s reportable segments is as follows: SCHEDULE OF SEGMENT REPORTING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20260101__20260331__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zu8FlNS70gg6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2026</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20250101__20250331__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zXxOqN9rK6Ec" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">For the Three Months Ended March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2026</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 16%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 16%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_msOEzaZH_zjx5fhgOSdy6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenues</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less Segment expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzaZH_zwolPeNCMI5b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_i01_pn3n3_maOEzaZH_z85jRYG34uoh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,884</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">883</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--GeneralAndAdministrativeStockbasedCompensationExpenses_i01_pn3n3_maOEzaZH_z6b7VuGTVL76" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">General and administrative - stock-based compensation expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,370</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,074</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DepreciationAndAmortization_i01_pn3n3_maOEzaZH_zU42Tp0OBYXi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,492</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingExpenses_i01NT_pn3n3_di_msPLzVm7_mtOEzaZH_maITEBzHoy_zHwIzBQmURfl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total operating and segment expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(35,746</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,984</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InterestIncomeExpenseNet_pn3n3_maNIEzY2h_zmQUiUwYkple" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Interest expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(12,195</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_msNIEzY2h_zudeaQQL7NHk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Realized gain on sale of gold</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,938</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--RealizedGainOnMarketableSecurities_pn3n3_maNIEzY2h_zc1r8cv79gXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Realized gain on marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">484</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_maNIEzY2h_zkX1KVsQ0MRa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Change in fair value of marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(134</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_maNIEzY2h_zPWeiByJ9AI3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Change in fair value of embedded derivative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">497</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InterestExpenseJuniorSubordinatedDebentures_pn3n3_msNIEzY2h_zRsF2wQ6PQd8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Realized loss on extinguishment of convertible debenture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,057</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RealizedInvestmentGainsLosses_pn3n3_maNIEzY2h_zdGPgM6OUfU4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Realized loss on investment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(119</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_maNIEzY2h_zQDk72H7HKca" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Gain on settlement and forgiveness of debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">199</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_maNIEzY2h_zesgkUWiIS5h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Other income (expense), net</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">73</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_maPLzVm7_mtNIEzY2h_msITEBzHoy_z7IRJx7we6Kl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total other income (expense)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,513</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">184</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_i01NT_pn3n3_di_mtITEBzHoy_zbugeFkqAVWe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Income taxes (benefit)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(565</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProfitLoss_iT_pn3n3_mtPLzVm7_maNILzjcj_zE2OsKYrPRv6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Segment Net Loss</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(46,694</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,800</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_msNILzjcj_z73yZnogG6we" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Non-controlling interest</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILzjcj_zFdDVDa5LOwe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net loss attributable to Streamex Corp.</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(46,693</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,812</td><td style="text-align: left">)</td></tr> </table>

Information concerning the operations of the Company’s reportable segments is as follows: SCHEDULE OF SEGMENT REPORTING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_495_20260101__20260331__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zu8FlNS70gg6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2026</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_49B_20250101__20250331__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zXxOqN9rK6Ec" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">For the Three Months Ended March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2026</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2025</td><td style="padding-bottom: 1pt; text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 16%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 16%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_msOEzaZH_zjx5fhgOSdy6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Revenues</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Less Segment expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_i01_pn3n3_maOEzaZH_zwolPeNCMI5b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--GeneralAndAdministrativeExpense_i01_pn3n3_maOEzaZH_z85jRYG34uoh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">General and administrative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,884</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">883</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--GeneralAndAdministrativeStockbasedCompensationExpenses_i01_pn3n3_maOEzaZH_z6b7VuGTVL76" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">General and administrative - stock-based compensation expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,370</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,074</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DepreciationAndAmortization_i01_pn3n3_maOEzaZH_zU42Tp0OBYXi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Depreciation and amortization</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,492</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">21</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--OperatingExpenses_i01NT_pn3n3_di_msPLzVm7_mtOEzaZH_maITEBzHoy_zHwIzBQmURfl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total operating and segment expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(35,746</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,984</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InterestIncomeExpenseNet_pn3n3_maNIEzY2h_zmQUiUwYkple" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Interest expense, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(12,195</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DebtSecuritiesAvailableForSaleRealizedLoss_pn3n3_msNIEzY2h_zudeaQQL7NHk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Realized gain on sale of gold</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,938</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--RealizedGainOnMarketableSecurities_pn3n3_maNIEzY2h_zc1r8cv79gXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Realized gain on marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">484</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EquitySecuritiesFvNiGainLoss_pn3n3_maNIEzY2h_zkX1KVsQ0MRa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Change in fair value of marketable securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(134</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_maNIEzY2h_zPWeiByJ9AI3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Change in fair value of embedded derivative</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">497</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InterestExpenseJuniorSubordinatedDebentures_pn3n3_msNIEzY2h_zRsF2wQ6PQd8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Realized loss on extinguishment of convertible debenture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,057</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--RealizedInvestmentGainsLosses_pn3n3_maNIEzY2h_zdGPgM6OUfU4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Realized loss on investment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(119</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--GainsLossesOnExtinguishmentOfDebt_pn3n3_maNIEzY2h_zQDk72H7HKca" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Gain on settlement and forgiveness of debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">199</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_maNIEzY2h_zesgkUWiIS5h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Other income (expense), net</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">73</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--NonoperatingIncomeExpense_iT_pn3n3_maPLzVm7_mtNIEzY2h_msITEBzHoy_z7IRJx7we6Kl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total other income (expense)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(11,513</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">184</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--IncomeTaxExpenseBenefit_i01NT_pn3n3_di_mtITEBzHoy_zbugeFkqAVWe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Income taxes (benefit)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(565</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--ProfitLoss_iT_pn3n3_mtPLzVm7_maNILzjcj_zE2OsKYrPRv6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Segment Net Loss</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(46,694</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,800</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_msNILzjcj_z73yZnogG6we" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Non-controlling interest</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(12</td><td style="text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--NetIncomeLoss_iT_pn3n3_mtNILzjcj_zFdDVDa5LOwe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Net loss attributable to Streamex Corp.</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(46,693</td><td style="text-align: left">)</td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,812</td><td style="text-align: left">)</td></tr> </table>

6000

8884000

883000

25370000 2074000

1492000

21000

35746000

2984000

-12195000

2938000

484000

-134000

497000

-3057000

-119000

199000

73000

-15000

-11513000

184000

565000

-46694000

-2800000

-1000

12000

-46693000

-2812000

NOTE 18– RELATED PARTY TRANSACTIONS Accounts payable and accrued expenses as of March 31, 2026 include $907 due to related parties, compared to $66 as of December 31, 2025. These amounts primarily relate to executives and board compensation, severance, and reimbursements. During the three months ended March 31, 2026, two officers of the Company subscribed for GLDY Tokens issued by Streamex Ltd. (the Company’s consolidated VIE): (i) the Company’s Chief Investment Officer, subscribed for approximately $200 of GLDY Tokens, and (ii) the Company’s General Counsel, subscribed for approximately $<span id="xdx_90C_eus-gaap--NoncontrollingInterestInVariableInterestEntity_iI_pn3n3_c20260331__srt--ConsolidatedEntitiesAxis__custom--StreamexLtdMember__srt--TitleOfIndividualAxis__custom--GeneralCounselOfficersMember_zm1mQmZiKoN9" title="Variable interst entity">25 of GLDY Tokens. Both subscriptions were made on the same terms and at the same per-token price as the Company’s own subscriptions pursuant to the GLDY Subscription Agreement. As of March 31, 2026, the officers’ combined GLDY Token holdings represented approximately <span id="xdx_905_ecustom--VariableInterestPercentage_pid_dp_uPure_c20260101__20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVYxBq1gPgM4" title="Variable interest percentage">1.5% of total outstanding tokens. See Note 9, Streamex Ltd. (VIE), for additional information.

907000

66000

25000

0.015

NOTE 19 – SUBSEQUENT EVENTS The Company has evaluated subsequent events from the balance sheet date through the date on which these unaudited condensed financial statements were issued. Other than as described in the notes below, the Company did not have any material subsequent events that impacted its unaudited condensed financial statements or disclosures. GLDY Dividend <span id="xdx_900_eus-gaap--DividendPaymentRestrictionsScheduleDescription_c20260417__20260417__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zeYYU1OxCxTf" title="Dividend payment description">On April 17, 2026, the Board of Directors of Streamex Ltd., acting through GLDY ServiceCo, LLC as servicer, declared a scrip dividend of 0.000085 ounces of gold per GLDY Token for the month of March 2026, payable on April 17, 2026 to tokenholders of record as of that date. The dividend was funded by gold lease income earned on Streamex Ltd.’s gold holdings during March 2026 and was paid in the form of additional fractional GLDY Tokens. Each GLDY Token continues to represent one troy ounce of gold on a 1:1 basis, as confirmed by the third-party fund administrator. The noncontrolling interest holders’ share of the dividend was not material. Appointment of Director and Equity Awards On April 28, 2026, the Board appointed the Company’s Chief Investment Officer (“CIO”), to serve as a non-independent director of the Board for a term expiring at the Company’s 2026 annual meeting of stockholders or until his successor is duly elected and qualified, or until the earlier of his death, resignation or removal. In connection with the CIO’s amended employment agreement effective April 6, 2026, the Board granted the CIO <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20260406__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ChiefInvestmentOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zQhxpxVPu5Ph" title="Shares granted">1,250,000 RSUs and a special incentive award of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20260406__20260406__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ChiefInvestmentOfficerMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zjTR45Hvsnsc" title="Incentive award shares">1,000,000 RSUs. Both awards vest in sixteen equal quarterly installments commencing July 1, 2026, subject to continued service, and become fully vested upon a protected termination, a change in control, or the termination. Amended Employment Agreements and Equity Awards On May 1, 2026, the Company entered into amended and restated employment agreements with the Company’s Chief Executive Officer (“CEO”) and the Company’s Interim Executive Chairman (“Interim Chairman”). In connection with the amended agreements, the Board granted each of the CEO and Interim Chairman <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20260501__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefInvestmentOfficerMember__us-gaap--AwardTypeAxis__custom--PerformanceVestingRestrictedStockUnitsMember_z1U4hQT5BEFd" title="Number of shares granted">1,500,000 PSUs for shares of the Company’s common stock, divided into five equal tranches of <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260501__20260501__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefInvestmentOfficerMember_z4p4NYUADSp8" title="Common stock, shares divided">300,000 shares each. Each tranche vests upon the Company’s cumulative sales of GLDY reaching the following milestones: (i) $<span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20260501__20260501__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefInvestmentOfficerMember__us-gaap--AwardTypeAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_z6kSylQqPSnj" title="Vested shares">250,000,000; (ii) $<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20260501__20260501__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefInvestmentOfficerMember__us-gaap--AwardTypeAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zgX1j2uptNgj" title="Vested shares">500,000,000; (iii) $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20260501__20260501__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefInvestmentOfficerMember__us-gaap--AwardTypeAxis__us-gaap--ShareBasedCompensationAwardTrancheThreeMember_z9r0T8echfHf" title="Vested shares">1,000,000,000; (iv) $<span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20260501__20260501__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefInvestmentOfficerMember__us-gaap--AwardTypeAxis__custom--ShareBasedCompensationAwardTrancheFourMember_zn5exNI7kUQ1" title="Vested shares">2,000,000,000; and (v) $<span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20260501__20260501__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__srt--TitleOfIndividualAxis__custom--ChiefInvestmentOfficerMember__us-gaap--AwardTypeAxis__custom--ShareBasedCompensationAwardTrancheFiveMember_zmE9F9deINl3" title="Vested shares">3,000,000,000. Cumulative GLDY sales are measured in good faith by the Company and certified by the Compensation Committee. Vesting is subject to continued employment, except that the awards become fully vested upon a protected termination or a change in control. Any tranche that has not vested on or before the tenth anniversary of the effective date shall be forfeited. Equity Transactions Between April 1, 2026 and May 14, 2026, an aggregate of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20260401__20260514__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zh8NYK1eUYRc" title="Shares converted">5,890,148 Exchangeable Shares were converted into the same number of common stock by holders of the Exchangeable Shares. Between April 1, 2026 and May 14, 2026, the Company issued <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20260401__20260514__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUOV3uyB5lEk" title="Vested restricted stock, shares">1,157,973 shares of common stock for vested restricted stock units, of which <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20260401__20260514__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember_zEDNgGrWiHH7" title="Shares issued">723,611 shares were issued to related parties, including certain executive officers and directors of the Company. On April 10, 2026, the Company entered into an Advisory & Consulting Agreement with a third-party consultant. In connection with the agreement, the Company granted an RSU award for <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20260410__20260410__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ThirdPartyMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zk0LlSVdObV4" title="Incentive award shares">100,000 shares of the Company’s common stock, with <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20260410__20260410__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ThirdPartyMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zy1DcjZ8W4lk" title="Shares vested">50,000 RSUs vesting and issued on the effective date and the remaining <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20260410__20260410__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ThirdPartyMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--SixMonthAnniversariesMember_z2D8h5xY9eZ1" title="Shares vested"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20260410__20260410__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ThirdPartyMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--AwardDateAxis__custom--TwelveMonthAnniversariesMember_zJoWHBHVL0aa" title="Shares vested">50,000 RSUs vesting in two installments on the six-month and twelve-month anniversaries of the vesting commencement date, subject to continued service. On April 6, 2026, the Company entered into a Consulting Agreement with a third-party consultant. In connection with the agreement, the Company granted an RSU award for <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_c20260406__20260406__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ThirdPartyMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0NcTSkhjm5" title="Shares issued">155,000 shares of the Company’s common stock that were vested and issued on April 29, 2026. In May 2026, the Company rescinded a previously approved equity compensation arrangement with the Company’s General Counsel covering <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260501__20260531__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ThirdPartyMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zZkEV0Be39o4" title="Number of shares issued">700,000 shares of common stock. As part of this rescission, the shares were cancelled and the arrangement was terminated with no further equity compensation obligations.

On April 17, 2026, the Board of Directors of Streamex Ltd., acting through GLDY ServiceCo, LLC as servicer, declared a scrip dividend of 0.000085 ounces of gold per GLDY Token for the month of March 2026, payable on April 17, 2026 to tokenholders of record as of that date. The dividend was funded by gold lease income earned on Streamex Ltd.’s gold holdings during March 2026 and was paid in the form of additional fractional GLDY Tokens. Each GLDY Token continues to represent one troy ounce of gold on a 1:1 basis, as confirmed by the third-party fund administrator. The noncontrolling interest holders’ share of the dividend was not material.

1250000

1000000

1500000

300000

250000000

500000000

1000000000

2000000000

3000000000

5890148

1157973

723611

100000

50000

155000

700000

- less than $1 Related to the acquisition of the Streamex Exchange. See Note 4 for more details. Goodwill was initially measured in the functional currency of Streamex Exchange and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in foreign exchange rates are reflected in the cumulative translation adjustment within other comprehensive loss. Intangible assets acquired in connection with the Streamex Exchange acquisition were initially measured in Canadian dollars and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in exchange rates are reflected in the carrying amounts presented above and recorded in other comprehensive loss as part of the cumulative translation adjustment. On August 27, 2025, the Company entered into a premium finance agreement for the policy period beginning August 3, 2025. The total premium was $2,172, of which $544 was paid as a down payment and $1,600 was financed. The agreement includes a finance charge of $51, resulting in total payments of $1,700 payable in nine monthly installments of $187 through May 2026 at an annual percentage rate of 7.48%. The financing obligation is secured by unearned premiums under the financed policies. As of March 31, 2026, the amount included in prepaid insurance is approximately $570 and AFCO loan payable of approximately $370. Prepaid insurance is amortized over the policy term, and the financing liability is reduced as payments are made. Interest expense is recognized using the effective interest method. Includes approximately $779 related to severance and other separation-related obligations associated with the Company’s former Chief Financial Officer pursuant to a Separation and General Release Agreement entered into in March 2026. The accrued amount includes cash severance, pro rata bonus components, and other related obligations expected to be paid in accordance with the terms of the agreement. Grant-date fair value (“GDFV”) GDFV per unit, determined using a Monte Carlo simulation model. The weighted-average grant-date fair value per unit for the stock price-based PSUs was $3.56. Aggregate fair value (“Agg FV”) Derived service period (“DSP”) Less than $0.5 thousand